GlaxoSmithKline_NNP 180_CD Glossary_NNP of_IN terms_NNS Terms_NNS used_VBN in_IN the_DT Annual_JJ Report_NNP US_NNP equivalent_JJ or_CC brief_JJ description_NN Accelerated_VBN capital_NN allowances_NNS Tax_NNP allowance_NN in_IN excess_NN of_IN depreciation_NN arising_VBG from_IN the_DT purchase_NN of_IN fixed_JJ assets_NNS that_WDT delay_VBP the_DT charging_VBG and_CC payment_NN of_IN tax_NN ._.
The_DT US_NNP equivalent_NN of_IN tax_NN depreciation_NN ._.
Advance_NNP Corporation_NNP Tax_NNP ACT_NNP An_DT advance_NN payment_NN of_IN UK_NNP tax_NN that_WDT was_VBD made_VBN when_WRB dividends_NNS are_VBP paid_VBN ._.
American_JJ Depositary_NNP Receipt_NNP ADR_NNP Receipt_NNP evidencing_VBG title_NN to_TO an_DT ADS_NNPS ._.
Each_DT GlaxoSmithKline_NNP ADR_NNP represents_VBZ two_CD ordinary_JJ shares_NNS ._.
American_JJ Depositary_NNP Shares_NNP ADSs_NNP Ordinary_NNP Shares_NNP registered_VBD on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
Called-up_JJ share_NN capital_NN Ordinary_NNP Shares_NNP ,_, issued_VBN and_CC fully_RB paid_VBN ._.
CER_NNP growth_NN Growth_NN at_IN constant_JJ exchange_NN rates_NNS ._.
Combined_NNP Code_NNP Guidelines_NNS required_VBN by_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS Authority_NNP to_TO address_VB the_DT principal_JJ aspects_NNS of_IN Corporate_JJ Governance_NN ._.
Currency_NNP swap_NN An_DT exchange_NN of_IN two_CD currencies_NNS ,_, coupled_VBN with_IN a_DT subsequent_JJ re-exchange_NN of_IN those_DT currencies_NNS ,_, at_IN agreed_VBN exchange_NN rates_NNS and_CC dates_NNS ._.
Defined_VBN benefit_NN plan_NN Pension_NNP plan_NN with_IN specific_JJ employee_NN benefits_NNS ,_, often_RB called_VBN final_JJ salary_NN scheme_NN ._.
Defined_VBN contribution_NN plan_NN Pension_NNP plan_NN with_IN specific_JJ contributions_NNS and_CC a_DT level_NN of_IN pension_NN dependent_JJ upon_IN the_DT growth_NN of_IN the_DT pension_NN fund_NN ._.
Derivative_JJ financial_JJ instrument_NN A_DT financial_JJ instrument_NN that_WDT derives_VBZ its_PRP$ value_NN from_IN the_DT price_NN or_CC rate_NN of_IN some_DT underlying_VBG item_NN ._.
Diluted_JJ earnings_NNS per_IN share_NN Diluted_JJ income_NN per_IN share_NN ._.
Earnings_NNS per_IN share_NN Basic_JJ income_NN per_IN share_NN ._.
Employee_NN Share_NN Ownership_NN Plan_NN Trusts_VBZ Trusts_NNS established_VBN by_IN the_DT Group_NNP to_TO satisfy_VB share_NN based_VBN employee_NN incentive_NN plans_NNS ._.
Equity_NNP shareholders_NNS funds_NNS The_DT aggregation_NN of_IN shares_NNS and_CC reserves_NNS owned_VBN by_IN shareholders_NNS ._.
The_DT US_NNP equivalent_NN is_VBZ shareholders_NNS equity_NN ._.
Freehold_NNP Ownership_NNP with_IN absolute_JJ rights_NNS in_IN perpetuity_NN ._.
Gearing_VBG ratio_NN Net_JJ debt_NN as_IN a_DT percentage_NN of_IN shareholders_NNS funds_NNS net_JJ debt_NN and_CC minority_NN interests_NNS ._.
The_DT Group_NNP GlaxoSmithKline_NNP plc_NN and_CC its_PRP$ subsidiary_NN undertakings_NNS ._.
Hedging_VBG The_DT reduction_NN of_IN risk_NN ,_, normally_RB in_IN relation_NN to_TO foreign_JJ currency_NN or_CC interest_NN rate_NN movements_NNS ,_, by_IN making_VBG off-setting_JJ commitments_NNS ._.
Intangible_JJ fixed_JJ assets_NNS Assets_NNS without_IN physical_JJ substance_NN ,_, such_JJ as_IN brands_NNS ,_, licences_NNS ,_, patents_NNS ,_, know-how_NN and_CC marketing_NN rights_NNS purchased_VBN from_IN outside_JJ parties_NNS ._.
Interest_NN cover_NN The_DT number_NN of_IN times_NNS profit_NN before_IN interest_NN exceeds_VBZ net_JJ interest_NN payable_JJ ._.
Non-equity_JJ minority_NN interest_NN Preference_NN shares_NNS issued_VBN by_IN a_DT subsidiary_NN to_TO outside_JJ parties_NNS ._.
Preference_NN shares_NNS Shares_NNP issued_VBD at_IN varying_VBG dividend_NN rates_NNS that_WDT are_VBP treated_VBN as_IN outside_JJ interests_NNS ._.
Profit_NN and_CC loss_NN account_NN reserve_NN Retained_VBN earnings_NNS ._.
Profit_NN attributable_JJ to_TO shareholders_NNS Net_JJ income_NN ._.
Share_NN capital_NN Ordinary_NNP Shares_NNP ,_, capital_NN stock_NN or_CC common_JJ stock_NN issued_VBN and_CC fully_RB paid_VBN ._.
Share_NN premium_NN account_NN Additional_JJ paid-up_JJ capital_NN or_CC paid-in_NN surplus_NN not_RB distributable_JJ ._.
Shares_NNS in_IN issue_NN Shares_NNS outstanding_JJ ._.
Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Statement_NN of_IN comprehensive_JJ income_NN ._.
Subsidiary_JJ undertaking_NN An_DT affiliate_NN in_IN which_WDT GlaxoSmithKline_NNP holds_VBZ a_DT majority_NN shareholding_NN and_CC or_CC exercises_VBZ control_NN ._.
Tangible_JJ fixed_JJ assets_NNS Property_NN ,_, plant_NN and_CC equipment_NN ._.
Contact_NN details_NNS INTERNET_NNP Information_NNP for_IN investors_NNS and_CC about_IN the_DT company_NN is_VBZ available_JJ on_IN GlaxoSmithKlines_NNP corporate_JJ website_NN at_IN www_NN ._.
com_NN HEAD_NNP OFFICE_NNP AND_CC REGISTERED_NNP OFFICE_NNP GlaxoSmithKline_NNP plc_NN 980_CD Great_NNP West_NNP Road_NNP Brentford_NNP Middlesex_NNP TW8_NNP 9GS_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD UNITED_NNP KINGDOM_NNP UNITED_NNP STATES_NNS OF_IN AMERICA_NNP Investor_NNP relations_NNS Investor_NNP relations_NNS 980_CD Great_NNP West_NNP Road_NNP One_CD Franklin_NNP Plaza_NNP Brentford_NNP PO_NNP Box_NNP 7929_CD Middlesex_NNP TW8_NNP 9GS_NNP Philadelphia_NNP PA_NNP 19101_CD Tel_NNP :_: 44_CD 0_CD 20 8047 5557 5558_CD Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Fax_NN :_: 44_CD 0_CD 20 8047 7807_CD Tel_NNP :_: 1_CD 215 751 7003_CD outside_IN the_DT USA_NNP Fax_NNP :_: 1_CD 215 751 3233_CD Registrar_NNP Lloyds_NNP TSB_NNP Registrars_NNPS ADR_NNP program_NN administrator_NN The_DT Causeway_NNP The_NNP Bank_NNP of_IN New_NNP York_NNP Worthing_NNP Shareholder_NN Relations_NNP West_NNP Sussex_NNP BN99_NNP 6DA_NNP PO_NNP Box_NNP 11258_CD www_NN ._.
co._FW uk_FW Church_NNP Street_NNP Station_NNP New_NNP York_NNP NY_NNP 10286-1258_CD General_NNP enquiries_NNS ,_, Annual_JJ Report_NNP orderline_NN and_CC www_NN ._.
com_NN Corporate_JJ Nominee_NN service_NN Tel_NNP :_: 1_CD 877 353 1154_CD toll_NN free_JJ Tel_NNP :_: 0870 600 3991_CD inside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 610 382 7836_CD outside_IN the_DT USA_NNP Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP Customer_NN response_NN center_NN Shareholder_NN Investment_NN Plans_NNS Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Dividend_NN re-investment_NN enquiries_NNS Tel_NNP :_: 0870 241 3018_CD inside_IN the_DT UK_NNP Corporate_NNP Share_NNP dealing_VBG facility_NN Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP -_: Ordinary_NNP holders_NNS Smith_NNP Barney_NNP Tel_NNP :_: 44_CD 0_CD 121 415 7146_CD outside_IN the_DT UK_NNP -_: Employees_NNS Attn_NNP :_: GSK_NNP Services_NNPS 53_CD State_NNP Street_NNP Monthly_JJ Savings_NNPS Plan_NNP enquiries_VBZ 39th_JJ Floor_NNP Tel_NNP :_: 0870 606 0268_CD inside_IN the_DT UK_NNP Boston_NNP ,_, MA_NNP 02109_CD Tel_NNP :_: 44_CD 0_CD 131 527 3746_CD outside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 800 347 6179_CD toll_NN free_JJ ISA_NNP enquiries_NNS Tel_NNP :_: 1_CD 617 589 3341_CD outside_IN the_DT USA_NNP Tel_NNP :_: 0870 242 4244_CD inside_IN the_DT UK_NNP Fax_NNP :_: 1_CD 617 589 3474_CD Tel_NNP :_: 44_CD 0_CD 1903 854 062_CD outside_IN the_DT UK_NNP TheTaylorGroup@SmithBarney_NNP ._.
com_NN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP corporate_JJ PEPs_NNS The_DT Share_NN Centre_NNP Limited_NNP Oxford_NNP House_NNP Oxford_NNP Road_NNP Aylesbury_NNP Bucks_NNP HP21_NNP 8SZ_NNP Tel_NNP :_: 44_CD 0_CD 1296 414 144_CD Corporate_JJ Share_NN dealing_VBG facility_NN Smith_NNP Barney_NNP Attn_NNP :_: GSK_NNP Services_NNPS Citigroup_NNP Centre_NNP ,_, Level_NNP 20_CD Canada_NNP Square_NNP ,_, Canary_NNP Wharf_NNP London_NNP E14_NNP 5LB_NNP Tel_NNP :_: 44_CD 0_CD 20 7508 1795_CD Fax_NNP :_: 44_CD 0_CD 20 7890 7281_CD TheBalaesGroup@Citigroup_NNP ._.
com_NN Printed_NNP by_IN The_DT Midas_NNP Press_NNP in_IN the_DT UK_NNP ._.
The_DT paper_NN used_VBN in_IN the_DT production_NN of_IN this_DT document_NN is_VBZ made_VBN from_IN pulp_NN harvested_VBN from_IN sustainable_JJ forests_NNS ,_, also_RB using_VBG sawmill_NN residues_NNS and_CC forest_NN thinnings_NNS ._.
GlaxoSmithKline_NNP Annual_JJ Report_NNP 2004_CD Annual_JJ Report_NNP 2004_CD New_NNP challenges_NNS New_NNP thinking_VBG www_NN ._.
com_NN Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_JJR Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS New_NNP thinking_VBG Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR The_DT world_NN is_VBZ changing_VBG ..._: Todays_NNP global_JJ healthcare_NN challenges_NNS mean_VBP that_IN new_JJ thinking_NN is_VBZ called_VBN for_IN by_IN the_DT pharmaceutical_JJ industry_NN R&D_NNP productivity_NN Healthcare_NNP funding_NN crisis_NN It_PRP is_VBZ getting_VBG more_RBR difficult_JJ and_CC taking_VBG longer_RBR currently_RB an_DT average_JJ The_DT demand_NN for_IN quality_NN healthcare_NN is_VBZ growing_VBG faster_RBR than_IN of_IN 12_CD years_NNS to_TO develop_VB new_JJ medicines_NNS ._.
Despite_IN a_DT substantial_JJ governments_NNS and_CC healthcare_NN purchasers_NNS ability_NN to_TO support_VB it_PRP ._.
GSKs_NNS increase_NN in_IN global_JJ R&D_NNP expenditure_NN ,_, fewer_JJR novel_NN medicines_NNS were_VBD challenge_NN is_VBZ to_TO deliver_VB innovative_JJ and_CC affordable_JJ medicines_NNS that_WDT meet_VBP launched_VBN in_IN 2003_CD than_IN at_IN any_DT time_NN during_IN the_DT last_JJ 20_CD years_NNS ._.
the_DT real_JJ and_CC unmet_JJ needs_NNS of_IN people_NNS burdened_VBN by_IN disease_NN ._.
By_IN working_VBG GSKs_NNS challenge_NN is_VBZ to_TO discover_VB new_JJ medicines_NNS faster_RBR and_CC more_RBR closely_RB with_IN patient_JJ groups_NNS ,_, we_PRP are_VBP able_JJ to_TO tailor_VB our_PRP$ development_NN economically_RB ._.
In_IN recent_JJ years_NNS ,_, we_PRP have_VBP transformed_VBN our_PRP$ R&D_NNP process_NN to_TO better_JJR meet_VB patient_JJ needs_NNS and_CC maximize_VB the_DT effectiveness_NN function_NN ._.
The_DT result_NN has_VBZ been_VBN a_DT nearly_RB 80_CD %_NN increase_NN in_IN the_DT of_IN our_PRP$ R&D_NNP expenditure_NN ._.
number_NN of_IN New_NNP Chemical_NNP Entities_NNPS in_IN our_PRP$ pipeline_NN ,_, which_WDT is_VBZ now_RB one_CD of_IN the_DT largest_JJS in_IN our_PRP$ industry_NN ._.
Access_NN to_TO medicines_NNS Transparency_NNP In_IN the_DT developing_VBG world_NN ,_, where_WRB infectious_JJ diseases_NNS present_VBP an_DT Today_NN ,_, physicians_NNS ,_, patients_NNS ,_, stakeholders_NNS and_CC investors_NNS quite_RB rightly_RB enormous_JJ burden_NN ,_, there_EX is_VBZ an_DT urgent_JJ need_NN for_IN medicines_NNS but_CC a_DT lack_NN demand_NN greater_JJR levels_NNS of_IN transparency_NN about_IN the_DT safety_NN and_CC of_IN resources_NNS to_TO pay_VB for_IN them_PRP ._.
GSK_NNP is_VBZ the_DT only_JJ company_NN that_WDT is_VBZ efcacy_NN of_IN medicines_NNS ._.
In_IN 2004_CD ,_, GSK_NNP started_VBD publishing_VBG its_PRP$ clinical_JJ developing_VBG medicines_NNS and_CC vaccines_NNS to_TO treat_VB all_DT three_CD of_IN the_DT World_NNP trial_NN data_NNS on_IN the_DT internet_NN for_IN anyone_NN to_TO access_NN ._.
We_PRP are_VBP the_DT first_JJ Health_NNP Organizations_NNPS top_JJ priority_NN diseases_NNS :_: malaria_NN ,_, tuberculosis_NN pharmaceutical_JJ company_NN to_TO offer_VB this_DT level_NN of_IN transparency_NN ._.
In_IN 2004_CD ,_, GSK_NNP shipped_VBD 33_CD million_CD tablets_NNS of_IN have_VBP also_RB increased_VBN the_DT information_NN made_VBN available_JJ through_IN our_PRP$ Combivir_NNP GSKs_NNP HIV_NNP treatment_NN to_TO Africa_NNP ._.
reporting_VBG and_CC on_IN our_PRP$ corporate_JJ website_JJ www_NN ._.
And_CC were_VBD changing_VBG too_RB ..._: GSK_NNP recognizes_VBZ the_DT implications_NNS of_IN todays_NNS changing_VBG world_NN ._.
We_PRP are_VBP committed_VBN to_TO embracing_VBG change_NN ,_, turning_VBG challenges_NNS into_IN opportunities_NNS and_CC new_JJ thinking_NN into_IN new_JJ ways_NNS of_IN working_VBG In_IN the_DT past_JJ four_CD years_NNS ,_, we_PRP have_VBP transformed_VBN our_PRP$ R&D_NNP function_NN ,_, introducing_VBG innovative_JJ ways_NNS of_IN working_VBG ,_, and_CC advanced_VBD technology_NN and_CC automation_NN to_TO help_VB us_PRP discover_VB and_CC develop_VB medicines_NNS and_CC vaccines_NNS more_RBR efficiently_RB and_CC effectively_RB ._.
We_PRP have_VBP sharpened_VBN our_PRP$ operations_NNS ,_, introducing_VBG operational_JJ excellence_NN programs_NNS ,_, streamlining_VBG our_PRP$ processes_NNS ,_, building_VBG partnerships_NNS with_IN our_PRP$ stakeholders_NNS ,_, and_CC focusing_VBG on_IN the_DT unmet_JJ needs_NNS of_IN patients_NNS ._.
And_CC we_PRP have_VBP invested_VBN in_IN the_DT communities_NNS in_IN which_WDT we_PRP operate_VBP ,_, developing_VBG medicines_NNS for_IN the_DT developing_VBG world_NN ,_, supporting_VBG community_NN health_NN education_NN programs_NNS ,_, donating_VBG medicines_NNS ,_, and_CC introducing_VBG preferential_JJ pricing_NN for_IN those_DT in_IN need_NN ._.
This_DT is_VBZ an_DT ongoing_JJ challenge_NN ,_, and_CC much_RB remains_VBZ to_TO be_VB done_VBN ._.
We_PRP are_VBP committed_VBN to_TO participating_VBG in_IN the_DT debate_NN on_IN healthcare_NN reform_NN and_CC playing_VBG our_PRP$ part_NN in_IN addressing_VBG the_DT key_JJ issues_NNS ._.
This_DT Annual_JJ Review_NNP explains_VBZ how_WRB GSK_NNP is_VBZ embracing_VBG change_NN and_CC how_WRB our_PRP$ efforts_NNS are_VBP delivering_VBG results_NNS ._.
Front_NN cover_NN We_PRP have_VBP chosen_VBN the_DT image_NN of_IN a_DT pill_NN Contents_VBZ Annual_JJ Review_NNP 2004_CD for_IN our_PRP$ front_JJ cover_NN because_IN it_PRP is_VBZ the_DT essence_NN of_IN what_WP New_NNP challenges_NNS 14_CD Business_NN operating_NN review_NN 02_CD Chairmans_NNPS and_CC CEOs_NNS statement_NN New_NNP thinking_VBG we_PRP do_VBP :_: discovering_VBG ,_, developing_VBG ,_, manufacturing_VBG and_CC 18_CD The_DT Board_NNP 03_CD Highlights_NNS of_IN the_DT year_NN delivering_VBG medicines_NNS to_TO the_DT people_NNS who_WP need_VBP them_PRP ._.
19_CD The_DT Corporate_JJ Executive_NNP Team_NNP 04_CD So_IN what_WP is_VBZ the_DT big_JJ challenge_NN ?_.
It_PRP also_RB represents_VBZ the_DT 20_CD Summary_NNP remuneration_NN report_NN 06_CD Transforming_VBG R&D_NNP global_JJ nature_NN of_IN our_PRP$ business_NN and_CC our_PRP$ global_JJ 23_CD Corporate_JJ governance_NN 08_CD Delivering_VBG the_DT pipeline_NN responsibility_NN to_TO provide_VB access_NN to_TO medicines_NNS for_IN both_DT 25_CD Summary_NNP financial_JJ statements_NNS 10_CD Sharpening_VBG our_PRP$ operations_NNS the_DT developed_VBN and_CC developing_VBG world_NN ._.
27_CD Shareholder_NN information_NN 12_CD Contributing_VBG to_TO society_NN Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR New_JJ challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD 1_CD Chairmans_NNPS and_CC CEOs_NNS Statement_NNP We_PRP knew_VBD 2004_CD would_MD be_VB a_DT challenging_JJ year_NN for_IN GSK_NNP and_CC we_PRP are_VBP pleased_JJ to_TO report_VB that_IN we_PRP have_VBP achieved_VBN our_PRP$ financial_JJ and_CC business_NN objectives_NNS In_IN our_PRP$ last_JJ Annual_JJ Review_NNP ,_, we_PRP predicted_VBD that_IN Our_PRP$ pipeline_NN is_VBZ focused_VBN on_IN developing_VBG new_JJ 2004_CD would_MD be_VB a_DT challenging_JJ year_NN as_IN we_PRP felt_VBD medicines_NNS and_CC vaccines_NNS to_TO treat_VB diseases_NNS of_IN the_DT full_JJ impact_NN of_IN generic_JJ competition_NN to_TO Paxil_NNP unmet_JJ medical_JJ need_NN ,_, such_JJ as_IN cancer_NN and_CC and_CC the_DT introduction_NN of_IN generic_JJ Wellbutrin_NNP ._.
Many_JJ of_IN these_DT have_VBP the_DT GSK_NNP managed_VBD this_DT year_NN well_RB ,_, thanks_NNS to_TO the_DT potential_NN to_TO be_VB important_JJ new_JJ products_NNS ._.
underlying_VBG strength_NN of_IN the_DT business_NN ._.
In_IN fact_NN ,_, For_IN example_NN ,_, we_PRP believe_VBP that_IN Cervarix_NNP ,_, our_PRP$ GSK_NNP is_VBZ a_DT much_JJ stronger_JJR company_NN today_NN than_IN promising_JJ vaccine_NN candidate_NN against_IN cervical_JJ it_PRP was_VBD a_DT year_NN ago_RB ._.
cancer_NN ,_, has_VBZ the_DT potential_JJ to_TO make_VB a_DT major_JJ contribution_NN to_TO healthcare_NN globally_RB and_CC to_TO Our_PRP$ broad-based_JJ portfolio_NN of_IN fast-growing_JJ become_VBN our_PRP$ best-selling_JJ vaccine_NN ._.
We_PRP expect_VBP Sir_NNP Christopher_NNP Gent_NNP ,_, Non-Executive_NNP Chairman_NNP products_NNS and_CC continued_VBD focus_NN on_IN controlling_VBG to_TO le_FW Cervarix_NNP in_IN the_DT European_NNP Union_NNP and_CC costs_NNS enabled_VBD us_PRP to_TO absorb_VB the_DT loss_NN of_IN more_JJR international_JJ markets_NNS in_IN 2006_CD ._.
than_IN 1.5_CD billion_CD of_IN business_NN to_TO generics_NNS and_CC still_RB achieve_VB a_DT 1_CD %_NN increase_NN in_IN global_JJ Great_JJ opportunities_NNS lie_VBP ahead_RB of_IN us_PRP ._.
Turnover_NN of_IN 20_CD billion_CD This_DT year_NN ,_, we_PRP will_MD work_VB to_TO ensure_VB a_DT greater_JJR grew_VBD 1_CD %_NN at_IN constant_JJ exchange_NN rates_NNS CER_NNP ,_, understanding_NN by_IN key_JJ stakeholders_NNS of_IN the_DT and_CC we_PRP achieved_VBD our_PRP$ guidance_NN of_IN earnings_NNS value_NN of_IN innovative_JJ medicines_NNS ._.
We_PRP will_MD per_IN share_NN EPS_NNP at_IN least_JJS in_IN line_NN with_IN business_NN continue_VBP our_PRP$ contribution_NN to_TO nding_VBG a_DT performance_NN EPS_NNP in_IN 2003_CD at_IN CER_NNP ._.
Our_PRP$ EPS_NNP solution_NN to_TO the_DT healthcare_NN funding_NN crisis_NN ,_, and_CC grew_VBD 2_CD %_NN to_TO 75p_VB in_IN 2004_CD ._.
we_PRP will_MD seek_VB new_JJ ways_NNS of_IN improving_VBG access_NN to_TO our_PRP$ medicines_NNS for_IN the_DT people_NNS who_WP need_VBP them_PRP In_IN 2005_CD ,_, we_PRP expect_VBP to_TO see_VB faster_JJR growth_NN most_RBS but_CC are_VBP least_RBS able_JJ to_TO pay_VB for_IN them_PRP ._.
Our_PRP$ with_IN an_DT EPS_NNP percentage_NN CER_NNP growth_NN in_IN the_DT Corporate_JJ Responsibility_NN Principles_NNS continue_VBP low_JJ double-digit_JJ range_NN on_IN an_DT International_NNP to_TO guide_VB the_DT way_NN we_PRP do_VBP business_NN ._.
A_DT separate_JJ Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP basis_NN ._.
2004_CD Corporate_JJ Responsibility_NN Report_NNP This_DT is_VBZ being_VBG driven_VBN by_IN the_DT strong_JJ growth_NN of_IN available_JJ from_IN the_DT GSK_NNP website_NN explains_VBZ Jean-Pierre_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN key_NN products_NNS and_CC continuing_VBG efficiencies_NNS in_IN progress_NN against_IN these_DT Principles_NNS during_IN our_PRP$ operations_NNS ._.
Our_PRP$ most_RBS exciting_JJ phase_NN of_IN the_DT year_NN ._.
growth_NN will_MD come_VB when_WRB the_DT new_JJ compounds_NNS and_CC vaccines_NNS currently_RB in_IN development_NN start_NN Acknowledgements_NNP contributing_VBG to_TO our_PRP$ performance_NN over_IN the_DT next_JJ We_PRP acknowledge_VBP with_IN gratitude_NN the_DT few_JJ years_NNS ._.
contribution_NN of_IN Sir_NNP Christopher_NNP Hogg_NNP and_CC Sir_NNP Peter_NNP Job_NNP ,_, who_WP retired_VBD from_IN the_DT Board_NNP at_IN GSK_NNP has_VBZ one_CD of_IN the_DT largest_JJS and_CC most_RBS the_DT end_NN of_IN 2004_CD ._.
Sir_NNP Christopher_NNP chaired_VBD promising_JJ pipelines_NNS in_IN the_DT industry_NN ,_, with_IN GSK_NNP through_IN a_DT period_NN that_WDT saw_VBD the_DT Company_NN 140_CD projects_NNS in_IN clinical_JJ development_NN as_IN at_IN the_DT derive_NN the_DT full_JJ benets_NNS of_IN the_DT merger_NN and_CC end_NN of_IN February_NNP 2005_CD ,_, including_VBG 88_CD New_NNP meet_VB the_DT challenges_NNS caused_VBN by_IN the_DT loss_NN of_IN Chemical_NNP Entities_NNPS NCEs_NNP ,_, 32_CD Product_NNP Line_NNP patent_NN protection_NN on_IN major_JJ products_NNS ._.
Of_IN these_DT compounds_NNS ,_, 43_CD NCEs_NNS have_VBP moved_VBN into_IN Phase_NN John_NNP Coombe_NNP ,_, Chief_NNP Financial_NNP officer_NN ,_, will_MD II_NNP trials_NNS ,_, including_VBG compounds_NNS to_TO treat_VB HIV_NNP ,_, retire_VBP from_IN the_DT Board_NNP of_IN GSK_NNP on_IN 31_CD March_NNP diabetes_NN ,_, blood_NN disorders_NNS and_CC multiple_JJ 2005_CD ._.
John_NNP has_VBZ served_VBN GSK_NNP and_CC its_PRP$ sclerosis_NN ,_, and_CC data_NNS on_IN at_IN least_JJS 15_CD of_IN these_DT predecessor_NN companies_NNS in_IN an_DT exemplary_JJ are_VBP expected_VBN during_IN 2005_CD ._.
In_IN 2005_CD ,_, we_PRP also_RB manner_NN for_IN more_JJR than_IN 18_CD years_NNS ,_, playing_VBG a_DT anticipate_VBP the_DT launch_NN of_IN six_CD new_JJ products_NNS ,_, major_JJ role_NN in_IN guiding_VBG the_DT Company_NN through_IN including_VBG Rotarix_NNP for_IN rotavirus_NNS ,_, Vesicare_NNP for_IN the_DT post-merger_JJ period_NN and_CC establishing_VBG overactive_JJ bladder_NN ,_, Boniva_NNP for_IN osteoporosis_NN ,_, GSK_NNP as_IN a_DT leader_NN within_IN the_DT global_JJ Avandaryl_NNP for_IN diabetes_NN ,_, Requip_NNP for_IN restless_JJ pharmaceutical_JJ industry_NN ._.
legs_NNS syndrome_NN and_CC Entereg_NNP for_IN post-operative_JJ bowel_NN disorders_NNS ._.
We_PRP thank_VBP all_DT three_CD departing_VBG directors_NNS for_IN All_DT percentage_NN growth_NN rates_NNS are_VBP at_IN constant_JJ their_PRP$ substantial_JJ contributions_NNS to_TO GSK_NNP and_CC exchange_NN rates_NNS CER_NNP ,_, unless_IN otherwise_RB stated_VBN ._.
See_NNP Business_NNP operating_VBG review_NN page_NN 15_CD wish_NN them_PRP well_RB for_IN the_DT future_NN ._.
2_CD 2_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG New_NNP challenges_NNS ,_, new_JJ thinking_VBG HIGHLIGHTS_NNPS OF_IN THE_DT YEAR_NN FINANCIAL_NNP PERFORMANCE_NN PRODUCT_NN PIPELINE_NNP GSKS_NNP BUSINESS_NNP STRATEGY_NNP GSKs_NNPS business_NN strategy_NN developed_VBD projects_NNS in_IN 2001_CD at_IN the_DT time_NN of_IN the_DT merger_NN in_IN clinical_JJ is_VBZ delivering_VBG results_NNS :_: development_NN 20bn_JJ 140_CD Total_JJ turnover_NN grew_VBD 1_CD %_NN despite_IN a_DT Our_PRP$ promising_JJ product_NN pipeline_NN is_VBZ one_CD To_TO build_VB the_DT best_JJS product_NN pipeline_NN 1.5_CD billion_CD loss_NN of_IN sales_NNS to_TO generics_NNS of_IN the_DT largest_JJS in_IN the_DT industry_NN in_IN the_DT industry_NN To_TO achieve_VB commercial_JJ and_CC spent_VBD each_DT operational_JJ excellence_NN day_NN on_IN R&D_NNP 8m_CD To_TO improve_VB access_NN to_TO medicines_NNS GSK_NNP spends_VBZ more_RBR on_IN R&D_NNP than_IN any_DT for_IN those_DT who_WP can_MD not_RB afford_VB them_PRP 6bn_VB other_JJ UK_NNP company_NN profit_NN before_IN tax_NN grew_VBD 2_CD %_NN To_TO make_VB GSK_NNP the_DT best_JJS place_NN for_IN the_DT best_JJS people_NNS to_TO do_VB their_PRP$ best_JJS work_NN To_TO contribute_VB to_TO investment_NN in_IN 04_CD X._NNP Xbn_NNP Nearly80_CD %_NN communities_NNS around_IN the_DT world_NN increase_NN in_IN New_NNP Chemical_NNP Entities_NNPS To_TO ensure_VB our_PRP$ business_NN decisions_NNS take_VBP NCEs_NNS in_IN pipeline_NN since_IN merger_NN into_IN consideration_NN ethical_JJ ,_, social_JJ and_CC 75p_JJ environmental_JJ concerns_NNS Earnings_NNS per_IN share_NN grew_VBD 2_CD %_NN in_IN 2004_CD ,_, in_IN line_NN with_IN our_PRP$ BEST_NNP PEOPLE_NNP earnings_NNS guidance_NN 82_CD %_NN CARING_NN FOR_IN THE_DT ENVIRONMENT_NN of_IN managers_NNS surveyed_VBN believe_VBP that_IN GSK_NNP employees_NNS are_VBP committed_VBN and_CC enabled_VBN to_TO make_VB meaningful_JJ contributions_NNS 2nd_RB largest_JJS 7_CD %_NN 83_CD %_NN pharmaceutical_NN of_IN managers_NNS surveyed_VBN are_VBP proud_JJ to_TO be_VB part_NN decrease_NN in_IN greenhouse_NN gas_NN company_NN in_IN of_IN GSK_NNP and_CC 77_CD %_NN would_MD gladly_RB refer_VB a_DT emissions_NNS per_IN unit_NN sales_NNS the_DT world_NN friend_NN or_CC family_NN member_NN to_TO work_VB for_IN GSK_NNP ACCESS_NNP TO_TO MEDICINES_NNP COMMERCIAL_NNP &_CC OPERATIONAL_NNP EXCELLENCE_NNP More_RBR than_IN 475,000_CD 500m_JJ patients_NNS have_VBP access_NN to_TO GSKs_NNS medicines_NNS 12_CD GSK_NNP products_NNS achieved_VBD sales_NNS of_IN more_JJR mostly_RB free_JJ of_IN charge_NN ,_, through_IN the_DT US_NNP Patient_NNP than_IN 500_CD million_CD in_IN 2004_CD Assistance_NNP Program_NNP More_RBR than_IN 2.5_CD bn_NN 85m_NN sales_NNS of_IN Seretide_NNP Advair_NNP up_RB 19_CD %_NN people_NNS protected_VBN from_IN lymphatic_JJ lariasis_NN GSKs_NNS largest_JJS product_NN and_CC the_DT worlds_NNS with_IN GSK-donated_JJ albendazole_NN sixth_RB largest_JJS pharmaceutical_JJ product_NN 50m_JJ value_NN of_IN donated_VBN INVESTMENT_NNP IN_IN COMMUNITIES_NNP medicines_NNS Method_NNP of_IN giving_VBG Value_NN of_IN global_JJ community_NN including_VBG US_NNP Patient_NNP Assistance_NNP Program_NNP investment_NN activities_NNS 33m_VBP 5_CD %_NN Management_NN 328m_NN costs_NNS 15_CD %_NN Combivir_NNP tablets_NNS 5.4_CD %_NN of_IN profit_NN before_IN tax_NN Cash_NN HIV_NNP treatment_NN 1_CD %_NN In_IN kind_NN shipped_VBN to_TO Africa_NNP 21m_CD Health_NNP programs_NNS and_CC activities_NNS 79_CD %_NN Product_NNP 18m_CD Education_NNP programs_NNS and_CC activities_NNS New_NNP challenges_NNS ,_, new_JJ thinking_VBG New_NNP challenges_NNS ,_, new_JJ thinking_VBG New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 3_CD 3_CD 3_CD So_IN what_WP is_VBZ the_DT big_JJ challenge_NN ?_.
An_DT interview_NN with_IN JP_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN Ultimately_RB ,_, it_PRP is_VBZ the_DT crisis_NN of_IN healthcare_NN nancing_NN and_CC pricing_NN pressures_NNS largely_RB due_JJ to_TO ageing_VBG populations_NNS in_IN the_DT developed_JJ world_NN What_WP is_VBZ the_DT main_JJ challenge_NN facing_VBG the_DT How_WRB healthy_JJ is_VBZ GSKs_JJ pipeline_NN of_IN In_IN September_NNP 2004_CD ,_, GSK_NNP was_VBD ranked_VBN first_RB in_IN pharmaceutical_JJ industry_NN and_CC how_WRB is_VBZ potential_JJ new_JJ medicines_NNS ?_.
terms_NNS of_IN market_NN share_NN in_IN 10_CD of_IN the_DT 21_CD therapy_NN GSK_NNP responding_VBG to_TO it_PRP ?_.
We_PRP currently_RB have_VBP 54_CD New_NNP Chemical_NNP areas_NNS in_IN which_WDT GSK_NNP has_VBZ launched_VBN products_NNS ._.
Ultimately_RB ,_, it_PRP is_VBZ the_DT crisis_NN of_IN healthcare_NN Entities_NNS NCEs_NNS in_IN Phases_NNP II_NNP and_CC III_NNP late_JJ stage_NN nancing_NN and_CC pricing_NN pressures_NNS largely_RB due_JJ to_TO clinical_JJ trials_NNS ,_, and_CC have_VBP achieved_VBN good_JJ results_NNS In_IN 2004_CD ,_, our_PRP$ turnover_NN grew_VBD 1_CD %_NN despite_IN the_DT ageing_JJ populations_NNS in_IN the_DT developed_JJ world_NN ._.
over_IN the_DT last_JJ few_JJ months_NNS from_IN studies_NNS of_IN some_DT significant_JJ loss_NN of_IN more_JJR than_IN 1.5_CD billion_CD of_IN our_PRP$ An_DT increasing_VBG ageing_JJ population_NN means_VBZ that_IN of_IN our_PRP$ key_JJ compounds_NNS ,_, including_VBG Lapatinib_NNP for_IN business_NN to_TO generics_NNS during_IN the_DT year_NN ._.
We_PRP also_RB there_EX is_VBZ an_DT increasing_VBG demand_NN for_IN new_JJ cancer_NN and_CC Cervarix_NNP ,_, a_DT vaccine_NN against_IN cervical_JJ continued_VBN to_TO focus_VB on_IN managing_VBG our_PRP$ costs_NNS medicines_NNS to_TO treat_VB chronic_NN and_CC degenerative_JJ cancer_NN ._.
A_DT lot_NN remains_VBZ to_TO be_VB done_VBN ,_, of_IN course_NN ,_, through_IN our_PRP$ operational_JJ excellence_NN diseases_NNS ._.
and_CC there_EX will_MD always_RB be_VB some_DT pipeline_NN programs_NNS see_VBP Sharpening_VBG our_PRP$ operations_NNS ,_, attrition_NN ,_, but_CC we_PRP are_VBP making_VBG good_JJ progress_NN ._.
In_IN 2005_CD ,_, we_PRP expect_VBP to_TO see_VB faster_JJR While_IN this_DT presents_VBZ an_DT opportunity_NN for_IN GSK_NNP We_PRP believe_VBP we_PRP have_VBP one_CD of_IN the_DT largest_JJS and_CC growth_NN ._.
Continued_VBN scrutiny_NN of_IN costs_NNS and_CC new_JJ and_CC other_JJ pharmaceutical_JJ companies_NNS ,_, it_PRP is_VBZ also_RB most_RBS promising_JJ pipelines_NNS in_IN the_DT industry_NN -_: in_IN initiatives_NNS to_TO streamline_VB our_PRP$ operations_NNS remains_VBZ placing_VBG a_DT financial_JJ burden_NN on_IN governments_NNS fact_NN ,_, the_DT number_NN of_IN NCEs_NNS in_IN the_DT pipeline_NN has_VBZ a_DT key_JJ strategic_JJ focus_NN for_IN us_PRP ._.
and_CC healthcare_NN purchasers_NNS that_WDT is_VBZ growing_VBG increased_VBN by_IN nearly_RB 80_CD %_NN since_IN the_DT merger_NN ._.
faster_JJR than_IN their_PRP$ ability_NN to_TO support_VB it_PRP ._.
In_IN the_DT Many_JJ patients_NNS in_IN both_DT the_DT developed_VBN developing_VBG world_NN ,_, where_WRB infectious_JJ diseases_NNS In_IN 2005_CD ,_, data_NNS are_VBP expected_VBN on_IN at_IN least_JJS 15_CD and_CC developing_VBG worlds_NNS do_VBP not_RB have_VB present_JJ an_DT enormous_JJ burden_NN ,_, there_EX products_NNS and_CC vaccines_NNS in_IN Phase_NN II_NNP clinical_JJ trials_NNS ,_, access_NN to_TO the_DT medicines_NNS they_PRP need_VBP ._.
is_VBZ an_DT urgent_JJ need_NN for_IN medicines_NNS but_CC a_DT lack_NN of_IN including_VBG compounds_NNS to_TO treat_VB HIV_NNP ,_, diabetes_NN ,_, What_WP is_VBZ GSK_NNP doing_VBG to_TO improve_VB this_DT resources_NNS to_TO pay_VB for_IN them_PRP ._.
blood_NN disorders_NNS and_CC multiple_JJ sclerosis_NN ._.
Our_PRP$ pipeline_NN is_VBZ targeted_VBN at_IN developing_VBG Therefore_RB ,_, GSKs_NNS challenge_NN is_VBZ to_TO deliver_VB In_IN the_DT meantime_NN ,_, can_MD GSK_NNP continue_VBP to_TO medicines_NNS that_WDT address_VBP real_JJ and_CC unmet_JJ affordable_JJ medicines_NNS that_WDT meet_VBP the_DT needs_NNS deliver_VBP strong_JJ performance_NN ?_.
medical_JJ needs_NNS ,_, both_DT in_IN the_DT developed_VBN and_CC of_IN people_NNS burdened_VBN by_IN disease_NN ._.
We_PRP have_VBP been_VBN able_JJ to_TO stay_VB on_IN track_NN developing_VBG world_NN ._.
we_PRP must_MD continue_VB to_TO build_VB partnerships_NNS with_IN nancially_RB because_IN of_IN the_DT performance_NN governments_NNS and_CC healthcare_NN purchasers_NNS ,_, of_IN our_PRP$ key_JJ pharmaceutical_JJ products_NNS ,_, such_JJ as_IN We_PRP have_VBP learned_VBN valuable_JJ lessons_NNS from_IN being_VBG and_CC other_JJ external_JJ stakeholders_NNS ._.
They_PRP need_VBP Seretide_NNP Advair_NNP and_CC Avandia_NNP ._.
We_PRP have_VBP also_RB proactive_JJ and_CC innovative_JJ ,_, and_CC we_PRP arent_VBP afraid_JJ to_TO understand_VB the_DT scale_NN ,_, complexity_NN and_CC cost_NN done_VBN very_RB well_RB with_IN products_NNS such_JJ as_IN Coreg_NNP to_TO be_VB first_RB ._.
For_IN example_NN ,_, GSK_NNP started_VBD the_DT first_JJ of_IN research_NN and_CC development_NN ,_, and_CC we_PRP need_VBP for_IN heart_NN failure_NN and_CC Lamictal_NNP for_IN epilepsy_NN and_CC savings_NNS card_NN for_IN prescription_NN medicines_NNS the_DT to_TO work_VB with_IN them_PRP to_TO nd_VB new_JJ solutions_NNS bipolar_JJ disorder_NN ,_, Valtrex_NNP for_IN genital_JJ herpes_NNS and_CC Orange_NNP Card_NNP ,_, for_IN US_NNP senior_JJ citizens_NNS and_CC we_PRP to_TO funding_NN ._.
These_DT products_NNS grew_VBD were_VBD the_DT first_JJ company_NN to_TO sell_VB our_PRP$ HIV_NNP drugs_NNS 22_CD %_NN in_IN 2004_CD ._.
on_IN a_DT non-profit_JJ basis_NN in_IN Africa_NNP ,_, where_WRB we_PRP also_RB now_RB have_VBP six_CD voluntary_JJ licensing_NN agreements_NNS ._.
4_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG We_PRP have_VBP learned_VBN valuable_JJ lessons_NNS from_IN being_VBG proactive_JJ and_CC innovative_JJ ,_, and_CC we_PRP arent_VBP afraid_JJ to_TO be_VB first_JJ I_PRP am_VBP proud_JJ of_IN our_PRP$ commitment_NN to_TO increasing_VBG Our_PRP$ Corporate_JJ Responsibility_NN Principles_NNPS How_WRB do_VBP you_PRP expect_VBP GSK_NNP to_TO look_VB in_IN access_NN to_TO medicines_NNS and_CC our_PRP$ generosity_NN in_IN a_DT articulate_VBP the_DT standards_NNS we_PRP are_VBP committed_JJ five_CD years_NNS time_NN ?_.
wide_JJ variety_NN of_IN philanthropic_JJ undertakings_NNS ._.
to_TO meeting_NN in_IN our_PRP$ work_NN and_CC interaction_NN with_IN JPG_NNP ._.
Our_PRP$ goal_NN is_VBZ to_TO develop_VB innovative_JJ communities_NNS ._.
These_DT are_VBP embedded_VBN in_IN the_DT medicines_NNS of_IN value_NN faster_RBR than_IN our_PRP$ In_IN 2004_CD ,_, we_PRP invested_VBD 328_CD million_CD in_IN way_NN we_PRP do_VBP business_NN ,_, and_CC we_PRP report_VBP annually_RB competitors_NNS ,_, and_CC to_TO sell_VB and_CC market_VB our_PRP$ community_NN programs_NNS ,_, product_NN donations_NNS on_IN our_PRP$ progress_NN against_IN each_DT of_IN these_DT products_NNS in_IN new_JJ and_CC innovative_JJ ways_NNS ._.
We_PRP will_MD and_CC charitable_JJ contributions_NNS ._.
Principles_NNS see_VBP Corporate_JJ Responsibility_NN continue_VBP to_TO collaborate_VB with_IN key_JJ stakeholders_NNS Report_NNP at_IN www_NN ._.
to_TO nd_VB new_JJ ways_NNS to_TO help_VB people_NNS receive_VB the_DT We_PRP believe_VBP that_IN we_PRP have_VBP a_DT key_JJ role_NN to_TO play_VB in_IN medicines_NNS they_PRP need_VBP ._.
improving_VBG access_NN to_TO medicines_NNS ,_, and_CC we_PRP are_VBP How_WRB does_VBZ GSK_NNP keep_VB its_PRP$ employees_NNS committed_VBN to_TO continuing_VBG our_PRP$ efforts_NNS ._.
motivated_VBN in_IN this_DT challenging_JJ As_IN now_RB ,_, we_PRP will_MD aim_VB to_TO meet_VB the_DT demands_NNS environment_NN ?_.
of_IN our_PRP$ patients_NNS ,_, our_PRP$ customers_NNS and_CC our_PRP$ The_DT pharmaceutical_JJ industry_NN JPG_NNP ._.
We_PRP are_VBP open_JJ with_IN our_PRP$ people_NNS about_IN the_DT employees_NNS with_IN integrity_NN ._.
And_CC we_PRP will_MD generally_RB receives_VBZ a_DT negative_JJ press_NN ._.
challenges_NNS we_PRP face_VBP ,_, the_DT actions_NNS we_PRP are_VBP taking_VBG continue_VBP to_TO be_VB a_DT company_NN that_WDT highly_RB talented_VBD How_WRB can_MD GSKs_NNS reputation_NN be_VB and_CC the_DT progress_NN being_VBG made_VBN ._.
Im_NNP pleased_JJ people_NNS want_VBP to_TO join_VB in_IN order_NN to_TO make_VB their_PRP$ improved_VBN ?_.
to_TO say_VB that_IN employees_NNS are_VBP highly_RB engaged_VBN ._.
contribution_NN ,_, and_CC to_TO enjoy_VB a_DT challenging_JJ and_CC JPG_NNP ._.
GSK_NNP has_VBZ a_DT very_RB high_JJ standing_NN among_IN the_DT GSK_NNP people_NNS continue_VBP to_TO be_VB enthusiastic_JJ and_CC meaningful_JJ career_NN ._.
The_DT innovation_NN show_NN enormous_JJ passion_NN for_IN their_PRP$ company_NN ._.
and_CC quality_NN associated_VBN with_IN many_JJ of_IN our_PRP$ initiatives_NNS is_VBZ widely_RB recognized_VBN ,_, often_RB through_IN We_PRP undertook_VBD a_DT management_NN survey_NN prestigious_JJ awards_NNS ._.
However_RB ,_, this_DT is_VBZ not_RB last_JJ year_NN ._.
The_DT results_NNS showed_VBD that_IN people_NNS feel_VBP always_RB visible_JJ to_TO the_DT general_JJ public_NN ._.
better_RB about_IN working_VBG at_IN GSK_NNP today_NN than_IN they_PRP did_VBD two_CD years_NNS ago_RB ,_, despite_IN the_DT challenging_JJ By_IN continuing_VBG to_TO be_VB more_RBR open_JJ and_CC environment_NN ._.
transparent_JJ in_IN the_DT way_NN we_PRP run_VBP our_PRP$ business_NN ,_, we_PRP will_MD be_VB able_JJ to_TO increase_VB our_PRP$ external_JJ Employees_NNS take_VBP our_PRP$ companys_NNS quest_NN to_TO bring_VB stakeholders_NNS understanding_VBG of_IN the_DT industry_NN ._.
medicines_NNS of_IN value_NN to_TO patients_NNS very_RB seriously_RB Good_JJ examples_NNS include_VBP making_VBG our_PRP$ clinical_JJ indeed_RB ._.
GSK_NNP will_MD continue_VB to_TO engage_VB and_CC trial_NN results_NNS available_JJ to_TO the_DT public_NN by_IN putting_VBG support_NN our_PRP$ employees_NNS in_IN driving_VBG changes_NNS them_PRP on_IN the_DT internet_NN see_VB page_NN 9_CD and_CC the_DT through_IN the_DT organization_NN ,_, and_CC to_TO recognize_VB extension_NN of_IN our_PRP$ Patient_NNP Advocacy_NNP initiative_NN and_CC reward_NN exceptional_JJ and_CC innovative_JJ work_NN ._.
see_VB page_NN 10_CD throughout_IN the_DT world_NN ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD 5_CD Transforming_VBG R&D_NNP In_IN 2004_CD ,_, GSK_NNP invested_VBD more_JJR than_IN 2.8_CD billion_CD 15.9_CD %_NN of_IN pharmaceutical_JJ turnover_NN in_IN Research_NNP and_CC Development_NNP R&D_NNP Ten_CD years_NNS ago_RB ,_, we_PRP conducted_VBD 500,000_CD screening_VBG tests_NNS in_IN a_DT year_NN ._.
In_IN 2004_CD ,_, we_PRP ran_VBD more_JJR than_IN 65_CD million_CD tests_NNS in_IN our_PRP$ screening_VBG No._NN ._.
1_CD facilities_NNS investor_NN in_IN R&D_NNP among_IN UK_NNP companies_NNS Bob_NNP Hertzberg_NNP ,_, Vice_NNP President_NNP ,_, Molecular_NNP Screening_NNP ,_, Discovery_NNP Research_NNP ,_, Upper_NNP Providence_NNP ,_, US_NNP 15,037_CD R&D_NNP employees_NNS worldwide_VBP GSKs_NNS continuing_VBG success_NN depends_VBZ on_IN a_DT Each_DT of_IN R&D_NNP s_VBZ seven_CD Centres_NNP of_IN Excellence_NNP can_MD maximize_VB its_PRP$ return_NN on_IN investment_NN is_VBZ vibrant_JJ and_CC productive_JJ Research_NN and_CC for_IN Drug_NN Discovery_NNP CEDDs_NNP is_VBZ focused_VBN on_IN a_DT through_IN partnerships_NNS and_CC collaborations_NNS with_IN Development_NNP R&D_NNP function_NN ._.
Because_IN of_IN their_PRP$ smaller_JJR academic_JJ institutions_NNS ,_, and_CC other_JJ scale_NN and_CC focus_NN ,_, the_DT CEDDs_NNS are_VBP able_JJ to_TO make_VB pharmaceutical_JJ and_CC biotechnology_NN It_PRP takes_VBZ well_RB over_IN 500_CD million_CD and_CC between_IN rapid_JJ and_CC informed_JJ decisions_NNS about_IN whether_IN companies_NNS ._.
These_DT partnerships_NNS work_VBP on_IN the_DT 10_CD and_CC 12_CD years_NNS to_TO develop_VB a_DT new_JJ drug_NN ._.
to_TO progress_VB a_DT compound_NN to_TO midand_VB lateprinciple_NN of_IN shared_VBN risk_NN and_CC reward_NN for_IN the_DT For_IN every_DT million_CD compounds_NNS screened_VBD ,_, stage_NN development_NN ._.
The_DT strength_NN of_IN GSKs_NNS partners_NNS ,_, through_IN in-licensing_NN and_CC third-party_JJ approximately_RB 250_CD make_VBP it_PRP to_TO pre-clinical_JJ pipeline_NN is_VBZ an_DT early_JJ sign_NN that_IN this_DT innovative_JJ arrangements_NNS ._.
This_DT allows_VBZ GSK_NNP to_TO co-develop_JJ testing_NN ,_, 10_CD advance_NN to_TO clinical_JJ trials_NNS and_CC just_RB approach_NN is_VBZ working_VBG ._.
or_CC co-market_JJ compounds_NNS that_IN we_PRP consider_VBP one_CD is_VBZ approved_VBN for_IN patient_JJ use_NN ._.
would_MD enhance_VB our_PRP$ product_NN portfolio_NN ._.
Building_NN on_IN the_DT successful_JJ CEDD_NNP structure_NN ,_, in_IN With_IN these_DT odds_NNS ,_, GSKs_NNP R&D_NNP must_MD be_VB fast_JJ 2004_CD ,_, R&D_NNP introduced_VBD six_CD Medicine_NNP GSK_NNP is_VBZ one_CD of_IN the_DT largest_JJS collaborators_NNS in_IN the_DT and_CC accurate_JJ in_IN its_PRP$ screening_NN ,_, identication_NN ,_, Development_NNP Centres_NNP MDCs_NNP ._.
Their_PRP$ remit_JJ pharmaceutical_JJ industry_NN ,_, with_IN a_DT network_NN of_IN development_NN and_CC testing_NN of_IN new_JJ quality_NN is_VBZ to_TO streamline_VB decision-making_NN and_CC more_JJR than_IN 50_CD collaborators_NNS partners_NNS ._.
compounds_NNS if_IN it_PRP is_VBZ to_TO meet_VB the_DT needs_NNS of_IN maximize_VBP the_DT worldwide_JJ development_NN patients_NNS ._.
The_DT MDCs_NNP Pipeline_NNP momentum_NN February_NNP 2005_CD are_VBP responsible_JJ for_IN managing_VBG compounds_NNS Focus_NN on_IN patient_JJ needs_NNS from_IN the_DT proof-of-concept_JJ stage_NN ,_, through_IN 160_CD Late-Stage_NNP 26_CD %_NN of_IN 140_CD R&D_NNP s_VBZ starting_VBG point_NN is_VBZ always_RB the_DT real_JJ and_CC midand_JJ late-stage_JJ development_NN Phases_NNP II_NNP Growth_NNP pipeline_NN 11_CD 39_CD %_NN of_IN unmet_JJ needs_NNS of_IN patients_NNS ._.
The_DT information_NN and_CC III_NNP ,_, see_VBP page_NN 9_CD to_TO manufacturing_VBG and_CC 120_CD 118_CD pipeline_NN gleaned_VBN from_IN consultation_NN with_IN patients_NNS ,_, marketing_NN ._.
The_DT MDCs_NNS collaborate_VBP at_IN an_DT early_JJ 12_CD 43_CD 19_CD their_PRP$ doctors_NNS ,_, key_JJ opinion_NN leaders_NNS and_CC experts_NNS stage_NN with_IN the_DT CEDDs_NNS ._.
By_IN integrating_VBG the_DT 80_CD 25_CD in_IN the_DT health_NN sector_NN is_VBZ used_VBN to_TO shape_VB GSKs_NNS technical_JJ development_NN and_CC manufacturing_NN 34_CD drug_NN development_NN program_NN ._.
functions_NNS ,_, GSK_NNP can_MD ensure_VB the_DT rapid_JJ and_CC 41_CD 40_CD effective_JJ launch_NN and_CC delivery_NN of_IN products_NNS to_TO 32_CD Innovative_JJ ways_NNS of_IN working_VBG the_DT patients_NNS who_WP need_VBP them_PRP ._.
21_CD 20_CD R&D_NNP s_VBZ exible_JJ and_CC innovative_JJ structure_NN ,_, 0_CD 2001_CD 2004_CD introduced_VBN at_IN the_DT formation_NN of_IN GSK_NNP ,_, allows_VBZ it_PRP Partnerships_NNS and_CC collaborations_NNS to_TO concentrate_VB resources_NNS where_WRB they_PRP will_MD There_EX will_MD always_RB be_VB more_RBR opportunities_NNS to_TO n_VB Vaccines_NNS n_VBP Product_NNP Line_NNP Extensions_NNS n_VBP New_NNP Chemical_NNP Entities_NNPS NCEs_NNP Phase_NN I_PRP have_VBP the_DT maximum_NN impact_NN and_CC benefit_VB the_DT develop_VB new_JJ medicines_NNS and_CC vaccines_NNS than_IN n_JJ NCEs_NNS Phase_NN II_NNP n_FW NCEs_NNP Phase_NN III_NNP registration_NN most_RBS patients_NNS ._.
One_CD way_NN that_IN R&D_NNP 6_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG Using_VBG the_DT latest_JJS in_IN ultra_NN high-throughput_JJ screening_NN robotic_JJ systems_NNS at_IN Tres_NNP Cantos_NNP in_IN Spain_NNP ,_, we_PRP will_MD be_VB able_JJ to_TO do_VB 300,000_CD experiments_NNS a_DT day_NN ,_, as_RB well_RB as_IN manage_VB the_DT large_JJ amount_NN of_IN information_NN gathered_VBN Emilio_NNP Diez_NNP ,_, Director_NNP ,_, Discovery_NNP Research_NNP Automation_NNP Facilities_NNP Innovation_NNP and_CC investment_NN :_: By_IN introducing_VBG innovative_JJ new_JJ ways_NNS of_IN working_VBG and_CC by_IN investing_VBG in_IN advanced_JJ technology_NN ,_, GSK_NNP has_VBZ been_VBN able_JJ to_TO achieve_VB three_CD years_NNS of_IN sustained_VBN increase_NN in_IN R&D_NNP productivity_NN ._.
In_IN 2001_CD ,_, we_PRP had_VBD 118_CD projects_NNS in_IN the_DT clinic_NN and_CC in_IN 2004_CD we_PRP had_VBD 140_CD projects_NNS in_IN the_DT clinic_NN see_VB Pipeline_NNP momentum_NN opposite_NN ._.
Imaging_NNP techniques_NNS :_: Imaging_NNP techniques_NNS are_VBP providing_VBG increasingly_RB accurate_JJ predictions_NNS of_IN the_DT clinical_JJ effect_NN of_IN potential_JJ medicines_NNS early_RB on_IN in_IN the_DT development_NN process_NN ._.
The_DT objective_NN is_VBZ to_TO save_VB time_NN and_CC money_NN ,_, and_CC to_TO increase_VB the_DT chances_NNS of_IN success_NN in_IN the_DT subsequent_JJ clinical_JJ trials_NNS ._.
Automation_NN :_: The_DT automation_NN of_IN our_PRP$ chemicalsynthesis_NN and_CC molecule-screening_JJ operations_NNS is_VBZ intended_VBN to_TO take_VB up_RP to_TO two_CD years_NNS off_IN the_DT drug_NN discovery_NN process_NN ._.
New_NNP facilities_NNS are_VBP fully_RB operational_JJ in_IN Tres_NNP Cantos_NNP ,_, Spain_NNP and_CC in_IN Harlow_NNP ,_, UK_NNP ._.
In_IN 2004_CD ,_, GSK_NNP opened_VBD a_DT new_JJ combined_VBN facility_NN for_IN high-throughput_JJ screening_NN of_IN drug_NN targets_NNS and_CC high-throughput_JJ chemistry_NN in_IN Upper_NNP Providence_NNP ,_, US_NNP ._.
R&D_NNP is_VBZ using_VBG advanced_JJ technology_NN in_IN the_DT search_NN for_IN new_JJ drugs_NNS Pharmacogenetics_NNP :_: Pharmacogenetics_NNP is_VBZ being_VBG applied_VBN in_IN early_JJ clinical_JJ trials_NNS to_TO identify_VB Electronic_JJ data_NNS capture_NN :_: The_DT greater_JJR the_DT types_NNS of_IN patients_NNS most_RBS likely_JJ to_TO benefit_VB use_NN of_IN electronic_JJ capture_NN of_IN clinical_JJ trial_NN from_IN a_DT potential_JJ drug_NN ._.
The_DT goal_NN is_VBZ to_TO define_VB data_NNS is_VBZ allowing_VBG scientists_NNS to_TO be_VB more_RBR more_RBR precisely_RB the_DT populations_NNS to_TO be_VB enrolled_VBN productive_JJ throughout_IN the_DT in_IN subsequent_JJ ,_, larger_JJR clinical_JJ trials_NNS ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD 7_CD Delivering_VBG the_DT pipeline_NN GSKs_NNS product_NN pipeline_NN is_VBZ maturing_VBG rapidly_RB and_CC is_VBZ one_CD of_IN the_DT largest_JJS in_IN the_DT industry_NN My_PRP$ son_NN Mario_NNP was_VBD 14_CD weeks_NNS old_JJ when_WRB he_PRP received_VBD his_PRP$ first_JJ dose_NN of_IN Rotarix_NNP ._.
I_PRP am_VBP happy_JJ I_PRP was_VBD able_JJ to_TO give_VB the_DT vaccine_NN 195_CD projects_NNS to_TO Mario_NNP and_CC to_TO protect_VB him_PRP against_IN rotavirus_NN diarrhoea_NN in_IN development_NN ,_, of_IN which_WDT 140_CD are_VBP in_IN the_DT clinic_NN Yolanda_NNP Cervantes_NNP and_CC Mario_NNP ,_, now_RB six_CD months_NNS old_JJ Nearly_RB 80_CD %_NN increase_NN in_IN New_NNP Chemical_NNP Entities_NNPS in_IN the_DT pipeline_NN since_IN the_DT merger_NN GSKs_NNS pipeline_NN shows_VBZ considerable_JJ strength_NN ._.
candidate_NN against_IN cervical_JJ cancer_NN ,_, which_WDT type_NN 2_CD diabetes_NN ,_, Entereg_NNP for_IN post-operative_JJ At_IN the_DT end_NN of_IN February_NNP 2005_CD ,_, there_EX were_VBD 140_CD turned_VBD out_RP to_TO be_VB even_RB better_JJR than_IN we_PRP had_VBD bowel_NN problems_NNS and_CC Requip_NNP for_IN restless_JJ legs_NNS projects_NNS in_IN clinical_JJ development_NN ,_, including_VBG hoped_VBN for_IN ._.
Cervarix_NNP showed_VBD a_DT 100_CD %_NN efcacy_NN in_IN syndrome_NN ._.
88_CD New_NNP Chemical_NNP Entities_NNPS NCEs_NNP ,_, 32_CD Product_NNP Phase_NN II_NNP trials_NNS against_IN the_DT most_RBS common_JJ strains_NNS Line_NNP Extensions_NNS PLEs_NNS and_CC 20_CD vaccines_NNS ._.
of_IN the_DT human_JJ papilloma_NN virus_NN HPV_NNP ,_, which_WDT Meeting_VBG unmet_JJ medical_JJ needs_NNS cause_VBP more_JJR than_IN 70_CD %_NN of_IN cervical_JJ cancers_NNS ._.
GSK_NNP is_VBZ making_VBG significant_JJ progress_NN with_IN Since_IN the_DT merger_NN ,_, the_DT number_NN of_IN NCEs_NNS in_IN Major_JJ resources_NNS are_VBP being_VBG allocated_VBN to_TO this_DT potential_JJ new_JJ medicines_NNS to_TO treat_VB depression_NN ,_, clinical_JJ development_NN has_VBZ increased_VBN by_IN nearly_RB project_NN in_IN 2005_CD in_IN order_NN to_TO complete_VB Phase_NN III_NNP schizophrenia_NN ,_, multiple_JJ sclerosis_NN ,_, Alzheimer_NNP 's_POS 80_CD %_NN and_CC our_PRP$ pipeline_NN has_VBZ matured_VBN ._.
In_IN 2001_CD ,_, trials_NNS and_CC to_TO apply_VB for_IN a_DT licence_NN in_IN early_JJ 2006_CD ._.
disease_NN and_CC migraine_NN ._.
more_JJR than_IN half_PDT our_PRP$ NCEs_NNS were_VBD in_IN Phase_NN I_PRP :_: by_IN the_DT end_NN of_IN February_NNP 2005_CD ,_, almost_RB two-thirds_NNS New_JJ product_NN launches_NNS in_IN 2005_CD In_IN 2004_CD ,_, we_PRP announced_VBD the_DT establishment_NN of_IN a_DT of_IN our_PRP$ NCEs_NNS were_VBD in_IN Phases_NNP II_NNP and_CC III_NNP ._.
GSK_NNP plans_VBZ to_TO launch_VB six_CD new_JJ products_NNS in_IN 2005_CD ._.
pre-clinical_JJ research_NN facility_NN in_IN Singapore_NNP ,_, which_WDT Two_CD of_IN these_DT ,_, Rotarix_NNP and_CC Vesicare_NNP ,_, have_VBP will_MD employ_VB a_DT team_NN of_IN 30_CD to_TO 35_CD scientists_NNS ._.
This_DT We_PRP expect_VBP to_TO see_VB a_DT significant_JJ increase_NN in_IN the_DT already_RB been_VBN launched_VBN ._.
will_MD focus_VB on_IN new_JJ therapies_NNS to_TO treat_VB neuronumber_NN of_IN major_JJ new_JJ compounds_NNS entering_VBG degenerative_JJ diseases_NNS such_JJ as_IN Alzheimers_NNP Phase_NN III_NNP trials_NNS in_IN the_DT next_JJ three_CD years_NNS ._.
Rotarix_NNP ,_, our_PRP$ two-dose_JJ oral_JJ vaccine_NN against_IN disease_NN ,_, Parkinsons_NNPS disease_NN and_CC schizophrenia_NN ._.
rotavirus_NNS ,_, which_WDT causes_VBZ severe_JJ diarrhoea_NN and_CC New_JJ product_NN extensions_NNS in_IN 2004_CD vomiting_VBG in_IN infants_NNS ,_, was_VBD launched_VBN in_IN Mexico_NNP Diseases_NNPS of_IN the_DT developing_VBG world_NN In_IN 2004_CD ,_, PLEs_NNPS new_JJ indications_NNS and_CC dosage_NN in_IN January_NNP 2005_CD ._.
This_DT disease_NN kills_VBZ more_JJR than_IN GSK_NNP is_VBZ the_DT only_JJ company_NN that_WDT is_VBZ developing_VBG forms_NNS for_IN existing_VBG products_NNS continued_VBN to_TO half_PDT a_DT million_CD children_NNS each_DT year_NN or_CC one_CD child_NN medicines_NNS and_CC vaccines_NNS to_TO treat_VB all_DT three_CD of_IN contribute_VBP to_TO turnover_NN and_CC mitigate_VB every_DT minute_NN ,_, mainly_RB in_IN developing_VBG countries_NNS ._.
the_DT World_NNP Health_NNP Organizations_NNPS top_JJ priority_NN competition_NN from_IN generic_JJ medicines_NNS ._.
New_NNP With_IN Rotarix_NNP ,_, GSK_NNP pioneered_VBD its_PRP$ South_NNP First_NNP diseases_NNS :_: malaria_NN ,_, tuberculosis_NN and_CC HIV_NNP AIDS_NNP ._.
indications_NNS for_IN Seretide_NNP Advair_NNP made_VBD this_DT launch_NN strategy_NN ,_, which_WDT focuses_VBZ first_RB on_IN important_JJ asthma_NN medicine_NN available_JJ for_IN use_NN countries_NNS where_WRB there_EX is_VBZ most_RBS need_VB ._.
The_DT In_IN 2004_CD ,_, GSKs_NNP pyridone_NN project_NN was_VBD awarded_VBN by_IN children_NNS aged_VBN 4_CD to_TO 11_CD years_NNS ._.
Kivexa_NNP Mexican_NNP government_NN will_MD pay_VB for_IN a_DT the_DT Medicines_NNP for_IN Malaria_NNP Venture_NNP Project_NNP of_IN Epizicom_NNP ,_, a_DT single_JJ tablet_NN combining_VBG two_CD vaccination_NN campaign_NN in_IN order_NN to_TO eliminate_VB the_DT Year_NN ._.
This_DT potential_JJ medicine_NN has_VBZ since_IN successful_JJ HIV_NNP treatments_NNS ,_, was_VBD introduced_VBN ,_, the_DT infection_NN ._.
simplifying_VBG the_DT medication_NN regime_NN for_IN patients_NNS ._.
Vesicare_NNP ,_, a_DT treatment_NN for_IN overactive_JJ bladder_NN ,_, GSK_NNP is_VBZ the_DT industry_NN leader_NN in_IN HIV_NNP R&D_NNP and_CC ,_, was_VBD launched_VBN in_IN the_DT US_NNP in_IN January_NNP 2005_CD ._.
for_IN many_JJ years_NNS ,_, our_PRP$ products_NNS have_VBP formed_VBN Best_JJS news_NN in_IN 2004_CD The_DT four_CD other_JJ new_JJ products_NNS expected_VBN to_TO be_VB the_DT core_NN of_IN HIV_NNP AIDS_NNP treatment_NN guidelines_NNS The_DT best_JJS news_NN in_IN 2004_CD was_VBD the_DT results_NNS from_IN launched_VBN in_IN 2005_CD are_VBP :_: Boniva_NNP a_DT once-monthly_JJ around_IN the_DT world_NN ._.
our_PRP$ clinical_JJ program_NN for_IN Cervarix_NNP ,_, a_DT vaccine_NN treatment_NN for_IN osteoporosis_NN ,_, Avandaryl_NNP for_IN 8_CD 8_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG One_CD of_IN the_DT largest_JJS pipelines_NNS in_IN the_DT industry_NN Number_NN of_IN projects_NNS in_IN clinical_JJ trials_NNS in_IN each_DT therapeutic_JJ area_NN end_NN February_NNP 2005_CD Clinical_NNP Trial_NNP Register_NNP During_IN 2004_CD ,_, GSK_NNP established_VBD a_DT website_JJ called_VBN the_DT GSK_NNP Clinical_NNP Phase_NN I_PRP Phase_NN II_NNP Phase_NN III_NNP Total_NNP Trial_NNP Register_NNP to_TO publish_VB clinical_JJ Cardiovascular_NNP 6_CD 8_CD 8_CD 22_CD trial_NN data_NNS relating_VBG to_TO marketed_VBN &_CC Metabolic_NNP medicines_NNS ._.
Although_IN prescribing_VBG Infectious_JJ diseases_NNS 2_CD 5_CD 4_CD 11_CD information_NN approved_VBN by_IN regulatory_JJ authorities_NNS will_MD Musculoskeletal_NNP ,_, 9_CD 6_CD 8_CD 23_CD Inammation_NNP ,_, GI_NNP &_CC Urology_NNP continue_VBP to_TO guide_VB appropriate_JJ use_NN of_IN GSK_NNP medicines_NNS ,_, the_DT 13_CD 10_CD 8_CD Neurosciences_NNP 31_CD Register_NNP serves_VBZ as_IN another_DT resource_NN for_IN researchers_NNS ,_, medical_JJ Oncology_NNP 2_CD 7_CD 5_CD 14_CD professionals_NNS and_CC the_DT public_NN ._.
Along_IN with_IN publications_NNS in_IN Respiratory_JJ 3_CD 10_CD 6_CD 19_CD medical_JJ journals_NNS and_CC presentations_NNS at_IN medical_JJ Vaccines_NNS 6_CD 6_CD 8_CD 20_CD congresses_NNS ,_, the_DT Register_NNP demonstrates_VBZ GSKs_NNP Total_NNP 41_CD 52_CD 47_CD 140_CD commitment_NN to_TO ensuring_VBG the_DT clear_JJ communication_NN of_IN data_NNS Phase_NN I_PRP Evaluation_NN of_IN clinical_JJ pharmacology_NN ,_, usually_RB conducted_VBN in_IN volunteers_NNS ._.
Phase_NN II_NNP Determination_NNP of_IN dose_NN and_CC initial_JJ evaluation_NN of_IN efcacy_NN ,_, conducted_VBN in_IN a_DT small_JJ number_NN of_IN patients_NNS ._.
Phase_NN III_NNP Large_JJ comparative_JJ studies_NNS compound_VBP versus_IN placebo_NN and_CC or_CC established_VBN treatment_NN in_IN patients_NNS to_TO determine_VB clinical_JJ benefit_NN and_CC safety_NN ._.
The_DT number_NN of_IN New_NNP Chemical_NNP Entities_NNPS NCEs_NNPS in_IN the_DT pipeline_NN has_VBZ increased_VBN by_IN nearly_RB 80_CD %_NN since_IN 2001_CD Oct_NNP 2001_CD Dec_NNP 2003_CD Feb_NNP 2005_CD Phase_NN III_NNP 8_CD Phase_NN III_NNP 12_CD Phase_NN III_NNP 11_CD Phase_NN II_NNP 15_CD Phase_NN II_NNP 32_CD Phase_NN II_NNP 43_CD Cervarix_NNP :_: Our_PRP$ vaccine_NN candidate_NN against_IN cervical_JJ cancer_NN showed_VBD 100_CD %_NN efcacy_NN in_IN Phase_NN Phase_NN I_PRP 27_CD Phase_NN I_PRP 38_CD Phase_NN I_PRP 34_CD II_NNP trials_NNS against_IN HPV_NNP 16_CD and_CC 18_CD ._.
Cervical_JJ cancer_NN is_VBZ the_DT second_JJ most_RBS common_JJ cancer_NN in_IN women_NNS 50_CD NCEs_NNS 82_CD NCEs_NNS 88_CD NCEs_NNS 510,000_CD are_VBP diagnosed_VBN and_CC 288,000_CD die_NN Developing_VBG new_JJ from_IN the_DT disease_NN each_DT year_NN ._.
GSK_NNP believes_VBZ that_IN Cervarix_NNP will_MD save_VB many_JJ lives_NNS and_CC has_VBZ the_DT medicines_NNS potential_JJ to_TO be_VB our_PRP$ best-selling_JJ vaccine_NN yet_RB ._.
Planned_NNP GSK_NNP pipeline_NN lings_NNS ,_, 2005-07_JJ New_NNP Chemical_NNP Entities_NNPS Product_NNP Line_NNP Extensions_NNPS 115_CD Allermist_NNP Arixtra_NNP Lamictal_NNP XR_NNP TPO_NNP antagonist_NN -_: low_JJ steroid_JJ rhinitis_NN acute_JJ coronary_JJ syndrome_NN once_IN a_DT day_NN platelets_VBZ Cervarix_NNP 140_CD Avandamet_NNP XR_NNP Requip_NNP CR_NNP HPV_NNP vac_NN cervical_JJ cancer_NN CCR5_CD antagonist_NN -_: HIV_NNP once_IN a_DT day_NN once_RB a_DT day_NN Lapatinib_NNP :_: GSKs_NNS new_JJ anti-cancer_JJ compound_NN Rotarix_NNP Radafaxine_NNP Coreg_NNP CR_NNP Trexima_NNP is_VBZ designed_VBN to_TO destroy_VB cancer_NN cells_NNS while_IN vaccine_NN -_: rotavirus_NN NDRI_NNP -_: depression_NN once_RB a_DT day_NN migraine_NN causing_VBG less_JJR toxic_JJ side-effects_NNS than_IN conventional_JJ chemotherapy_NN ._.
Having_VBG shown_VBN Lapatinib_NNP 381_CD Avandia_NNP Wellbutrin_NNP XL_NNP dual_JJ kinase_NN inhibitor_NN -_: promise_NN in_IN women_NNS with_IN advanced_JJ breast_NN COX-2_NN inhibitor_NN -_: pain_NN Alzheimers_NNP disease_NN EU_NNP ling_NN cancer_NN cancer_NN who_WP had_VBD not_RB responded_VBN to_TO existing_VBG 381_CD ling_JJ date_NN to_TO be_VB confirmed_VBN therapy_NN ,_, it_PRP is_VBZ being_VBG evaluated_VBN in_IN an_DT expanded_VBN clinical_JJ program_NN ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 9_CD 9_CD 9_CD Sharpening_VBG our_PRP$ operations_NNS Commercial_JJ and_CC operational_JJ excellence_NN initiatives_NNS help_VBP GSK_NNP to_TO continually_RB improve_VB performance_NN Were_VBD establishing_VBG global_JJ standards_NNS for_IN the_DT quality_NN of_IN sales_NNS calls_NNS and_CC expectations_NNS for_IN our_PRP$ frontline_NN sales_NNS managers_NNS 6_CD billion_CD David_NNP Pernock_NNP ,_, Senior_NNP Vice_NNP President_NNP ,_, US_NNP Pharmaceuticals_NNP profit_NN before_IN tax_NN grew_VBD 2_CD %_NN in_IN 2004_CD More_JJR than_IN 2_CD billion_CD total_JJ cost_NN savings_NNS since_IN the_DT merger_NN in_IN 2001_CD GSKs_NNS business_NN comprises_VBZ Pharmaceuticals_NNP Product_NNP life_NN cycle_NN management_NN Summit_NNP was_VBD attended_VBN by_IN more_JJR than_IN 400_CD prescription_NN medicines_NNS and_CC vaccines_NNS and_CC The_DT Product_NNP Line_NNP Extension_NNP PLE_NNP approach_NN people_NNS including_VBG patient_JJ group_NN Consumer_NN Healthcare_NNP over-the-counter_JJ allows_VBZ GSK_NNP to_TO create_VB what_WP is_VBZ effectively_RB an_DT representatives_NNS from_IN 23_CD countries_NNS ._.
medicines_NNS ,_, oral_JJ care_NN and_CC nutritional_JJ entirely_RB new_JJ drug_NN within_IN the_DT life_NN cycle_NN of_IN an_DT Consumer_NN Healthcare_NNP healthcare_NN ,_, supported_VBN by_IN Global_JJ existing_VBG drug_NN ._.
This_DT offers_VBZ the_DT patient_JJ significant_JJ In_IN 2004_CD ,_, Consumer_NNP Healthcare_NNP developed_VBD a_DT Manufacturing_NNP &_CC Supply_NNP GMS_NNP ._.
clinical_JJ advantages_NNS ,_, such_JJ as_IN increased_VBN new_JJ business_NN strategy_NN and_CC operating_NN model_NN compliance_NN and_CC safety_NN ,_, increased_VBD efcacy_NN The_DT Pharmaceutical_NNP and_CC Consumer_NNP Healthcare_NNP designed_VBN to_TO deliver_VB faster_JJR sales_NNS growth_NN ._.
It_PRP will_MD and_CC or_CC more_JJR convenient_JJ dosage_NN forms_NNS ._.
businesses_NNS aim_VBP to_TO maximize_VB their_PRP$ commercial_JJ achieve_VB this_DT through_IN a_DT vigorous_JJ focus_NN on_IN potential_JJ by_IN introducing_VBG innovative_JJ products_NNS to_TO In_IN recent_JJ years_NNS ,_, PLEs_NNS such_JJ as_IN Wellbutrin_NNP XL_NNP and_CC product_NN innovation_NN that_WDT is_VBZ tightly_RB aligned_VBN to_TO as_RB many_JJ markets_NNS as_IN possible_JJ ,_, accelerating_VBG the_DT Paxil_NNP CR_NNP have_VBP helped_VBN GSK_NNP mitigate_VB the_DT impact_NN consumer_NN needs_NNS ._.
The_DT new_JJ model_NN more_RBR process_NN of_IN bringing_VBG new_JJ products_NNS to_TO market_NN ,_, of_IN generic_JJ medicines_NNS and_CC have_VBP contributed_VBN to_TO effectively_RB links_NNS together_RB R&D_NNP ,_, marketing_NN and_CC increasing_VBG brand_NN recognition_NN and_CC ensuring_VBG that_IN pipeline_NN momentum_NN ._.
In_IN 2004_CD ,_, GSK_NNP lost_VBD sales_NNS commercial_JJ operating_VBG units_NNS ,_, organised_VBN to_TO patients_NNS have_VBP access_NN to_TO new_JJ medicines_NNS ._.
of_IN 1.5_CD billion_CD to_TO generic_JJ medicines_NNS ,_, but_CC this_DT support_NN three_CD categories_NNS of_IN brands_NNS :_: was_VBD partially_RB offset_VBN by_IN sales_NNS of_IN PLEs_NNS worth_JJ Global_NNP brands_NNS :_: significant_JJ brands_NNS marketed_VBN Worldwide_NNP Sales_NNS Force_NNP Excellence_NNP 0.6_CD billion_CD ._.
In_IN 2005_CD ,_, GSK_NNP has_VBZ plans_NNS to_TO le_FW four_CD in_IN multiple_JJ markets_NNS GSKs_NNS sales_NNS force_NN ranks_VBZ high_JJ in_IN industry_NN surveys_NNS new_JJ PLEs_NNS :_: Avandamet_NNP XR_NNP ,_, Coreg_NNP CR_NNP ,_, Requip_NNP Lead_JJ market_NN brands_NNS :_: significant_JJ brands_NNS of_IN healthcare_NN professionals_NNS see_VBP opposite_JJ ._.
marketed_VBN in_IN a_DT few_JJ markets_NNS The_DT Worldwide_NNP Sales_NNS Force_NNP Excellence_NN initiative_NN Enterprise_NN brands_NNS :_: valuable_JJ local_JJ brands_NNS ._.
WSFE_NNP aims_VBZ to_TO improve_VB customer_NN satisfaction_NN Patient_NNP Advocacy_NNP :_: supporting_VBG by_IN identifying_VBG and_CC sharing_VBG best_JJS practice_NN within_IN patient_JJ needs_NNS Global_JJ Manufacturing_NNP &_CC Supply_NNP the_DT sales_NNS force_NN ,_, and_CC by_IN strengthening_VBG sales_NNS GSKs_NNP Patient_NNP Advocacy_NNP initiative_NN is_VBZ designed_VBN GMS_NNP focuses_VBZ on_IN the_DT secure_JJ supply_NN of_IN highrepresentatives_NNS product_NN knowledge_NN ._.
More_JJR to_TO bring_VB GSK_NNP closer_JJR to_TO patients_NNS and_CC advocacy_NN quality_NN products_NNS to_TO meet_VB patient_JJ expectations_NNS ._.
than_IN 25,000_CD sales_NNS representatives_NNS have_VBP been_VBN groups_NNS ,_, with_IN the_DT goal_NN of_IN improving_VBG GSKs_NNS It_PRP continues_VBZ to_TO deliver_VB significant_JJ and_CC trained_VBN through_IN this_DT initiative_NN ._.
understanding_NN of_IN patient_JJ needs_NNS and_CC sustainable_JJ efficiency_NN improvements_NNS across_IN its_PRP$ enhancing_VBG its_PRP$ reputation_NN as_IN a_DT patient-centred_JJ network_NN of_IN more_JJR than_IN 80_CD factories_NNS ._.
For_IN The_DT time_NN available_JJ to_TO physicians_NNS for_IN learning_VBG company_NN ._.
After_IN all_DT ,_, there_EX are_VBP no_RB better_RB example_NN ,_, the_DT global_JJ program_NN that_WDT focuses_VBZ about_IN new_JJ medicines_NNS and_CC clinical_JJ studies_NNS is_VBZ spokespeople_NN than_IN patients_NNS whose_WP$ lives_NNS on_IN principles_NNS for_IN lean_JJ manufacturing_NN and_CC precious_JJ ._.
GSKs_NNS When_WRB ,_, Why_WRB ,_, How_WRB approach_NN are_VBP affected_VBN by_IN GSK_NNP products_NNS ._.
technology_NN has_VBZ resulted_VBN in_IN better_JJR process_NN see_VBP opposite_JJ enables_VBZ sales_NNS representatives_NNS to_TO yields_NNS ,_, improved_VBN quality_NN and_CC simpler_JJR business_NN deliver_VBP patient-specic_JJ treatment_NN options_NNS more_RBR This_DT initiative_NN originated_VBN in_IN the_DT US_NNP in_IN 2002_CD but_CC processes_VBZ ._.
Global_JJ procurement_NN expenditure_NN efficiently_RB and_CC effectively_RB ._.
has_VBZ since_IN been_VBN incorporated_VBN into_IN GSKs_NNS has_VBZ reduced_VBN due_JJ to_TO a_DT continued_VBN focus_NN on_IN lowstrategic_JJ plans_NNS throughout_IN the_DT world_NN ._.
In_IN 2004_CD ,_, cost_NN supply_NN and_CC e-procurement_NN techniques_NNS ,_, the_DT annual_JJ Patient_NNP Advocacy_NNP Leadership_NNP such_JJ as_IN electronic_JJ auctions_NNS ._.
10_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG Harnessing_NNP natures_VBZ power_NN The_DT turbines_NNS have_VBP contributed_VBN to_TO the_DT sites_NNS overall_JJ 25_CD %_NN reduction_NN in_IN its_PRP$ spend_VBP on_IN energy_NN and_CC utilities_NNS Paul_NNP Londesborough_NNP ,_, Site_NNP Director_NNP ,_, Barnard_NNP Castle_NNP ,_, pictured_VBD below_IN GSKs_NNP Environment_NNP ,_, Health_NNP &_CC Safety_NNP Excellence_NNP initiative_NN includes_VBZ the_DT long-term_JJ goal_NN to_TO drive_VB down_RP the_DT environmental_JJ impact_NN of_IN manufacturing_NN and_CC to_TO switch_VB to_TO renewable_JJ energy_NN sources_NNS ._.
At_IN Barnard_NNP Castle_NNP in_IN the_DT UK_NNP ,_, two_CD wind_NN turbines_NNS have_VBP been_VBN installed_VBN ,_, which_WDT are_VBP capable_JJ of_IN providing_VBG 10_CD %_NN of_IN the_DT sites_NNS electricity_NN when_WRB running_VBG at_IN full_JJ speed_NN ._.
Surveys_NNS of_IN US_NNP physicians_NNS have_VBP recently_RB rated_VBN GSK_NNP sales_NNS representatives_NNS number_NN one_CD in_IN four_CD physician_NN specialities_NNS :_: Sites_NNS reduced_VBN by_IN allergists_NNS ,_, immunologists_NNS ,_, paediatricians_NNS No._NN ._.
Sales_NNS force_VBP ranking_JJ 29_CD %_NN Since_IN the_DT merger_NN ,_, GSK_NNP has_VBZ reduced_VBN the_DT number_NN of_IN manufacturing_VBG sites_NNS from_IN 115_CD to_TO 82_CD through_IN rationalisation_NN and_CC operational_JJ excellence_NN initiatives_NNS ._.
When_WRB ,_, Why_WRB ,_, How_WRB GSK_NNP has_VBZ introduced_VBN a_DT global_JJ sales_NNS call_VBP model_NN that_IN focuses_VBZ on_IN When_WRB a_DT GSK_NNP medicine_NN is_VBZ appropriate_JJ ,_, Why_WRB a_DT physician_NN should_MD consider_VB it_PRP for_IN a_DT patient_NN and_CC Delivering_VBG How_WRB to_TO administer_VB it_PRP appropriately_RB ._.
By_IN the_DT end_NN of_IN 2004_CD ,_, all_DT sales_NNS representatives_NNS in_IN GSKs_NNS key_JJ markets_NNS commercial_JJ and_CC had_VBD been_VBN trained_VBN in_IN this_DT approach_NN ._.
operational_JJ excellence_NN 300m_CD GMSs_NNP Operational_NNP Excellence_NNP Programme_NNP has_VBZ realized_VBN annualised_JJ cost_NN savings_NNS of_IN 300_CD million_CD through_IN operational_JJ efficiencies_NNS with_IN its_PRP$ network_NN of_IN manufacturing_VBG sites_NNS ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD 11_CD Contributing_VBG to_TO society_NN Our_PRP$ success_NN as_IN a_DT company_NN and_CC the_DT nature_NN of_IN our_PRP$ products_NNS enable_VBP us_PRP to_TO invest_VB in_IN under-served_JJ communities_NNS around_IN the_DT world_NN We_PRP would_MD be_VB able_JJ to_TO do_VB only_RB a_DT tiny_JJ fraction_NN of_IN what_WP we_PRP do_VBP without_IN reliable_JJ donations_NNS of_IN medicines_NNS from_IN 328_CD million_CD companies_NNS like_IN GSK_NNP GSKs_NNS global_JJ community_NN investment_NN in_IN 2004_CD Curtis_NNP R._NNP Welling_NNP ,_, President_NNP and_CC CEO_NNP ,_, AmeriCares_NNP More_JJR than_IN 100_CD countries_NNS benefited_VBD from_IN humanitarian_JJ product_NN donations_NNS from_IN GSK_NNP GSKs_NNS biggest_JJS contribution_NN to_TO society_NN is_VBZ the_DT In_NNP 2004_CD ,_, the_DT sixth_JJ year_NN of_IN the_DT program_NN ,_, GSKs_NNP work_NN on_IN behavioural_JJ change_NN continues_VBZ discovery_NN and_CC development_NN of_IN medicines_NNS that_WDT 67_CD million_CD albendazole_NN treatments_NNS ,_, worth_NN through_IN its_PRP$ award-winning_JJ Personal_JJ Hygiene_NNP help_NN people_NNS to_TO do_VB more_JJR ,_, feel_VB better_JJR and_CC live_VBP 7_CD million_CD at_IN wholesale_JJ cost_NN ,_, were_VBD donated_VBN and_CC Sanitation_NNP Education_NNP PHASE_NNP program_NN longer_RBR ._.
Our_PRP$ success_NN as_IN a_DT company_NN and_CC the_DT to_TO 34_CD countries_NNS ._.
Since_IN the_DT inception_NN of_IN the_DT for_IN children_NNS in_IN five_CD African_JJ and_CC Latin_JJ American_JJ nature_NN of_IN our_PRP$ products_NNS also_RB enable_VBP us_PRP to_TO global_JJ elimination_NN program_NN ,_, GSK_NNP has_VBZ countries_NNS ._.
invest_VB in_IN under-served_JJ communities_NNS around_IN donated_VBN a_DT total_NN of_IN 307_CD million_CD albendazole_IN the_DT world_NN ._.
treatments_NNS ,_, reaching_VBG more_JJR than_IN 85_CD million_CD Humanitarian_JJ aid_NN people_NNS living_VBG in_IN endemic_JJ areas_NNS ._.
During_IN 2004_CD ,_, GSK_NNP donated_VBD 50_CD million_CD worth_JJ GSK_NNP contributes_VBZ to_TO society_NN through_IN active_JJ of_IN products_NNS mainly_RB life-saving_JJ antibiotics_NNS to_TO engagement_NN with_IN numerous_JJ external_JJ Support_NN for_IN communities_NNS affected_VBN by_IN more_JJR than_IN 100_CD impoverished_JJ or_CC disaster-struck_JJ stakeholders_NNS ,_, including_VBG the_DT World_NNP Health_NNP HIV_NNP AIDS_NNP countries_NNS through_IN non-profit_JJ partners_NNS such_JJ as_IN Organization_NNP and_CC not-for-profit_JJ organizations_NNS ._.
2004_CD marked_VBD the_DT 12th_JJ year_NN of_IN Positive_NNP Action_NNP ,_, AmeriCares_NNP and_CC Project_NNP HOPE_NNP ._.
GSKs_NNS We_PRP fund_VBP community-led_JJ initiatives_NNS and_CC donate_VBP GSKs_NNS pioneering_JJ global_JJ program_NN that_WDT donations_NNS were_VBD critical_JJ to_TO the_DT medical_JJ needs_NNS of_IN essential_JJ products_NNS to_TO support_VB humanitarian_JJ partners_NNS with_IN grass-roots_JJ ,_, community-based_JJ communities_NNS affected_VBN by_IN the_DT oods_NNS in_IN efforts_NNS and_CC community-based_JJ healthcare_NN in_IN organizations_NNS in_IN 35_CD countries_NNS ._.
Positive_JJ Action_NNP Bangladesh_NNP ,_, hurricanes_NNS in_IN the_DT US_NNP and_CC the_DT more_JJR than_IN 100_CD countries_NNS ._.
addresses_NNS the_DT stigma_NN of_IN HIV_NNP AIDS_NNP through_IN Caribbean_NNP ,_, typhoons_NNS in_IN the_DT Philippines_NNPS ,_, the_DT education_NN ,_, and_CC supports_VBZ better_JJR care_NN for_IN people_NNS conict_VBP in_IN Sudan_NNP and_CC the_DT Asian_JJ tsunami_NN ._.
GSKs_NNS global_JJ community_NN investment_NN activities_NNS living_VBG with_IN or_CC affected_VBN by_IN HIV_NNP AIDS_NNP ._.
During_IN in_IN 2004_CD were_VBD valued_VBN at_IN 328_CD million_CD or_CC the_DT 2004_CD ,_, Positive_NNP Action_NNP established_VBD new_JJ GSK_NNP pledged_VBD 2_CD million_CD to_TO the_DT relief_NN effort_NN equivalent_NN of_IN 5.4_CD %_NN of_IN profit_NN before_IN tax_NN ._.
Not_RB programs_NNS in_IN Latin_NNP America_NNP ,_, Asia_NNP ,_, and_CC following_VBG the_DT earthquake_NN and_CC tsunami_NN in_IN Asia_NNP ,_, surprisingly_RB ,_, GSK_NNP has_VBZ been_VBN recognized_VBN as_IN the_DT central_JJ and_CC eastern_JJ Europe_NNP ._.
as_RB well_RB as_IN donating_VBG more_JJR than_IN 3.6_CD million_CD largest_JJS giver_NN of_IN any_DT FTSE_NNP 100_CD company_NN for_IN the_DT doses_NNS of_IN antibiotics_NNS and_CC 600,000_CD doses_NNS of_IN the_DT past_JJ three_CD years_NNS ._.
Preventing_VBG childhood_NN illnesses_NNS hepatitis_NNP A_NNP vaccine_NN ._.
We_PRP will_MD continue_VB to_TO offer_VB Malaria_NNP and_CC diarrhoea_JJ cause_NN the_DT deaths_NNS of_IN assistance_NN throughout_IN the_DT region_NN ._.
The_DT elimination_NN of_IN lymphatic_JJ lariasis_NN millions_NNS of_IN African_JJ children_NNS each_DT year_NN ,_, yet_RB GSKs_NNS agship_NN community_NN program_NN aims_VBZ to_TO these_DT deaths_NNS are_VBP preventable_JJ ._.
New_NNP malaria_NN eliminate_VB the_DT disguring_NN ,_, mosquito-borne_JJ education_NN programs_NNS in_IN eight_CD African_JJ disease_NN lymphatic_JJ lariasis_NN LF_NNP from_IN the_DT world_NN countries_NNS are_VBP teaching_VBG mothers_NNS about_IN the_DT by_IN 2020_CD ._.
GSK_NNP has_VBZ committed_VBN to_TO providing_VBG as_IN importance_NN of_IN early_JJ diagnosis_NN in_IN children_NNS and_CC much_JJ of_IN the_DT anti-parasitic_JJ drug_NN albendazole_NN as_IN the_DT value_NN of_IN using_VBG insecticide-treated_JJ bed_NN nets_NNS required_VBN to_TO treat_VB the_DT one_CD billion_CD adults_NNS and_CC to_TO prevent_VB infection_NN ._.
children_NNS at_IN risk_NN in_IN more_JJR than_IN 80_CD countries_NNS ._.
12_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG MORE_JJR THAN_IN MORE_JJR THAN_IN MILLION_NNP PEOPLE_NNP COUNTRIES_NNPS 100_CD have_VBP been_VBN protected_VBN against_IN 85_CD have_VBP benefited_VBN from_IN GSKs_NNP LF_NNP with_IN donated_VBN albendazole_JJ community-based_JJ support_NN Making_VBG a_DT difference_NN across_IN the_DT world_NN Tsunami_NNP GSK_NNP pledged_VBD 2_CD million_CD as_RB well_RB as_IN donating_VBG more_JJR than_IN 50_CD MILLION_NNP 3.6_CD million_CD doses_NNS of_IN antibiotics_NNS and_CC 600,000_CD doses_NNS of_IN the_DT hepatitis_NN A_DT value_NN of_IN vital_JJ medicines_NNS donated_VBN for_IN vaccine_NN humanitarian_JJ causes_NNS This_DT important_JJ public-private_JJ sector_NN collaboration_NN established_VBN between_IN WHO_WP and_CC GSK_NNP in_IN 1997_CD has_VBZ benefited_VBN millions_NNS of_IN individuals_NNS in_IN developing_VBG countries_NNS Dr_NNP LEE_NNP Jong-wook_NNP World_NNP Health_NNP Organization_NNP Elimination_NNP of_IN lymphatic_JJ lariasis_NN :_: In_IN 2004_CD ,_, Egypt_NNP completed_VBD five_CD rounds_NNS of_IN mass_NN drug_NN administration_NN in_IN a_DT bid_NN to_TO eliminate_VB LF_NNP ._.
Preliminary_JJ results_NNS look_VBP impressive_JJ and_CC it_PRP is_VBZ anticipated_VBN that_IN this_DT ancient_JJ disease_NN will_MD soon_RB be_VB eliminated_VBN in_IN Egypt_NNP ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 13_CD 13_CD Business_NN operating_NN review_NN Strong_JJ performance_NN of_IN key_JJ products_NNS absorbs_VBZ lost_VBN sales_NNS to_TO generics_NNS Total_JJ pharmaceutical_JJ turnover_NN grew_VBD 1_CD %_NN in_IN 2004_CD ,_, despite_IN the_DT loss_NN of_IN 1.5_CD billion_CD of_IN sales_NNS to_TO generic_JJ forms_NNS of_IN Paxil_NNP and_CC Wellbutrin_NNP ._.
Excluding_VBG sales_NNS of_IN these_DT products_NNS ,_, turnover_NN grew_VBD 7_CD %_NN In_IN 2004_CD ,_, 12_CD GSK_NNP products_NNS each_DT had_VBD sales_NNS of_IN over_IN 500million_CD EPS_NNP 75.0_CD pence_NN GSK_NNP delivered_VBD EPS_NNP growth_NN at_IN CER_NNP of_IN 2_CD %_NN ,_, in_IN line_NN with_IN guidance_NN The_DT strong_JJ growth_NN of_IN GSKs_NNS epilepsy_NN and_CC bi-polar_JJ Anti-bacterial_JJ sales_NNS ,_, reecting_VBG generic_JJ Pharmaceuticals_NNS disorder_NN treatment_NN Lamictal_NNP continued_VBD ,_, with_IN sales_NNS competition_NN in_IN all_DT regions_NNS ,_, declined_VBD 9_CD %_NN GSK_NNP continues_VBZ to_TO be_VB the_DT global_JJ leader_NN in_IN up_RB 32_CD %_NN to_TO 678_CD million_CD ._.
Ongoing_JJ US_NNP growth_NN worldwide_NN and_CC 24_CD %_NN in_IN the_DT US_NNP ._.
respiratory_JJ pharmaceuticals_NNS with_IN sales_NNS of_IN its_PRP$ three_CD up_IN 49_CD %_NN to_TO 414_CD million_CD is_VBZ being_VBG driven_VBN by_IN the_DT key_JJ products_NNS ,_, Seretide_NNP Advair_NNP ,_, Flixotide_NNP Flovent_NNP In_IN metabolic_JJ ,_, the_DT diabetes_NN treatments_NNS Avandia_NNP indication_NN for_IN the_DT maintenance_NN treatment_NN of_IN biand_NN Serevent_NNP ,_, amounting_VBG to_TO 3.4_CD billion_CD ,_, up_IN 9_CD %_NN ._.
Avandamet_NNP continued_VBD to_TO perform_VB very_RB strongly_RB ,_, polar_JJ disorder_NN received_VBN last_JJ year_NN ._.
Sales_NNS of_IN Seretide_NNP Advair_NNP ,_, the_DT Groups_NNS largest_JJS with_IN overall_JJ sales_NNS of_IN 1.1_CD billion_CD up_IN 32_CD %_NN ._.
product_NN ,_, grew_VBD 19_CD %_NN to_TO 2.5_CD billion_CD ,_, although_IN this_DT Sales_NNS in_IN the_DT US_NNP grew_VBD 26_CD %_NN to_TO 852_CD million_CD ._.
contributed_VBD to_TO declines_NNS in_IN Serevent_NNP and_CC Flixotide_NNP ,_, Encouragingly_RB ,_, Avandia_NNP Avandamet_NNP are_VBP also_RB GSKs_NNS underlying_VBG growth_NN driven_VBD its_PRP$ constituent_NN products_NNS ._.
In_IN the_DT US_NNP ,_, Advair_NNP sales_NNS growing_VBG very_RB strongly_RB in_IN Europe_NNP and_CC International_NNP by_IN strong_JJ sales_NNS performance_NN of_IN grew_VBD 20_CD %_NN to_TO 1.3_CD billion_CD ._.
Growth_NN in_IN Europe_NNP was_VBD markets_NNS with_IN sales_NNS up_IN 49_CD %_NN and_CC 62_CD %_NN respectively_RB ._.
key_JJ products_NNS :_: also_RB strong_JJ up_RB 18_CD %_NN to_TO 902_CD million_CD ._.
The_DT vaccines_NNS business_NN had_VBD a_DT strong_JJ year_NN ,_, with_IN International_NNP sales_NNS grew_VBD 15_CD %_NN to_TO 229_CD million_CD Seretide_NNP Advair_NNP 2.5_CD billion_CD up_IN 19_CD %_NN sales_NNS up_IN 11_CD %_NN to_TO 1.2_CD billion_CD ._.
Several_JJ key_JJ products_NNS reecting_VBG good_JJ growth_NN in_IN all_DT geographic_JJ areas_NNS ._.
Vaccines_NNS 1.2_CD billion_CD up_IN 11_CD %_NN are_VBP driving_VBG sales_NNS growth_NN Pediarix_NNP Infanrix_NNP up_IN Central_NNP Nervous_NNP System_NNP CNS_NNP sales_NNS declined_VBD 12_CD %_NN to_TO 357_CD million_CD ,_, Priorix_NNP up_IN 14_CD %_NN to_TO 95_CD Avandia_NNP Avandamet_NNP 1.1_CD billion_CD 16_CD %_NN to_TO 3.5_CD billion_CD with_IN declines_NNS in_IN all_DT regions_NNS ._.
million_CD and_CC Fluarix_NNP up_IN 38_CD %_NN to_TO 79_CD million_CD ._.
up_RB 32_CD %_NN Total_JJ sales_NNS of_IN the_DT Paxil_NNP franchise_NN were_VBD down_RB 39_CD %_NN In_IN oncology_NN ,_, sales_NNS of_IN Zofran_NNP grew_VBD 8_CD %_NN ,_, driven_VBN by_IN to_TO 1.1_CD billion_CD as_IN a_DT result_NN of_IN generic_JJ competition_NN Lamictal_NNP 0.7_CD billion_CD up_IN 32_CD %_NN a_DT strong_JJ US_NNP performance_NN up_IN 10_CD %_NN to_TO 565_CD million_CD ._.
to_TO Paxil_NNP IR_NNP sales_NNS of_IN which_WDT declined_VBD 53_CD %_NN to_TO 667_CD Valtrex_NNP 0.6_CD billion_CD up_IN 24_CD %_NN million_CD ._.
Mitigating_VBG this_DT decline_NN was_VBD the_DT strong_JJ In_IN cardiovascular_JJ and_CC urogenital_JJ ,_, Coreg_NNP sales_NNS performance_NN of_IN the_DT product_NN in_IN Japan_NNP with_IN sales_NNS of_IN Coreg_NNP 0.4_CD billion_CD up_IN 34_CD %_NN grew_VBD 34_CD %_NN to_TO 432_CD million_CD ._.
171_CD million_CD up_IN 25_CD %_NN and_CC the_DT performance_NN of_IN Paxil_NNP CR_NNP which_WDT generated_VBD sales_NNS of_IN 396_CD million_CD up_IN 14_CD %_NN ._.
Total_JJ sales_NNS of_IN Wellbutrin_NNP products_NNS fell_VBD Within_IN anti-virals_NNS ,_, global_JJ HIV_NNP product_NN sales_NNS 12_CD %_NN to_TO 751_CD million_CD ._.
Wellbutrin_NNP IR_NNP and_CC SR_NNP sales_NNS rose_VBD 4_CD %_NN to_TO 1.5_CD billion_CD and_CC sales_NNS of_IN the_DT herpes_NNS fell_VBD 64_CD %_NN to_TO 284_CD million_CD as_IN a_DT result_NN of_IN generic_JJ treatment_NN Valtrex_NNP exceeded_VBD the_DT 500_CD million_CD competition_NN ._.
This_DT impact_NN was_VBD partially_RB offset_VBN ,_, mark_NN for_IN the_DT first_JJ time_NN in_IN 2004_CD up_IN 24_CD %_NN to_TO however_RB ,_, by_IN the_DT exceptionally_RB strong_JJ 571_CD million_CD ._.
The_DT sales_NNS performance_NN of_IN Valtrex_NNP is_VBZ performance_NN of_IN Wellbutrin_NNP XL_NNP ,_, the_DT new_JJ oncebeing_NN driven_VBN by_IN the_DT US_NNP up_IN 30_CD %_NN to_TO 369_CD million_CD daily_JJ product_NN ,_, which_WDT achieved_VBD sales_NNS of_IN 467_CD where_WRB the_DT product_NN is_VBZ the_DT clear_JJ market_NN leader_NN in_IN million_CD in_IN its_PRP$ first_JJ full_JJ year_NN on_IN the_DT market_NN ._.
14_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG These_DT results_NNS confirm_VBP the_DT success_NN with_IN which_WDT GSK_NNP has_VBZ navigated_VBN a_DT difficult_JJ year_NN ,_, absorbing_VBG over_IN 1.5_CD billion_CD of_IN lost_VBN sales_NNS to_TO generics_NNS and_CC still_RB managing_VBG to_TO grow_VB the_DT business_NN ._.
The_DT continuing_VBG success_NN of_IN our_PRP$ key_JJ products_NNS means_VBZ we_PRP can_MD now_RB look_VB forward_RB to_TO a_DT good_JJ performance_NN in_IN 2005_CD JP_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN Net_NN of_IN currency_NN movements_NNS the_DT margin_NN declined_VBD Consumer_NNP Healthcare_NNP Several_JJ significant_JJ product_NN launches_NNS 0.7_CD percentage_NN points_NNS ,_, reecting_VBG higher_JJR R&D_NNP The_DT growth_NN in_IN Consumer_NNP Healthcare_NNP sales_NNS of_IN planned_VBN for_IN 2005_CD include_VBP :_: expenditure_NN ,_, a_DT higher_JJR cost_NN of_IN goods_NNS due_JJ to_TO a_DT less_RBR 3_CD %_NN to_TO 3.2_CD billion_CD comprised_VBD an_DT over-thefavourable_JJ product_NN mix_NN and_CC higher_JJR provisions_NNS for_IN counter_NN OTC_NNP medicine_NN sales_NNS increase_NN of_IN 2_CD %_NN ,_, legal_JJ matters_NNS ._.
These_DT were_VBD partially_RB offset_VBN by_IN cost_NN a_DT Nutritional_NNP healthcare_NN sales_NNS increase_NN of_IN 5_CD %_NN Vesicare_NNP for_IN overactive_JJ bladder_NN savings_NNS initiatives_NNS in_IN general_JJ and_CC administration_NN and_CC Oral_JJ care_NN sales_NNS increase_NN of_IN 4_CD %_NN ._.
Rotarix_NNP for_IN rotavirus_NNS and_CC lower_JJR charges_NNS related_VBN to_TO programs_NNS to_TO OTC_NNP medicine_NN sales_NNS were_VBD 1.5_CD billion_CD ,_, up_RB 2_CD %_NN ._.
Boniva_NNP for_IN osteoporosis_NN Sales_NNS growth_NN from_IN smoking_NN control_NN products_NNS in_IN Avandaryl_NNP for_IN diabetes_NN the_DT US_NNP up_IN 12_CD %_NN and_CC Europe_NNP up_IN 24_CD %_NN helped_VBD to_TO offset_VB the_DT decline_NN in_IN dermatological_JJ products_NNS ,_, During_IN the_DT years_NNS 2000_CD to_TO 2003_CD ,_, business_NN Requip_NNP for_IN restless_JJ legs_NNS syndrome_NN performance_NN was_VBD the_DT primary_JJ performance_NN measure_NN which_WDT were_VBD down_RB 14_CD %_NN due_JJ to_TO generic_JJ used_VBN by_IN management_NN and_CC was_VBD presented_VBN after_IN Entereg_NNP for_IN post-operative_JJ bowel_NN competition_NN to_TO Cutivate_NNP in_IN the_DT US_NNP ._.
excluding_VBG merger_NN items_NNS ,_, integration_NN and_CC disorders_NNS restructuring_VBG costs_NNS and_CC disposals_NNS of_IN businesses_NNS ,_, as_IN In_IN 2004_CD ,_, GSK_NNP obtained_VBD the_DT OTC_NNP marketing_NN rights_NNS management_NN believes_VBZ that_IN exclusion_NN of_IN these_DT items_NNS provides_VBZ a_DT better_JJR comparison_NN of_IN business_NN in_IN the_DT US_NNP for_IN orlistat_NN ,_, an_DT FDA-approved_JJ performance_NN for_IN the_DT periods_NNS presented_VBN ._.
For_IN 2004_CD ,_, prescription_NN product_NN for_IN obesity_NN management_NN ,_, with_IN the_DT completion_NN of_IN these_DT programs_NNS ,_, the_DT PHARMACEUTICAL_NNP TURNOVER_NNP BY_IN marketed_VBN by_IN Roche_NNP as_IN Xenical_NNP ._.
Group_NNP is_VBZ reporting_VBG results_NNS on_IN a_DT statutory_JJ basis_NN only_RB ._.
THERAPEUTIC_NNP AREA_NN Growth_NN rates_NNS are_VBP presented_VBN comparing_VBG 2004_CD results_NNS Oral_JJ care_NN sales_NNS were_VBD 1.1_CD billion_CD ,_, up_RB 4_CD %_NN ._.
Strong_JJ with_IN 2003_CD business_NN performance_NN results_NNS as_IN 2004_CD 2003_CD Growth_NN management_NN considers_VBZ that_IN this_DT gives_VBZ the_DT most_RBS m_JJ m_NN CER_NNP %_NN sales_NNS growth_NN in_IN International_NNP of_IN 9_CD %_NN was_VBD led_VBN by_IN appropriate_JJ indication_NN of_IN the_DT Group_NNP 's_POS performance_NN the_DT Sensodyne_NNP ,_, Polident_NNP and_CC Poligrip_NNP brands_NNS ._.
for_IN the_DT period_NN under_IN review_NN and_CC therefore_RB Respiratory_JJ 4,415_CD 4,417_CD 7_CD commentaries_NNS are_VBP presented_VBN on_IN this_DT basis_NN unless_IN CNS_NNP 3,463_CD 4,455_CD 16_CD Sales_NNS of_IN Nutritional_NNP healthcare_NN products_NNS grew_VBD otherwise_RB stated_VBN ._.
Lucozade_NNP grew_VBD 7_CD %_NN to_TO In_IN order_NN to_TO illustrate_VB underlying_VBG performance_NN ,_, it_PRP is_VBZ Anti-bacterials_JJ 1,561_CD 1,815_CD 9_CD 268_CD million_CD ._.
the_DT Groups_NNS practice_NN to_TO discuss_VB its_PRP$ results_NNS in_IN terms_NNS Metabolic_NNP 1,253_CD 1,079_CD 27_CD of_IN constant_JJ exchange_NN rate_NN CER_NNP growth_NN ._.
This_DT Vaccines_VBZ 1,196_CD 1,123_CD 11_CD represents_VBZ growth_NN calculated_VBN as_IN if_IN the_DT exchange_NN rates_NNS Trading_NN profit_NN used_VBN to_TO determine_VB the_DT results_NNS of_IN overseas_JJ companies_NNS Oncology_NNP and_CC emesis_NN 934_CD 1,001_CD 2_CD Trading_NN profit_NN was_VBD 6,150_CD million_CD ,_, a_DT 1_CD %_NN decrease_NN in_IN sterling_NN had_VBD remained_VBN unchanged_JJ from_IN those_DT used_VBN Cardiovascular_NNP and_CC in_IN the_DT previous_JJ year_NN ._.
All_DT commentaries_NNS are_VBP presented_VBN 11_CD %_NN decline_NN in_IN sterling_NN terms_NNS compared_VBN with_IN in_IN terms_NNS of_IN CER_NNP unless_IN otherwise_RB stated_VBN ._.
The_DT trading_NN margin_NN Other_JJ 1,031_CD 1,171_CD 7_CD declined_VBD two_CD percentage_NN points_NNS compared_VBN with_IN 17,146_CD 18,181_CD 1_CD 2003_CD ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD 15_CD Business_NN operating_NN review_NN continued_VBD Main_NNP differences_NNS :_: Legal_NNP proceedings_NNS Earnings_NNS per_IN share_NN The_DT Group_NNP is_VBZ involved_VBN in_IN patent_NN litigation_NN with_IN Full_NNP year_NN earnings_NNS per_IN share_NN EPS_NNP of_IN 75.0_CD pence_NN Share-based_JJ payments_NNS :_: Under_IN IFRS_NNP the_DT fair_JJ manufacturers_NNS seeking_VBG to_TO market_NN generic_JJ versions_NNS increased_VBD 2_CD %_NN ,_, compared_VBN to_TO business_NN performance_NN value_NN of_IN share_NN options_NNS and_CC awards_NNS granted_VBN of_IN many_JJ of_IN the_DT Groups_NNS most_RBS important_JJ products_NNS ,_, EPS_NNP in_IN 2003_CD ._.
In_IN sterling_JJ terms_NNS ,_, EPS_NNP declined_VBD 9_CD %_NN ,_, to_TO employees_NNS is_VBZ charged_VBN to_TO the_DT income_NN including_VBG Wellbutrin_NNP ,_, Seretide_NNP ,_, Avandia_NNP ,_, Imitrex_NNP ,_, reecting_VBG a_DT weakening_NN of_IN the_DT US_NNP dollar_NN ._.
On_IN a_DT statement_NN ,_, whereas_IN only_RB the_DT intrinsic_JJ loss_NN Valtrex_NNP ,_, Lamictal_NNP and_CC Zofran_NNP ,_, prior_RB to_TO the_DT expiration_NN statutory_JJ basis_NN EPS_NNP increased_VBD 8_CD %_NN ,_, but_CC declined_VBD usually_RB a_DT smaller_JJR amount_NN is_VBZ charged_VBN under_IN of_IN the_DT Groups_NNS patents_NNS ._.
The_DT Group_NNP is_VBZ currently_RB a_DT 3_CD %_NN in_IN sterling_NN terms_NNS ._.
defendant_NN in_IN a_DT number_NN of_IN product_NN liability_NN lawsuits_NNS ,_, Amortisation_NNP of_IN intangible_JJ assets_NNS and_CC including_VBG class_NN actions_NNS ,_, that_WDT involve_VBP substantial_JJ Taxation_NNP goodwill_NN :_: Under_IN IFRS_NNP amortisation_NN of_IN claims_NNS for_IN damages_NNS related_VBN to_TO the_DT Groups_NNS GSK_NNP has_VBZ open_JJ issues_NNS with_IN the_DT taxation_NN authorities_NNS intangible_JJ assets_NNS may_MD only_RB start_VB when_WRB the_DT pharmaceutical_JJ products_NNS ._.
The_DT Group_NNP is_VBZ also_RB a_DT in_IN the_DT US_NNP ,_, UK_NNP ,_, Japan_NNP and_CC Canada_NNP ._.
By_IN far_RB the_DT asset_NN is_VBZ available_JJ for_IN use_NN ,_, whereas_IN it_PRP starts_VBZ defendant_NN in_IN anti-trust_JJ actions_NNS led_VBD following_VBG largest_JJS relates_VBZ to_TO Glaxo_NNP heritage_NN products_NNS ,_, in_IN immediately_RB under_IN UK_NNP GAAP_NNP ._.
Goodwill_NN is_VBZ adverse_JJ outcomes_NNS in_IN prosecution_NN of_IN patent_NN respect_NN of_IN which_WDT the_DT US_NNP Internal_NNP Revenue_NNP Service_NNP regarded_VBD as_IN having_VBG an_DT indefinite_JJ life_NN under_IN infringement_NN actions_NNS ._.
Further_RB ,_, the_DT Group_NNP is_VBZ IRS_NNP and_CC UK_NNP Inland_NNP Revenue_NN have_VBP made_VBN IFRS_NNP and_CC is_VBZ therefore_RB not_RB amortised_VBN ._.
Any_DT UK_NNP responding_VBG to_TO federal_JJ and_CC state_NN governmental_JJ competing_VBG and_CC contradictory_JJ claims_NNS ._.
GAAP_NNP goodwill_NN amortisation_NN has_VBZ to_TO be_VB investigations_NNS in_IN the_DT US_NNP into_IN pricing_NN ,_, marketing_NN and_CC GSK_NNP has_VBZ attempted_VBN to_TO settle_VB the_DT US_NNP dispute_NN ,_, first_JJ reversed_JJ ._.
reimbursement_NN of_IN a_DT number_NN of_IN prescription_NN drug_NN through_IN direct_JJ discussion_NN with_IN the_DT IRS_NNP and_CC products_NNS ._.
See_VB Note_VB 30_CD to_TO the_DT Financial_NNP statements_NNS Deferred_JJ tax_NN :_: The_DT deferred_VBN tax_NN difference_NN subsequently_RB through_IN discussions_NNS between_IN the_DT US_NNP Legal_NNP proceedings_NNS in_IN the_DT Annual_JJ Report_NNP 2004_CD for_IN a_DT principally_RB relates_VBZ to_TO intercompany_NN items_NNS on_IN and_CC UK_NNP authorities_NNS under_IN the_DT terms_NNS of_IN the_DT double_JJ discussion_NN of_IN proceedings_NNS and_CC governmental_JJ which_WDT a_DT deferred_JJ tax_NN credit_NN is_VBZ available_JJ under_IN tax_NN convention_NN between_IN the_DT two_CD countries_NNS and_CC investigations_NNS in_IN which_WDT the_DT Group_NNP is_VBZ currently_RB UK_NNP GAAP_NNP ,_, but_CC not_RB under_IN IFRS_NNP ._.
This_DT particular_JJ discussions_NNS were_VBD terminated_VBN in_IN July_NNP 2003_CD ._.
difference_NN in_IN taxation_NN treatment_NN is_VBZ not_RB January_NNP 2004_CD ,_, the_DT IRS_NNP issued_VBD a_DT Notice_NNP of_IN expected_VBN to_TO recur_VB ._.
deficiency_NN for_IN the_DT years_NNS 1989-1996_CD claiming_VBG International_NNP Financial_NNP Reporting_NNP additional_JJ taxes_NNS of_IN $_$ 2.7_CD billion_CD ._.
On_IN 2_CD April_NNP 2004_CD Pensions_NNS and_CC other_JJ post-employment_NN benets_NNS :_: Standards_NNPS IFRS_NNP the_DT Group_NNP led_VBD a_DT petition_NN in_IN the_DT US_NNP Tax_NNP Court_NNP IFRS_NNP adopts_VBZ a_DT different_JJ valuation_NN approach_NN In_IN June_NNP 2002_CD ,_, the_DT Council_NNP of_IN the_DT European_NNP Union_NNP disputing_VBG the_DT IRS_NNP claim_NN and_CC seeking_VBG a_DT refund_NN of_IN than_IN UK_NNP GAAP_NNP and_CC this_DT usually_RB results_NNS in_IN a_DT adopted_VBN a_DT Regulation_NN requiring_VBG listed_VBN companies_NNS $_$ 1_CD billion_CD in_IN taxes_NNS ._.
On_IN 25_CD January_NNP 2005_CD the_DT IRS_NNP higher_JJR charge_NN ._.
In_IN addition_NN IFRS_NNP recognizes_VBZ the_DT in_IN the_DT EU_NNP Member_NNP States_NNPS to_TO prepare_VB their_PRP$ issued_VBN a_DT further_JJ Notice_NNP of_IN deficiency_NN for_IN the_DT years_NNS funding_VBG surplus_JJ deficit_NN immediately_RB through_IN consolidated_JJ financial_JJ statements_NNS in_IN accordance_NN 1997-2000_CD claiming_VBG additional_JJ taxes_NNS of_IN $_$ 1.9_CD reserves_NNS ,_, whereas_IN UK_NNP GAAP_NNP spreads_VBZ the_DT with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS billion_CD ._.
If_IN the_DT IRS_NNP claims_NNS for_IN the_DT years_NNS 1989-2000_CD surplus_NN deficit_NN over_IN the_DT members_NNS average_JJ IFRS_NNP with_IN effect_NN from_IN 1_CD January_NNP 2005_CD ._.
were_VBD upheld_VBN ,_, the_DT Group_NNP would_MD additionally_RB be_VB expected_VBN service_NN lives_NNS through_IN the_DT income_NN liable_JJ for_IN interest_NN on_IN late_JJ payment_NN ,_, estimated_VBN to_TO GSK_NNP initiated_VBD its_PRP$ IFRS_NNP conversion_NN project_NN in_IN 2002_CD statement_NN ._.
amount_NN to_TO $_$ 3.0_CD billion_CD net_NN of_IN federal_JJ tax_NN relief_NN at_IN and_CC this_DT has_VBZ now_RB been_VBN completed_VBN ._.
Brief_NN 31_CD December_NNP 2004_CD ,_, giving_VBG a_DT total_NN of_IN $_$ 7.6_CD billion_CD ._.
explanations_NNS of_IN the_DT main_JJ IFRS_NNP adjustments_NNS to_TO The_DT Group_NNP expects_VBZ to_TO le_FW a_DT petition_NN against_IN these_DT profit_NN are_VBP given_VBN below_IN ,_, together_RB with_IN the_DT impact_NN further_JJ claims_NNS in_IN April_NNP 2005_CD ,_, including_VBG a_DT further_RBR on_IN profit_NN before_IN tax_NN and_CC EPS_NNP for_IN 2004_CD and_CC 2003_CD ._.
claim_NN for_IN refund_NN of_IN taxes_NNS ,_, and_CC will_MD ask_VB the_DT Tax_NNP Fuller_NNP details_NNS are_VBP given_VBN in_IN the_DT Annual_JJ Report_NNP 2004_CD Court_NNP to_TO consolidate_VB the_DT IRS_NNP claims_NNS for_IN all_PDT the_DT and_CC on_IN the_DT companys_NNS website_VBP ._.
EFFECT_NN OF_IN IFRS_NNP ON_NNP PROFIT_NNP BEFORE_IN TAX_NN AND_CC EPS_NNP Business_NNP performance_NN A_DT provisional_JJ trial_NN date_NN for_IN the_DT 1989-1996_CD Statutory_JJ restated_VBN claims_NNS has_VBZ been_VBN set_VBN for_IN October_NNP 2006_CD ._.
As_IN 2004_CD 2003_CD similar_JJ tax_NN issues_NNS remain_VBP open_JJ for_IN 2001_CD to_TO date_NN ,_, profit_NN profit_NN GSK_NNP expects_VBZ to_TO receive_VB further_JJ substantial_JJ claims_NNS before_IN tax_NN EPS_NNS before_IN tax_NN EPS_NNS from_IN the_DT IRS_NNP for_IN these_DT years_NNS ._.
m_NN pence_NN m_NN pence_NN UK_NNP GAAP_NNP 6,119_CD 75.0_CD 6,703_CD 82.0_CD GSK_NNP continues_VBZ to_TO believe_VB that_IN the_DT profits_NNS reported_VBD IFRS_NNP adjustments_NNS :_: by_IN its_PRP$ US_NNP subsidiaries_NNS for_IN the_DT period_NN 1989_CD to_TO date_NN ,_, Share-based_JJ payments_NNS 309_CD 5.5_CD 368_CD 5.9_CD on_IN which_WDT it_PRP has_VBZ paid_VBN taxes_NNS in_IN the_DT US_NNP ,_, are_VBP more_RBR Amortisation_NNP of_IN intangible_JJ assets_NNS and_CC goodwill_NN 54_CD 0.9_CD 38_CD 0.6_CD than_IN sufficient_JJ to_TO reect_VB the_DT activities_NNS of_IN its_PRP$ US_NNP Deferred_NNP tax_NN on_IN intercompany_NN items_NNS 1.9_CD operations_NNS ._.
Pensions_NNS and_CC other_JJ post-employment_NN benets_VBZ 36_CD 0.4_CD 11_CD GSK_NNP is_VBZ in_IN continuing_VBG discussions_NNS with_IN the_DT Inland_NNP Other_JJ adjustments_NNS 49_CD 35_CD 0.5_CD Revenue_NN in_IN respect_NN of_IN UK_NNP transfer_NN pricing_NN disputes_NNS ._.
IFRS_NNP 5,779_CD 68.1_CD 6,349_CD 77.2_CD See_VB Note_VB 12_CD of_IN Annual_JJ Report_NNP 2004_CD for_IN further_JJ details_NNS ._.
16_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_NN Product_NNP overview_VBD GSKs_NNP underlying_VBG growth_NN in_IN 2004_CD was_VBD driven_VBN by_IN the_DT strong_JJ performance_NN of_IN our_PRP$ key_JJ products_NNS Total_JJ turnover_NN Consumer_NN Healthcare_NNP 16_CD %_NN turnover_NN 3.2_CD bn_NN ,_, Consumer_NNP Healthcare_NNP grew_VBD 3_CD %_NN 20.3_CD bn_NN Pharmaceuticals_NNS 84_CD %_NN turnover_NN grew_VBD 1_CD %_NN ,_, despite_IN the_DT loss_NN Pharmaceutical_NNP turnover_NN 17.1_CD bn_NN ,_, of_IN 1.5_CD billion_CD of_IN sales_NNS to_TO generics_NNS grew_VBD 1_CD %_NN KEY_NNP PHARMACEUTICAL_NNP PRODUCTS_NNP CONSUMER_NN HEALTHCARE_NN 3.2_CD bn_NN GSKs_NNP Consumer_NNP Healthcare_NNP 6.5_CD bn_NN business_NN grew_VBD 3_CD %_NN ._.
turnover_NN of_IN five_CD key_JJ products_NNS Top_JJ 5_CD Consumer_NN Healthcare_NNP products_NNS and_CC vaccines_NNS grew_VBD by_IN 22_CD %_NN total_JJ turnover_NN Seretide_NNP Advair_NNP Valtrex_NNP Coreg_NNP 1_CD Nicotine_JJ replacement_NN therapy_NN 341m_CD 2,461_CD m_NN 571m_NN 2_CD Aquafresh_NNP 329m_CD 432m_JJ grew_VBD 19_CD %_NN grew_VBD 24_CD %_NN 3_CD Lucozade_NNP 268m_CD grew_VBD 34_CD %_NN Strong_JJ growth_NN has_VBZ been_VBN GSKs_RB largest_JJS selling_VBG Continues_NNS to_TO benefit_VB from_IN 4_CD Sensodyne_NNP 213m_CD driven_VBN by_IN the_DT genital_JJ herpes_NNS product_NN for_IN asthma_NN and_CC its_PRP$ wide_JJ range_NN of_IN indications_NNS 5_CD Panadol_NNP 208m_JJ medication_NN in_IN the_DT US_NNP ._.
chronic_JJ obstructive_JJ in_IN heart_NN disease_NN ._.
pulmonary_JJ disease_NN COPD_NNP Avandia_NNP Avandamet_NNP is_VBZ the_DT sixth_JJ largest_JJS Lamictal_JJ pharmaceutical_JJ product_NN 1,116_CD m_NN globally_RB and_CC the_DT second_JJ 678m_JJ Over-the-counter_NN largest_JJS in_IN Europe_NNP ._.
grew_VBD 32_CD %_NN grew_VBD 32_CD %_NN grew_VBD 2_CD %_NN to_TO 1,489_CD million_CD GSKs_NNS diabetes_NN treatment_NN Indicated_VBN for_IN epilepsy_NN continues_VBZ to_TO perform_VB strongly_RB ._.
and_CC bipolar_JJ disorder_NN Nutritional_NNP healthcare_NN Lamictal_NNP continues_VBZ to_TO grew_VBD 5_CD %_NN to_TO 636_CD million_CD grow_VBP strongly_RB ._.
Oral_JJ healthcare_NN grew_VBD 4_CD %_NN to_TO 1,088_CD million_CD VACCINES_NNP Infanrix_NNP Pediarix_NNP grew_VBD 12_CD %_NN to_TO 357_CD million_CD ._.
1,196_CD m_NN Fluarix_NNP GSKs_NNP vaccines_NNS business_NN had_VBD grew_VBN 38_CD %_NN to_TO 79_CD million_CD ._.
a_DT strong_JJ year_NN ,_, with_IN sales_NNS up_IN 11_CD %_NN ._.
12_CD GSK_NNP products_NNS achieved_VBD sales_NNS of_IN more_JJR than_IN 500_CD million_CD in_IN 2004_CD 1_CD Seretide_NNP Advair_NNP 2,461_CD m_NN 5_CD Wellbutrin_NNP 751m_CD 9_CD Flixotide_NNP Flovent_NNP 618m_NN 2_CD Avandia_NNP Avandamet_NNP 1,116_CD m_NN 6_CD Augmentin_NNP 708m_CD 10_CD Flixonase_NNP Flonase_NNP 578m_JJ 3_CD Seroxat_NNP Paxil_NNP 1,063_CD m_NN 7_CD Imigran_NNP Imitrex_NNP 682m_CD 11_CD Valtrex_NNP 571m_CD 4_CD Zofran_NNP 763m_CD 8_CD Lamictal_NNP 678m_CD 12_CD Combivir_NNP 571m_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD 17_CD THE_DT BOARD_NNP The_NNP Board_NNP of_IN Directors_NNS is_VBZ ultimately_RB accountable_JJ for_IN the_DT Groups_NNS activities_NNS ,_, strategy_NN and_CC financial_JJ performance_NN ._.
Sir_NNP Christopher_NNP Gent_NNP Dr_NNP Jean-Pierre_NNP Garnier_NNP John_NNP Coombe_NNP Lawrence_NNP Culp_NNP Sir_NNP Crispin_NNP Davis_NNP Sir_NNP Deryck_NNP Maughan_NNP Sir_NNP Ian_NNP Prosser_NNP Dr_NNP Ronaldo_NNP Schmitz_NNP Dr_NNP Lucy_NNP Shapiro_NNP Sir_NNP Robert_NNP Wilson_NNP Dr_NNP Tachi_NNP Yamada_NNP Sir_NNP Christopher_NNP Gent_NNP Aged_VBD 56_CD Sir_NNP Crispin_NNP Davis_NNP Aged_VBD 55_CD Dr_NNP Lucy_NNP Shapiro_NNP Aged_VBD 64_CD Chief_NNP Financial_NNP officer_NN Designate_NNP Appointed_VBN on_IN 1_CD June_NNP 2004_CD Appointed_VBN on_IN 1_CD July_NNP 2003_CD Appointed_VBN on_IN 23_CD May_NNP 2000_CD Julian_NNP Heslop_NNP Aged_VBD 51_CD Chairman_NNP ._.
Sir_NNP Christopher_NNP was_VBD the_DT Non-Executive_NNP Director_NNP ._.
Sir_NNP Crispin_NNP is_VBZ Non-Executive_JJ Director_NNP ._.
Dr_NNP Shapiro_NNP was_VBD Mr_NNP Heslop_NNP will_MD succeed_VB Mr_NNP Coombe_NNP Chief_NNP Executive_NNP officer_NN of_IN Vodafone_NNP Chief_NNP Executive_NNP of_IN Reed_NNP Elsevier_NNP PLC._NNP ._.
formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN as_IN Chief_NNP Financial_NNP officer_NN with_IN effect_NN plc_NN ,_, until_IN his_PRP$ retirement_NN in_IN July_NNP 2003_CD ._.
Prior_RB to_TO that_DT ,_, he_PRP was_VBD Chief_NNP Executive_NNP of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
She_PRP is_VBZ Ludwig_NNP from_IN 1_CD April_NNP 2005_CD when_WRB he_PRP will_MD also_RB He_PRP is_VBZ a_DT Non-Executive_JJ Director_NNP of_IN Aegis_NNP Group_NNP plc_NN ,_, which_WDT he_PRP joined_VBD from_IN Professor_NNP of_IN Cancer_NNP Research_NNP in_IN the_DT join_VB the_DT Board_NNP ._.
Mr_NNP Heslop_NNP joined_VBD Lehman_NNP Brothers_NNP Holdings_NNPS Inc_NNP ,_, a_DT Guinness_NNP plc_NN ,_, where_WRB he_PRP was_VBD a_DT member_NN Department_NNP of_IN Developmental_NNP Biology_NNP Glaxo_NNP Wellcome_NNP as_IN Financial_NNP Controller_NNP Director_NNP of_IN the_DT International_NNP Advisory_NNP of_IN the_DT main_JJ board_NN and_CC Group_NNP Managing_VBG and_CC Director_NNP of_IN the_DT Beckman_NNP Center_NNP in_IN April_NNP 1998_CD ._.
In_IN January_NNP 2001_CD ,_, Board_NNP of_IN Hakluyt_NNP &_CC Co_NNP ,_, and_CC is_VBZ a_DT Senior_JJ Director_NNP of_IN United_NNP Distillers_NNPS ._.
He_PRP spent_VBD for_IN Molecular_JJ and_CC Genetic_JJ Medicine_NN at_IN following_VBG the_DT merger_NN ,_, he_PRP was_VBD Adviser_NNP at_IN Bain_NNP &_CC Co._NNP his_PRP$ early_JJ career_NN with_IN Procter_NNP &_CC Gamble_NNP ._.
the_DT Stanford_NNP University_NNP School_NNP of_IN appointed_VBN Senior_JJ Vice_NNP President_NNP ,_, Medicine_NNP and_CC a_DT Non-Executive_JJ Director_NNP Operations_NNP Controller_NNP at_IN GSK_NNP ._.
Prior_RB to_TO Dr_NNP Jean-Pierre_NNP Garnier_NNP Aged_VBD 57_CD Sir_NNP Deryck_NNP Maughan_NNP Aged_VBD 57_CD of_IN Anacor_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
She_PRP joining_VBG Glaxo_NNP Wellcome_NNP ,_, he_PRP held_VBD senior_JJ Appointed_VBN on_IN 23_CD May_NNP 2000_CD Appointed_VBN on_IN 1_CD June_NNP 2004_CD holds_VBZ a_DT PhD_NNP in_IN molecular_JJ biology_NN from_IN finance_NN roles_NNS at_IN Grand_NNP Metropolitan_NNP Chief_NNP Executive_NNP officer_NN ._.
Dr_NNP Garnier_NNP was_VBD Non-Executive_JJ Director_NNP ._.
Sir_NNP Deryck_NNP was_VBD Albert_NNP Einstein_NNP College_NNP of_IN Medicine_NNP ._.
appointed_VBN an_DT Executive_NNP Director_NNP of_IN formerly_RB Chairman_NNP and_CC Chief_NNP SmithKline_NNP Beecham_NNP plc_NN in_IN 1992_CD ,_, and_CC Executive_NNP officer_NN of_IN Citigroup_NNP Sir_NNP Robert_NNP Wilson_NNP Aged_VBD 61_CD Other_JJ Directors_NNS became_VBD Chief_NNP Executive_NNP officer_NN in_IN April_NNP International_NNP and_CC of_IN Salomon_NNP Brothers_NNP Appointed_VBN on_IN 1_CD November_NNP 2003_CD Dr_NNP Michle_NNP Barzach_NNP ,_, Mr_NNP Donald_NNP 2000_CD ._.
He_PRP is_VBZ a_DT Non-Executive_NNP Director_NNP Inc._NNP ._.
He_PRP serves_VBZ on_IN the_DT Boards_NNPS of_IN Non-Executive_NNP Director_NNP ._.
Sir_NNP Robert_NNP is_VBZ McHenry_NNP and_CC Mr_NNP John_NNP McArthur_NNP ,_, all_DT of_IN United_NNP Technologies_NNPS Corporation_NNP Directors_NNS of_IN Carnegie_NNP Hall_NNP ,_, Lincoln_NNP Non-Executive_NNP Chairman_NNP of_IN BG_NNP Group_NNP Non-Executive_NNP Directors_NNS ,_, retired_VBN from_IN and_CC a_DT member_NN of_IN the_DT Board_NNP of_IN Trustees_NNPS Center_NNP and_CC NYU_NNP Medical_NNP Center_NNP ._.
He_PRP is_VBZ plc_NN and_CC the_DT Economist_NNP Group_NNP and_CC was_VBD the_DT Board_NNP following_VBG the_DT conclusion_NN of_IN of_IN the_DT Eisenhower_NNP Exchange_NNP Fellowships_NNP ._.
also_RB an_DT International_NNP Advisory_NNP Board_NNP previously_RB Executive_NNP Chairman_NNP of_IN Rio_NNP the_DT AGM_NNP on_IN 17_CD May_NNP 2004_CD and_CC Sir_NNP He_PRP holds_VBZ a_DT PhD_NNP in_IN pharmacology_NN from_IN member_NN of_IN British_JJ American_NNP Business_NNP Tinto_NNP plc._NN ._.
Christopher_NNP Hogg_NNP the_DT former_JJ the_DT University_NNP of_IN Louis_NNP Pasteur_NNP in_IN Inc._NNP and_CC a_DT Board_NNP member_NN of_IN the_DT Chairman_NNP and_CC Sir_NNP Peter_NNP Job_NNP ,_, both_DT Dr_NNP Tachi_NNP Yamada_NNP Aged_VBD 59_CD France_NNP and_CC an_DT MBA_NNP from_IN Stanford_NNP American_NNP Academy_NNP in_IN Berlin_NNP and_CC the_DT Non-Executive_JJ Directors_NNS ,_, retired_VBN from_IN Appointed_VBN on_IN 1_CD January_NNP 2004_CD University_NNP in_IN the_DT US_NNP ._.
He_PRP served_VBD as_IN the_DT Board_NNP on_IN 31_CD December_NNP 2004_CD ._.
Vice_NNP Chairman_NNP of_IN the_DT New_NNP York_NNP Stock_NNP John_NNP Coombe_NNP Aged_VBD 59_CD Dr_NNP Yamada_NNP was_VBD a_DT Non-Executive_NNP Exchange_NNP from_IN 1996_CD to_TO 2000_CD ._.
Details_NNS of_IN membership_NN of_IN the_DT Board_NNP Appointed_VBN 23_CD May_NNP 2000_CD ._.
Retiring_NNP Director_NNP ,_, and_CC subsequently_RB an_DT Executive_NNP Committees_NNS may_MD be_VB found_VBN in_IN the_DT on_IN 31_CD March_NNP 2005_CD ._.
Sir_NNP Ian_NNP Prosser_NNP Aged_VBD 61_CD Director_NNP ,_, of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
Mr_NNP Coombe_NNP Appointed_VBN on_IN 23_CD May_NNP 2000_CD Prior_RB to_TO joining_VBG SmithKline_NNP Beecham_NNP he_PRP was_VBD formerly_RB an_DT Executive_NNP Director_NNP of_IN Senior_NNP Independent_NNP Director_NNP ._.
Sir_NNP Ian_NNP was_VBD Chairman_NNP of_IN the_DT Department_NNP of_IN Glaxo_NNP Wellcome_NNP plc_NN where_WRB he_PRP was_VBD was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP Internal_NNP Medicine_NNP at_IN the_DT University_NNP of_IN responsible_JJ for_IN Finance_NNP and_CC Investor_NNP of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP was_VBD Michigan_NNP Medical_NNP School_NNP and_CC Relations_NNP ._.
He_PRP is_VBZ a_DT member_NN of_IN the_DT Chairman_NNP and_CC Chief_NNP Executive_NNP of_IN Bass_NNP Physician-in-Chief_NNP of_IN the_DT University_NNP of_IN Supervisory_NNP Board_NNP of_IN Siemens_NNP AG_NNP and_CC PLC_NNP latterly_RB Intercontinental_NNP Hotels_NNPS Michigan_NNP Medical_NNP Center_NNP ._.
He_PRP was_VBD a_DT the_DT Code_NNP Committee_NNP of_IN the_DT UK_NNP PLC_NNP and_CC Chairman_NNP of_IN the_DT World_NNP Travel_NNP member_NN of_IN the_DT Board_NNP of_IN Directors_NNS of_IN Takeover_NN Panel_NN and_CC was_VBD appointed_VBN a_DT &_CC Tourism_NNP Council_NNP ._.
He_PRP is_VBZ NondiaDexus_NNP ,_, Inc._NNP until_IN December_NNP 2004_CD Non-Executive_NNP Director_NNP of_IN HSBC_NNP Executive_NNP Deputy_NNP Chairman_NNP of_IN BP_NNP plc_NN and_CC is_VBZ a_DT Trustee_NN of_IN the_DT Rockefeller_NNP Holdings_NNPS plc_NN on_IN 1_CD March_NNP 2005_CD ._.
and_CC a_DT Non-Executive_JJ Director_NNP of_IN Sara_NNP Brothers_NNPS Fund_NNP ._.
He_PRP is_VBZ also_RB a_DT member_NN Lawrence_NNP Culp_NNP Aged_VBD 41_CD of_IN the_DT CBI_NNP Presidents_NNP Committee_NNP ._.
Corporate_JJ Appointed_VBN on_IN 1_CD July_NNP 2003_CD Audit_NNP Remuneration_NNP Nominations_NNPS Responsibility_NNP Non-Executive_NNP Director_NNP ._.
Mr_NNP Culp_NNP is_VBZ Dr_NNP Ronaldo_NNP Schmitz_NNP Aged_VBD 66_CD Sir_NNP Christopher_NNP Gent_NNP C_NNP C_NNP President_NNP and_CC Chief_NNP Executive_NNP officer_NN Appointed_VBN on_IN 23_CD May_NNP 2000_CD Mr_NNP L_NNP Culp_NNP M_NNP of_IN Danaher_NNP Corporation_NNP ._.
Dr_NNP Schmitz_NNP Sir_NNP Crispin_NNP Davis_NNP M_NNP joining_VBG Danaher_NNP ,_, he_PRP held_VBD positions_NNS in_IN was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP Sir_NNP Deryck_NNP Maughan_NNP M_NNP Accenture_NNP ,_, previously_RB Andersen_NNP of_IN Glaxo_NNP Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT NonSir_NNP Ian_NNP Prosser_NNP M_NNP M_NNP M_NNP Consulting_NNP ._.
Executive_NNP Director_NNP of_IN Legal_NNP &_CC General_NNP Dr_NNP R_NNP Schmitz_NNP C_NNP M_NNP Group_NNP plc_NN and_CC a_DT member_NN of_IN the_DT Boards_NNPS Dr_NNP L_NNP Shapiro_NNP M_NNP of_IN Directors_NNS of_IN Rohm_NNP and_CC Haas_NNP Sir_NNP Robert_NNP Wilson_NNP M_NNP C_NNP Company_NNP and_CC Cabot_NNP Corporation_NNP ._.
In_IN addition_NN ,_, each_DT Director_NNP is_VBZ a_DT member_NN of_IN the_DT Corporate_NNP Administration_NNP &_CC Transactions_NNS and_CC Financial_JJ Results_NNS Committees_NNS ._.
18_CD 18_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG THE_DT CORPORATE_JJ EXECUTIVE_NN TEAM_NN The_DT executive_NN management_NN of_IN the_DT Group_NNP is_VBZ through_IN the_DT Corporate_NNP Executive_NNP Team_NNP CET_NNP ,_, comprising_VBG the_DT Chief_NNP Executive_NNP officer_NN ,_, the_DT Chief_NNP Financial_NNP officer_NN and_CC other_JJ senior_JJ managers_NNS ._.
JP_NNP Garnier_NNP Rupert_NNP Bondy_NNP Ford_NNP Calhoun_NNP John_NNP Coombe_NNP Marc_NNP Dunoyer_NNP Russell_NNP Greig_NNP Dan_NNP Phelan_NNP David_NNP Pulman_NNP David_NNP Stout_NNP Chris_NNP Viehbacher_NNP Andrew_NNP Witty_NNP Tachi_NNP Yamada_NNP Jennie_NNP Younger_NNP Jack_NNP Ziegler_NNP JP_NNP Garnier_NNP Marc_NNP Dunoyer_NNP David_NNP Stout_NNP Jennie_NNP Younger_NNP Chief_NNP Executive_NNP officer_NN President_NNP President_NNP Senior_NNP Vice_NNP President_NNP As_IN Chief_NNP Executive_NNP officer_NN ,_, JP_NNP is_VBZ Pharmaceuticals_NNPS Japan_NNP Pharmaceutical_NNP Operations_NNP Corporate_NNP Communications_NNPS responsible_JJ for_IN the_DT management_NN of_IN Marc_NNP was_VBD appointed_VBN President_NNP ,_, David_NNP is_VBZ responsible_JJ for_IN the_DT global_JJ &_CC Community_NNP Partnerships_NNS the_DT Group_NNP ._.
He_PRP oversees_VBZ all_DT operational_JJ Pharmaceuticals_NNPS Japan_NNP in_IN March_NNP 2003_CD ._.
pharmaceuticals_NNS and_CC vaccines_NNS Jennie_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS aspects_NNS including_VBG establishing_VBG policies_NNS ,_, He_PRP joined_VBD the_DT Group_NNP in_IN 1999_CD and_CC was_VBD businesses_NNS ._.
He_PRP joined_VBD SmithKline_NNP internal_JJ and_CC external_JJ communications_NNS ,_, objectives_NNS and_CC initiatives_NNS ,_, and_CC he_PRP Senior_JJ Vice_NNP President_NNP and_CC Regional_NNP Beecham_NNP in_IN 1996_CD as_IN head_NN of_IN its_PRP$ US_NNP its_PRP$ image_NN and_CC partnerships_NNS with_IN global_JJ directs_VBZ long-term_JJ strategy_NN ._.
He_PRP was_VBD Director_NNP ,_, Japan_NNP until_IN his_PRP$ current_JJ Sales_NNS and_CC Marketing_NNP ,_, and_CC was_VBD communities_NNS ._.
She_PRP joined_VBD Glaxo_NNP formerly_RB Chief_NNP Executive_NNP officer_NN of_IN appointment_NN ._.
President_NNP US_NNP Pharmaceuticals_NNP until_IN his_PRP$ Wellcome_NNP in_IN 1996_CD as_IN Director_NNP of_IN SmithKline_NNP Beecham_NNP ,_, having_VBG joined_VBN current_JJ appointment_NN in_IN January_NNP 2003_CD ._.
Investor_NNP Relations_NNPS and_CC was_VBD appointed_VBN Russell_NNP Greig_NNP the_DT Group_NNP in_IN 1990_CD ._.
to_TO her_PRP$ current_JJ position_NN in_IN 2001_CD ._.
In_IN President_NNP Chris_NNP Viehbacher_NNP 2004_CD ,_, she_PRP won_VBD the_DT European_JJ Women_NNP Rupert_NNP Bondy_NNP Pharmaceuticals_NNP International_NNP President_NNP of_IN Achievement_NNP Award_NNP for_IN Business_NNP ._.
Senior_JJ Vice_NNP President_NNP and_CC General_NNP Russell_NNP leads_VBZ the_DT pharmaceutical_JJ US_NNP Pharmaceuticals_NNP Counsel_NNP operations_NNS outside_IN the_DT US_NNP and_CC most_JJS Chris_NNP has_VBZ been_VBN responsible_JJ for_IN US_NNP Jack_NNP Ziegler_NNP Rupert_NNP is_VBZ responsible_JJ for_IN legal_JJ matters_NNS of_IN Europe_NNP ,_, covering_VBG more_JJR than_IN 100_CD Pharmaceuticals_NNS since_IN January_NNP 2003_CD ._.
President_NNP across_IN the_DT Group_NNP ,_, together_RB with_IN countries_NNS ._.
He_PRP joined_VBD the_DT Group_NNP in_IN He_PRP joined_VBD Wellcome_NNP in_IN 1988_CD and_CC Consumer_NNP Healthcare_NNP environmental_JJ ,_, health_NN and_CC safety_NN 1980_CD and_CC was_VBD Senior_JJ Vice_NNP President_NNP ,_, became_VBD Director_NNP ,_, Continental_NNP Europe_NNP ,_, Jack_NNP is_VBZ head_NN of_IN the_DT global_JJ Consumer_NN issues_NNS ,_, insurance_NN and_CC security_NN ._.
He_PRP was_VBD Worldwide_NNP Business_NNP Development_NNP for_IN at_IN Glaxo_NNP Wellcome_NNP in_IN 1999_CD ._.
He_PRP was_VBD Healthcare_NNP business_NN ,_, which_WDT produces_VBZ a_DT lawyer_NN in_IN private_JJ practice_NN before_IN R&D_NNP prior_RB to_TO his_PRP$ current_JJ appointment_NN responsible_JJ for_IN GSKs_NNP European_NNP oral_JJ healthcare_NN ,_, over-the-counter_JJ joining_VBG SmithKline_NNP Beecham_NNP in_IN 1995_CD ._.
in_IN March_NNP 2003_CD ._.
Pharmaceuticals_NNS business_NN before_IN his_PRP$ medicines_NNS and_CC nutritional_JJ healthcare_NN current_JJ appointment_NN ._.
He_PRP joined_VBD SmithKline_NNP Ford_NNP Calhoun_NNP Dan_NNP Phelan_NNP Beecham_NNP in_IN 1991_CD and_CC in_IN 1998_CD was_VBD Chief_NNP Information_NNP officer_NN Senior_JJ Vice_NNP President_NNP Andrew_NNP Witty_NNP appointed_VBD President_NNP of_IN the_DT Consumer_NNP Ford_NNP is_VBZ responsible_JJ for_IN information_NN Human_NNP Resources_NNP President_NNP Healthcare_NNP business_NN ._.
technology_NN ,_, a_DT global_JJ function_NN that_WDT Dan_NNP is_VBZ responsible_JJ for_IN benets_NNS ,_, Pharmaceuticals_NNP Europe_NNP enables_VBZ key_JJ business_NN processes_VBZ across_IN compensation_NN ,_, recruitment_NN ,_, Andrew_NNP has_VBZ been_VBN responsible_JJ for_IN the_DT Julian_NNP Heslop_NNP all_DT parts_NNS of_IN the_DT Group_NNP ._.
With_IN doctoral_JJ organization_NN development_NN ,_, leadership_NN Groups_NNS pharmaceuticals_NNS operations_NNS in_IN Chief_NNP Financial_NNP officer_NN Designate_NNP and_CC post-doctoral_JJ training_NN in_IN development_NN and_CC succession_NN planning_NN ,_, Europe_NNP since_IN January_NNP 2003_CD ._.
He_PRP joined_VBD Julian_NNP Heslop_NNP will_MD succeed_VB John_NNP microbiology_NN ,_, genetics_NNS ,_, human_JJ resource_NN information_NN systems_NNS Glaxo_NNP in_IN 1985_CD and_CC at_IN GSK_NNP was_VBD Senior_JJ Coombe_NNP as_IN Chief_NNP Financial_NNP officer_NN with_IN biomathematics_NNS and_CC computer_NN and_CC employee_NN health_NN management_NN ._.
Vice_NNP President_NNP ,_, Asia_NNP Pacic_NNP ,_, until_IN his_PRP$ effect_NN from_IN 1_CD April_NNP 2005_CD when_WRB he_PRP will_MD science_NN ,_, he_PRP joined_VBD Smith_NNP Kline_NNP &_CC He_PRP was_VBD a_DT lawyer_NN in_IN private_JJ practice_NN ,_, current_JJ appointment_NN ._.
Julian_NNP joined_VBD Glaxo_NNP French_NNP in_IN 1984_CD ._.
before_IN joining_VBG Smith_NNP Kline_NNP &_CC French_NNP in_IN Wellcome_NNP as_IN Financial_NNP Controller_NNP in_IN Tachi_NNP Yamada_NNP 1981_CD and_CC in_IN 1994_CD was_VBD appointed_VBN April_NNP 1998_CD ._.
Following_VBG completion_NN of_IN John_NNP Coombe_NNP Chairman_NNP Senior_NNP Vice_NNP President_NNP and_CC Director_NNP ,_, the_DT merger_NN he_PRP was_VBD appointed_VBN Senior_JJ Chief_NNP Financial_NNP officer_NN Research_NNP &_CC Development_NNP Human_NNP Resources_NNPS ,_, SmithKline_NNP Vice_NNP President_NNP ,_, Operations_NNP Controller_NNP ._.
retiring_VBG on_IN 31_CD March_NNP 2005_CD Tachi_NNP leads_VBZ the_DT Groups_NNS complex_JJ Beecham_NNP ._.
As_IN head_NN of_IN the_DT finance_NN function_NN ,_, business_NN of_IN drug_NN discovery_NN and_CC Other_JJ members_NNS John_NNP is_VBZ responsible_JJ for_IN activities_NNS such_JJ David_NNP Pulman_NNP development_NN ,_, creating_VBG new_JJ medicines_NNS Robert_NNP Ingram_NNP continues_VBZ to_TO work_VB partas_NNS financial_JJ reporting_NN and_CC control_NN ,_, President_NNP through_IN research_NN ._.
He_PRP joined_VBD time_NN as_IN Vice_NNP Chairman_NNP of_IN tax_NN and_CC treasury_NN ,_, investor_NN relations_NNS ,_, Global_JJ Manufacturing_NNP &_CC Supply_NNP SmithKline_NNP Beecham_NNP in_IN 1994_CD as_IN a_DT NonPharmaceuticals_NNP ,_, acting_VBG as_IN a_DT special_JJ finance_NN systems_NNS ,_, internal_JJ audit_NN and_CC David_NNP is_VBZ responsible_JJ for_IN the_DT Global_NNP Executive_NNP member_NN of_IN the_DT Board_NNP and_CC advisor_NN to_TO the_DT Group_NNP ,_, and_CC attends_VBZ CET_NNP real_JJ estate_NN ._.
He_PRP joined_VBD Glaxo_NNP in_IN 1986_CD Manufacturing_NNP and_CC Supply_NNP became_VBD Chairman_NNP ,_, R&D_NNP ,_, meetings_NNS in_IN that_DT capacity_NN ._.
as_IN Group_NNP Financial_NNP Controller_NNP and_CC was_VBD organization_NN and_CC Global_JJ Procurement_NN ._.
He_PRP was_VBD appointed_VBN Group_NNP Finance_NNP Director_NNP He_PRP joined_VBD Glaxo_NNP in_IN 1978_CD and_CC was_VBD appointed_VBN to_TO the_DT Board_NNP of_IN Directors_NNS on_IN in_IN 1992_CD ._.
responsible_JJ for_IN the_DT North_JJ American_JJ 1_CD January_NNP 2004_CD ._.
supply_NN network_NN ,_, manufacturing_VBG strategy_NN and_CC logistics_NNS until_IN his_PRP$ current_JJ appointment_NN in_IN 2002_CD ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 19_CD 19_CD SUMMARY_NN REMUNERATION_NNP REPORT_NNP for_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD Overall_JJ ,_, the_DT policy_NN is_VBZ intended_VBN to_TO provide_VB median_JJ total_JJ remuneration_NN for_IN Introduction_NNP median_NN performance_NN ._.
Poor_NNP performance_NN will_MD result_VB in_IN total_JJ remuneration_NN signicantly_RB below_IN the_DT pay_NN comparator_NN group_NN median_NN ,_, with_IN the_DT opportunity_NN The_DT Summary_NNP Remuneration_NNP Report_NNP sets_VBZ out_RP the_DT annual_JJ remuneration_NN to_TO earn_VB upper_JJ quartile_JJ total_JJ remuneration_NN for_IN exceptional_JJ performance_NN ._.
of_IN the_DT Board_NNP earned_VBD in_IN 2004_CD ,_, together_RB with_IN any_DT gains_NNS under_IN long-term_JJ incentive_NN arrangements_NNS ._.
It_PRP also_RB describes_VBZ the_DT background_NN and_CC outlines_VBZ the_DT This_DT strong_JJ alignment_NN with_IN performance_NN is_VBZ demonstrably_RB in_IN the_DT interests_NNS of_IN Groups_NNS remuneration_VBP policy_NN ,_, together_RB with_IN the_DT performance_NN graph_NN required_VBN shareholders_NNS and_CC provides_VBZ the_DT Executives_NNS with_IN unambiguous_JJ signals_NNS about_IN by_IN the_DT Directors_NNS Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD the_DT Regulations_NNPS ._.
the_DT importance_NN of_IN delivering_VBG success_NN to_TO the_DT Companys_NNPS shareholders_NNS ._.
The_DT Remuneration_NNP Committee_NNP the_DT Committee_NNP is_VBZ responsible_JJ for_IN making_VBG COMMITMENT_NNP recommendations_NNS to_TO the_DT Board_NNP on_IN the_DT Companys_NNP remuneration_NN policy_NN and_CC ,_, The_DT Committee_NNP will_MD apply_VB this_DT policy_NN on_IN a_DT consistent_JJ and_CC transparent_JJ basis_NN ._.
within_IN the_DT terms_NNS of_IN the_DT agreed_JJ policy_NN ,_, determining_VBG the_DT total_JJ individual_JJ Any_DT significant_JJ change_NN will_MD be_VB discussed_VBN with_IN shareholders_NNS in_IN advance_NN of_IN remuneration_NN packages_NNS of_IN the_DT Executive_NNP Directors_NNS and_CC members_NNS of_IN the_DT implementation_NN ._.
The_DT members_NNS of_IN the_DT Committee_NNP are_VBP set_VBN out_RP on_IN page_NN 18_CD ._.
PAY_NN AND_CC PERFORMANCE_NN COMPARATORS_NNS The_DT Committee_NNP has_VBZ developed_VBN the_DT remuneration_NN policy_NN to_TO align_VB executive_JJ The_DT following_JJ table_NN sets_VBZ out_RP the_DT companies_NNS used_VBN for_IN pay_NN and_CC performance_NN remuneration_NN with_IN the_DT interests_NNS of_IN shareholders_NNS whilst_VBP meeting_VBG the_DT comparison_NN :_: imperative_NN of_IN recruiting_NN and_CC retaining_VBG the_DT executive_NN talent_NN essential_JJ to_TO the_DT Market_NN leadership_NN of_IN the_DT Company_NN ._.
Capitalisation_NNP 31.12.04_CD Company_NN Country_NN m_NN The_DT remuneration_NN policy_NN was_VBD nalised_VBN after_IN undertaking_VBG an_DT extensive_JJ consultation_NN process_NN with_IN shareholders_NNS and_CC institutional_JJ bodies_NNS during_IN the_DT Abbott_NNP Laboratories_NNP US_NNP 37,840_CD course_NN of_IN 2003_CD and_CC 2004_CD ._.
AstraZeneca_NNP UK_NNP 31,075_CD Bristol-Myers_NNP Squibb_NNP US_NNP 25,962_CD The_DT remuneration_NN policy_NN is_VBZ designed_VBN to_TO establish_VB a_DT framework_NN for_IN Eli_NNP Lilly_NNP US_NNP 33,448_CD remuneration_NN which_WDT is_VBZ consistent_JJ with_IN the_DT Companys_NNP scale_NN and_CC scope_NN of_IN GlaxoSmithKline_NNP UK_NNP 71,704_CD operations_NNS ,_, meets_VBZ the_DT recruitment_NN needs_NNS of_IN the_DT business_NN and_CC is_VBZ closely_RB Johnson_NNP &_CC Johnson_NNP US_NNP 98,028_CD aligned_VBN with_IN shareholder_NN guidelines_NNS ._.
Merck_NNP US_NNP 37,123_CD Novartis_NNP Switzerland_NNP 70,077_CD Deloitte_NNP &_CC Touche_NNP LLP_NNP have_VBP been_VBN appointed_VBN by_IN the_DT Committee_NNP to_TO provide_VB it_PRP Pzer_NNP US_NNP 105,473_CD with_IN independent_JJ advice_NN on_IN executive_NN remuneration_NN ._.
Roche_NNP Holdings_NNP Switzerland_NNP 42,122_CD Sano-Aventis_NNP France_NNP 57,954_CD Schering-Plough_NNP US_NNP 16,016_CD Remuneration_NNP policy_NN Takeda_NNP Pharmaceutical_NNP Company_NNP Japan_NNP 23,323_CD Wyeth_NNP US_NNP 29,596_CD PRINCIPLES_NNP The_NNP Committee_NNP has_VBZ established_VBN four_CD core_NN principles_NNS which_WDT underpin_VBP the_DT The_DT merger_NN of_IN Aventis_NNP and_CC Sano-Synthelabo_NNP during_IN 2004_CD reduced_VBD the_DT new_JJ remuneration_NN policy_NN for_IN GSK_NNP ._.
These_DT are_VBP :_: size_NN of_IN the_DT comparator_NN group_NN to_TO 13_CD companies_NNS and_CC GSK_NNP ._.
The_DT Committee_NNP subsequently_RB determined_VBD that_IN for_IN a_DT number_NN of_IN reasons_NNS ,_, including_VBG focus_NN of_IN securing_VBG outstanding_JJ executive_NN talent_NN :_: operation_NN and_CC market_NN capitalization_NN ,_, there_EX was_VBD no_DT other_JJ suitable_JJ company_NN pay_NN for_IN performance_NN and_CC only_RB for_IN performance_NN :_: to_TO add_VB to_TO the_DT group_NN ._.
robust_JJ and_CC transparent_JJ governance_NN structures_NNS :_: and_CC a_DT commitment_NN to_TO be_VB a_DT leader_NN of_IN good_JJ remuneration_NN practice_NN in_IN the_DT pharmaceutical_JJ industry_NN ._.
In_IN formulating_VBG the_DT policy_NN ,_, the_DT Committee_NNP decided_VBD that_IN :_: the_DT remuneration_NN structure_NN must_MD support_VB the_DT business_NN in_IN a_DT very_RB competitive_JJ market_NN place_NN :_: UK_NNP shareholder_NN guidelines_NNS will_MD be_VB followed_VBN to_TO the_DT maximum_NN extent_NN consistent_JJ with_IN the_DT needs_NNS of_IN the_DT business_NN and_CC the_DT Company_NN would_MD maintain_VB a_DT regular_JJ dialogue_NN with_IN shareholders_NNS :_: global_JJ pharmaceutical_JJ companies_NNS are_VBP the_DT primary_JJ pay_NN comparator_NN group_NN :_: performance_NN conditions_NNS would_MD be_VB based_VBN on_IN the_DT measurable_JJ delivery_NN of_IN strong_JJ financial_JJ performance_NN and_CC the_DT delivery_NN of_IN superior_JJ returns_NNS to_TO shareholders_NNS as_IN compared_VBN with_IN other_JJ pharmaceutical_JJ companies_NNS :_: a_DT high_JJ proportion_NN of_IN the_DT total_JJ remuneration_NN opportunity_NN will_MD be_VB based_VBN on_IN performance-related_JJ remuneration_NN ,_, which_WDT will_MD be_VB delivered_VBN over_IN the_DT medium-term_JJ to_TO long-term_JJ :_: and_CC no_DT ex-gratia_NN payments_NNS will_MD be_VB made_VBN ._.
20_CD 20_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG SUMMARY_NNP REMUNERATION_NNP REPORT_NNP for_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD GSKS_NNP EXECUTIVE_NNP REMUNERATION_NNP CONSISTS_NNPS OF_IN THE_DT FOLLOWING_VBG Performance_NNP is_VBZ measured_VBN over_IN the_DT three_CD financial_JJ years_NNS following_VBG the_DT COMPONENTS_NNS :_: grant_NN of_IN an_DT option_NN ._.
The_DT Committee_NNP has_VBZ decided_VBN for_IN the_DT 2004_CD grant_NN that_IN there_EX will_MD be_VB no_DT performance_NN retesting_NN ,_, so_RB if_IN the_DT performance_NN condition_NN is_VBZ BASE_NNP SALARY_NNP not_RB met_VBD after_IN the_DT three-year_JJ period_NN ,_, the_DT option_NN will_MD lapse_NN ._.
Base_NNP salaries_NNS will_MD be_VB set_VBN by_IN reference_NN to_TO the_DT median_NN for_IN the_DT relevant_JJ market_NN ._.
For_IN Executives_NNS this_DT is_VBZ the_DT pharmaceutical_JJ pay_NN comparator_NN group_NN ._.
Base_NNP salary_NN The_DT performance_NN criteria_NNS relating_VBG to_TO performance_NN shares_NNS and_CC share_NN options_NNS is_VBZ the_DT only_JJ element_NN of_IN remuneration_NN that_WDT is_VBZ xed_VBN ._.
awarded_VBN and_CC granted_VBN prior_RB to_TO 2004_CD are_VBP given_VBN in_IN the_DT Annual_JJ Report_NNP 2004_CD ._.
ANNUAL_JJ BONUS_NN PENSIONS_NNS All_DT bonuses_NNS are_VBP determined_VBN on_IN the_DT basis_NN of_IN a_DT formal_JJ review_NN of_IN annual_JJ The_DT Executives_NNS participate_VB in_IN GSK_NNP senior_JJ executive_NN pension_NN plans_NNS ._.
The_DT performance_NN against_IN stretching_VBG financial_JJ targets_NNS based_VBN on_IN profit_NN before_IN pension_NN arrangements_NNS are_VBP structured_VBN in_IN accordance_NN with_IN the_DT plans_NNS operated_VBD interest_NN and_CC tax_NN and_CC are_VBP subject_JJ to_TO detailed_JJ assessment_NN of_IN individual_JJ ,_, for_IN Executives_NNS in_IN the_DT country_NN in_IN which_WDT the_DT Executives_NNS are_VBP likely_JJ to_TO retire_VB ._.
business_NN unit_NN and_CC group_NN achievements_NNS against_IN objectives_NNS ._.
Benets_NNS are_VBP normally_RB payable_JJ at_IN age_NN 60_CD ,_, although_IN it_PRP has_VBZ been_VBN agreed_VBN that_IN Dr_NNP Yamada_NNP will_MD retire_VB at_IN age_NN 62_CD ._.
In_IN setting_VBG the_DT bonus_NN awards_NNS for_IN 2004_CD ,_, the_DT Committee_NNP took_VBD into_IN account_NN the_DT achievement_NN of_IN management_NN in_IN maintaining_VBG growth_NN on_IN a_DT CER_NNP basis_NN ,_, whilst_NN absorbing_VBG 1.5_CD billion_CD of_IN lost_VBN sales_NNS to_TO generics_NNS ._.
Executive_NNP Director_NNP terms_NNS and_CC LONG-TERM_JJ INCENTIVES_NNS conditions_NNS The_DT remuneration_NN policy_NN provides_VBZ that_IN annual_JJ long-term_JJ incentive_NN awards_NNS will_MD normally_RB be_VB made_VBN up_IN of_IN a_DT performance_NN share_NN award_NN and_CC a_DT share_NN option_NN The_DT policy_NN regarding_VBG the_DT Executive_NNP Directors_NNS contracts_NNS was_VBD the_DT subject_JJ award_NN ._.
The_DT remuneration_NN policy_NN places_NNS greater_JJR emphasis_NN on_IN the_DT use_NN of_IN of_IN extensive_JJ review_NN and_CC change_NN during_IN 2003_CD ._.
This_DT resulted_VBD in_IN a_DT new_JJ performance_NN shares_NNS rather_RB than_IN share_NN options_NNS ._.
framework_NN for_IN contracts_NNS for_IN Executive_NNP Directors_NNS appointed_VBN in_IN the_DT future_NN ._.
The_DT Committee_NNP has_VBZ considered_VBN which_WDT performance_NN conditions_NNS should_MD be_VB Dr_NNP Garnier_NNP ,_, Mr_NNP Coombe_NNP and_CC Dr_NNP Yamada_NNP agreed_VBD to_TO changes_NNS in_IN their_PRP$ applied_VBN to_TO the_DT long-term_JJ incentives_NNS ._.
The_DT Committee_NNP concluded_VBD that_IN it_PRP was_VBD contractual_JJ terms_NNS without_IN compensation_NN to_TO bring_VB their_PRP$ contractual_JJ appropriate_JJ to_TO measure_VB performance_NN using_VBG a_DT combination_NN of_IN absolute_JJ terms_NNS broadly_RB in_IN line_NN with_IN the_DT new_JJ contractual_JJ framework_NN ,_, including_VBG the_DT financial_JJ results_NNS based_VBN on_IN earnings_NNS per_IN share_NN -_: EPS_NNP and_CC the_DT delivery_NN of_IN reduction_NN of_IN contractual_JJ notice_NN period_NN from_IN 24_CD to_TO 12_CD calendar_NN months_NNS ._.
superior_JJ value_NN to_TO shareholders_NNS based_VBN on_IN Total_JJ Shareholder_NN Return_NN -_: TSR_NNP ._.
However_RB ,_, to_TO honor_VB certain_JJ aspects_NNS of_IN their_PRP$ old_JJ contractual_JJ terms_NNS ,_, there_EX are_VBP a_DT number_NN of_IN individual_JJ features_NNS which_WDT will_MD be_VB retained_VBN ._.
In_IN the_DT event_NN For_IN the_DT Executives_NNS ,_, the_DT level_NN of_IN performance_NN shares_NNS vesting_VBG is_VBZ based_VBN on_IN of_IN early_JJ termination_NN by_IN the_DT Company_NN ,_, Dr_NNP Garnier_NNP and_CC Dr_NNP Yamada_NNP would_MD the_DT Companys_NNPS TSR_NNP relative_JJ to_TO the_DT performance_NN comparator_NN group_NN over_IN receive_VB a_DT cash_NN sum_NN equivalent_NN to_TO the_DT total_NN of_IN their_PRP$ annual_JJ salary_NN ,_, on_IN target_NN a_DT three-year_JJ measurement_NN period_NN ._.
In_IN respect_NN of_IN the_DT awards_NNS granted_VBN in_IN bonus_NN and_CC pension_NN contributions_NNS for_IN the_DT 12_CD months_NNS notice_VBP period_NN ._.
2004_CD ,_, if_IN GSK_NNP is_VBZ ranked_VBN at_IN position_NN 7_CD the_DT mid-point_NN of_IN the_DT performance_NN Mr_NNP Coombe_NNP will_MD retire_VB from_IN the_DT company_NN on_IN 31_CD March_NNP 2005_CD ._.
comparator_NN group_NN ,_, 35_CD %_NN of_IN the_DT shares_NNS will_MD vest_NN and_CC if_IN it_PRP is_VBZ below_IN that_DT position_NN then_RB none_NN of_IN the_DT shares_NNS will_MD vest_NN ._.
Only_RB if_IN GSK_NNP is_VBZ one_CD of_IN the_DT top_JJ two_CD companies_NNS will_MD all_DT of_IN the_DT shares_NNS vest_NN ._.
When_WRB determining_VBG vesting_NN levels_NNS ,_, the_DT TSR_NNP PERFORMANCE_NN GRAPH_NNP Committee_NNP will_MD have_VB regard_NN for_IN the_DT Companys_NNP underlying_VBG financial_JJ The_DT graph_NN below_IN sets_NNS out_IN the_DT performance_NN of_IN the_DT Company_NN relative_JJ performance_NN ._.
to_TO the_DT FTSE_NNP 100_CD index_NN of_IN which_WDT the_DT Company_NN is_VBZ a_DT constituent_NN and_CC ,_, for_IN information_NN ,_, to_TO the_DT median_NN of_IN the_DT performance_NN comparator_NN group_NN since_IN The_DT share_NN options_NNS granted_VBN in_IN 2004_CD to_TO the_DT Executives_NNS are_VBP linked_VBN to_TO the_DT the_DT merger_NN on_IN 27_CD December_NNP 2000_CD ._.
The_DT graph_NN has_VBZ been_VBN prepared_VBN in_IN achievement_NN of_IN compound_JJ annual_JJ EPS_NNP growth_NN in_IN excess_NN of_IN the_DT Retail_NNP accordance_NN with_IN the_DT Regulations_NNPS and_CC is_VBZ not_RB an_DT indication_NN of_IN the_DT likely_JJ Prices_NNS Index_NNP RPI_NNP over_IN the_DT performance_NN period_NN ,_, which_WDT is_VBZ the_DT three_CD years_NNS vesting_VBG of_IN awards_NNS granted_VBN under_IN any_DT of_IN the_DT Companys_NNP incentive_NN plans_NNS ._.
following_VBG the_DT grant_NN of_IN an_DT option_NN ._.
When_WRB setting_VBG EPS_NNP targets_NNS ,_, the_DT Committee_NNP considers_VBZ the_DT Companys_NNP internal_JJ 100_CD projections_NNS and_CC analysts_NNS forecasts_NNS for_IN GSKs_NNP EPS_NNP performance_NN ,_, as_RB well_RB as_IN analysts_NNS forecasts_NNS for_IN the_DT pharmaceutical_JJ industry_NN ._.
90_CD For_IN the_DT 2004_CD grant_NN ,_, vesting_VBG increases_NNS on_IN a_DT straight-line_JJ basis_NN for_IN EPS_NNP 80_CD performance_NN between_IN the_DT hurdles_NNS set_VBN out_RP in_IN the_DT table_NN below_IN ._.
70_CD Annualised_NNP Percentage_NN of_IN growth_NN in_IN EPS_NNP award_NN vesting_VBG 60_CD 31_CD 12_CD 00_CD 31_CD 12_CD 01_CD 31_CD 12_CD 02_CD 31_CD 12_CD 03_CD 31_CD 12_CD 04_CD RPI_NNP 5_CD %_NN 100_CD %_NN GlaxoSmithKline_NNP Total_NNP Return_NN FTSE_NNP 100_CD Total_JJ Return_NN Index_NNP RPI_NNP 4_CD %_NN 75_CD %_NN GlaxoSmithKline_NNP Pharma_NNP Peers_NNP Return_NN Index_NNP RPI_NNP 3_CD %_NN 50_CD %_NN RPI_NNP 3_CD %_NN 0_CD %_NN This_DT performance_NN condition_NN is_VBZ substantially_RB consistent_JJ with_IN UK_NNP shareholder_NN guidelines_NNS and_CC expectations_NNS and_CC is_VBZ demanding_VBG when_WRB compared_VBN with_IN those_DT operated_VBN by_IN other_JJ global_JJ pharmaceutical_JJ companies_NNS ._.
This_DT is_VBZ consistent_JJ with_IN the_DT policy_NN of_IN providing_VBG pay_NN for_IN performance_NN and_CC only_RB for_IN performance_NN ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 21_CD 21_CD SUMMARY_NN REMUNERATION_NNP REPORT_NNP for_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD Annual_JJ remuneration_NN 2004_CD 2003_CD Total_JJ Total_JJ Fees_NNS and_CC Other_JJ Annual_JJ annual_JJ annual_JJ salary_NN benets_NNS bonus_NN remuneration_NN remuneration_NN Directors_NNS of_IN GSK_NNP 000 000 000 000_CD 000_CD Executive_NNP Directors_NNS Dr_VBP JP_NNP Garnier_NNP $_$ 1,523_CD $_$ 786_CD $_$ 2,250_CD $_$ 4,559_CD $_$ 4,570_CD Dr_NNP T_NNP Yamada_NNP $_$ 725_CD $_$ 577_CD $_$ 1,001_CD $_$ 2,303_CD Mr_NNP J_NNP Coombe_NNP 506_CD 9_CD 515_CD 1,237_CD Total_NNP Executive_NNP Directors_NNS 1,734_CD 754_CD 1,777_CD 4,265_CD 4,024_CD Current_JJ Non-Executive_JJ Directors_NNS Mr_NNP L_NNP Culp_NNP $_$ 97_CD $_$ 97_CD $_$ 48_CD Sir_NNP Deryck_NNP Maughan_NNP $_$ 57_CD $_$ 57_CD Dr_NN L_NNP Shapiro_NNP $_$ 182_CD $_$ 182_CD $_$ 179_CD Sir_NNP Christopher_NNP Gent_NNP 175_CD 175_CD Sir_NNP Crispin_NNP Davis_NNP 57_CD 57_CD 29_CD Sir_NNP Ian_NNP Prosser_NNP 65_CD 65_CD 66_CD Dr_NN R_NN Schmitz_NNP 72_CD 72_CD 67_CD Sir_NNP Robert_NNP Wilson_NNP 66_CD 66_CD 10_CD Total_JJ Current_JJ Non-Executive_JJ Directors_NNS 618 618 310_CD Former_JJ Non-Executive_JJ Directors_NNS Mr_NNP J_NNP McArthur_NNP $_$ 42_CD $_$ 18_CD $_$ 60_CD $_$ 102_CD Mr_NNP D_NNP McHenry_NNP $_$ 42_CD $_$ 42_CD $_$ 106_CD Mr_NNP P_NNP Allaire_NNP 28_CD Dr_NNP M_NNP Barzach_NNP 78_CD 78_CD 107_CD Sir_NNP Christopher_NNP Hogg_NNP 369_CD 1_CD 370_CD 374_CD Sir_NNP Roger_NNP Hurn_NNP 50_CD Sir_NNP Peter_NNP Job_NNP 57_CD 57_CD 57_CD Sir_NNP Richard_NNP Sykes_NNPS 1_CD 1_CD 958_CD Total_JJ Former_JJ Non-Executive_JJ Directors_NNS 550_CD 12_CD 562_CD 1,701_CD Total_JJ Non-Executive_JJ Directors_NNS 1,168_CD 12_CD 1,180_CD 2,011_CD Total_JJ remuneration_NN 2,902_CD 766_CD 1,777_CD 5,445_CD 6,035_CD Remuneration_NNP for_IN Directors_NNS on_IN the_DT US_NNP payroll_NN is_VBZ reported_VBN in_IN Dollars_NNP ._.
Amounts_NNS have_VBP been_VBN converted_VBN to_TO Sterling_NNP at_IN the_DT average_JJ exchange_NN rates_NNS for_IN the_DT year_NN ._.
Following_VBG the_DT merger_NN ,_, those_DT participants_NNS in_IN the_DT legacy_NN schemes_NNS who_WP elected_VBD to_TO exchange_VB their_PRP$ legacy_NN options_NNS for_IN options_NNS over_IN GSK_NNP shares_NNS were_VBD granted_VBN an_DT additional_JJ cash_NN benefit_NN equal_JJ to_TO 10_CD %_NN of_IN the_DT grant_NN price_NN of_IN the_DT original_JJ option_NN ._.
This_DT additional_JJ benefit_NN is_VBZ known_VBN as_IN the_DT Exchange_NNP Offer_NN Incentive_NNP EOI_NNP and_CC is_VBZ only_RB payable_JJ when_WRB the_DT new_JJ option_NN is_VBZ exercised_VBN or_CC lapses_NNS above_IN market_NN value_NN ._.
To_TO qualify_VB for_IN this_DT additional_JJ cash_NN benefit_NN ,_, participants_NNS would_MD have_VB had_VBN to_TO retain_VB these_DT options_NNS until_IN at_IN least_JJS the_DT second_JJ anniversary_NN of_IN the_DT effective_JJ date_NN of_IN the_DT merger_NN ._.
During_IN the_DT year_NN Dr_NNP Garnier_NNP received_VBD $_$ 335,730_CD 2003_CD $_$ 299,311_CD relating_VBG to_TO options_NNS exercised_VBN under_IN the_DT EOI_NNP ._.
Those_DT amounts_NNS are_VBP included_VBN in_IN other_JJ benets_NNS in_IN the_DT table_NN above_IN ._.
In_IN addition_NN to_TO the_DT remuneration_NN received_VBD as_IN a_DT former_JJ Director_NNP ,_, as_IN set_VBN out_RP above_IN ,_, Sir_NNP Richard_NNP Sykes_NNP received_VBD 20,417_CD 2003_CD 49,000_CD for_IN the_DT period_NN 1_CD January_NNP to_TO 30_CD May_NNP 2004_CD relating_VBG to_TO his_PRP$ appointment_NN as_IN Senior_JJ Advisor_NNP ._.
Non-Executive_JJ Directors_NNS are_VBP required_VBN to_TO receive_VB a_DT significant_JJ part_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS or_CC ADSs_NNS and_CC may_MD also_RB elect_VB to_TO invest_VB part_NN or_CC all_DT of_IN the_DT balance_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS or_CC ADSs_NNS ._.
The_DT value_NN of_IN these_DT shares_NNS and_CC ADSs_NNS at_IN the_DT dates_NNS of_IN award_NN are_VBP included_VBN in_IN fees_NNS and_CC salary_NN above_IN ._.
These_DT shares_NNS and_CC ADSs_NNS are_VBP not_RB paid_VBN out_RP until_IN the_DT Director_NNP leaves_VBZ the_DT Board_NNP ._.
Dr_NNP Barzach_NNP ,_, Mr_NNP McHenry_NNP and_CC Mr_NNP McArthur_NNP left_VBD the_DT Board_NNP on_IN 17_CD May_NNP 2004_CD ._.
Sir_NNP Christopher_NNP Hogg_NNP and_CC Sir_NNP Peter_NNP Job_NNP left_VBD the_DT Board_NNP on_IN 31_CD December_NNP 2004_CD ._.
These_DT Directors_NNS elected_VBN to_TO receive_VB their_PRP$ full_JJ entitlement_NN on_IN leaving_VBG the_DT Board_NNP ._.
In_IN addition_NN to_TO annual_JJ compensation_NN ,_, GSK_NNP operates_VBZ share_NN plans_NNS to_TO provide_VB incentives_NNS to_TO Executive_NNP Directors_NNS to_TO achieve_VB longer-term_JJ growth_NN in_IN shareholder_NN value_NN ._.
Gains_NNS under_IN such_JJ plans_NNS are_VBP recognized_VBN on_IN exercise_NN or_CC maturity_NN of_IN the_DT award_NN ,_, but_CC reect_JJ value_NN earned_VBN over_IN a_DT period_NN of_IN years_NNS ._.
The_DT timing_NN of_IN exercise_NN is_VBZ normally_RB at_IN the_DT discretion_NN of_IN the_DT Director_NNP ._.
Gains_NNS in_IN 2004_CD on_IN exercise_NN of_IN options_NNS were_VBD :_: share_NN option_NN plans_VBZ 3,618,060_CD 2003_CD 3,097,260_CD :_: long-term_JJ incentive_NN plan_NN nil_NN 2003_CD 256,134_CD :_: Performance_NNP Share_NNP Plan_NNP PSP_NNP 475,149_CD 2003_CD nil_NN ._.
Dr_NNP Garnier_NNP deferred_VBD receipt_NN of_IN PSPs_NNS vesting_VBG in_IN 2004_CD with_IN a_DT value_NN at_IN vesting_NN of_IN $_$ 1,496,608_CD ._.
Full_JJ details_NNS of_IN the_DT awards_NNS granted_VBN under_IN the_DT Companys_NNPS share_NN plans_NNS during_IN 2004_CD may_MD be_VB found_VBN in_IN the_DT Annual_JJ Report_NNP 2004_CD ._.
In_IN 2001_CD ,_, following_VBG the_DT merger_NN ,_, Dr_NNP Garnier_NNP ,_, Mr_NNP Coombe_NNP and_CC Dr_NNP Yamada_NNP were_VBD awarded_VBN a_DT one-off_JJ special_JJ deferred_VBN bonus_NN as_IN members_NNS of_IN the_DT CET_NNP ._.
Each_DT was_VBD awarded_VBN an_DT amount_NN equivalent_NN to_TO his_PRP$ salary_NN on_IN 31_CD December_NNP 2001_CD and_CC this_DT was_VBD notionally_RB invested_VBN in_IN GSK_NNP shares_NNS or_CC ADSs_NNS on_IN 15_CD February_NNP 2002_CD ._.
The_DT amount_NN of_IN the_DT bonus_NN vesting_VBG on_IN 15_CD February_NNP 2005_CD was_VBD equivalent_JJ to_TO the_DT then_RB value_NN of_IN shares_NNS or_CC ADSs_NNS notionally_RB acquired_VBN in_IN February_NNP 2002_CD plus_CC dividends_NNS reinvested_VBN over_IN the_DT period_NN ._.
These_DT amounts_NNS were_VBD paid_VBN in_IN February_NNP 2005_CD and_CC are_VBP not_RB included_VBN in_IN the_DT table_NN above_IN ._.
Mr_NNP Coombe_NNP has_VBZ waived_VBN his_PRP$ entitlements_NNS to_TO the_DT 2001_CD special_JJ deferred_VBN bonus_NN of_IN 383,924_CD and_CC 2004_CD annual_JJ bonus_NN of_IN 650,370_CD ._.
The_DT Company_NN will_MD make_VB a_DT contribution_NN to_TO the_DT pension_NN plan_NN of_IN 1,034,294_CD in_IN 2005_CD to_TO enhance_VB his_PRP$ pension_NN entitlement_NN ._.
The_DT accrued_VBN annual_JJ benets_NNS under_IN the_DT dened_VBN benefit_NN pension_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP were_VBD :_: Dr_NNP Garnier_NNP $_$ 1,039,718_CD 541,520_CD :_: Mr_NNP Coombe_NNP 345,417_CD :_: and_CC Dr_NNP Yamada_NNP $_$ 165,000_CD 85,938_CD ._.
In_IN addition_NN ,_, Dr_NNP Garnier_NNP and_CC Dr_NNP Yamada_NNP are_VBP members_NNS of_IN a_DT money_NN purchase_NN scheme_NN into_IN which_WDT contributions_NNS of_IN $_$ 66,173_CD 36,160_CD and_CC $_$ 82,057_CD 44,840_CD ,_, respectively_RB ,_, were_VBD paid_VBN during_IN 2004_CD ._.
None_NN of_IN the_DT above_JJ Directors_NNS received_VBD expenses_NNS during_IN the_DT year_NN requiring_VBG separate_JJ disclosure_NN as_IN dened_VBN by_IN the_DT Regulations_NNPS ._.
22_CD 22_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG CORPORATE_JJ GOVERNANCE_NN NOMINATIONS_NNS COMMITTEE_NNP Governance_NNP and_CC policy_NN The_DT Nominations_NNPS Committee_NNP reviews_VBZ the_DT structure_NN ,_, size_NN and_CC composition_NN of_IN the_DT Board_NNP and_CC the_DT appointment_NN of_IN members_NNS of_IN the_DT Board_NNP and_CC the_DT THE_DT BOARD_NNP AND_CC CORPORATE_JJ EXECUTIVE_NN TEAM_NN CET_NNP ,_, and_CC makes_VBZ recommendations_NNS to_TO the_DT Board_NNP as_IN appropriate_JJ ._.
The_DT The_DT Directors_NNS are_VBP listed_VBN under_IN The_DT Board_NNP on_IN page_NN 18_CD ._.
Committee_NNP also_RB monitors_VBZ the_DT planning_NN of_IN succession_NN to_TO the_DT Board_NNP and_CC Senior_NNP Management_NNP ._.
The_DT Committee_NNP consists_VBZ entirely_RB of_IN Non-Executive_JJ The_NNP Board_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS system_NN of_IN corporate_JJ governance_NN Directors_NNS ,_, of_IN whom_WP a_DT majority_NN are_VBP independent_JJ ,_, and_CC meets_VBZ at_IN least_JJS once_RB and_CC is_VBZ ultimately_RB accountable_JJ for_IN the_DT Groups_NNS activities_NNS ,_, strategy_NN and_CC a_DT year_NN to_TO consider_VB succession_NN planning_NN and_CC otherwise_RB as_RB necessary_JJ ._.
CORPORATE_JJ RESPONSIBILITY_NN COMMITTEE_NNP The_NNP CEO_NNP is_VBZ responsible_JJ for_IN executive_JJ management_NN of_IN the_DT Group_NNP and_CC is_VBZ The_DT Corporate_JJ Responsibility_NNP Committee_NNP consists_VBZ entirely_RB of_IN Non-Executive_JJ assisted_VBN in_IN this_DT by_IN the_DT CET_NNP ._.
The_DT CET_NNP meets_VBZ 11_CD times_NNS per_IN year_NN and_CC otherwise_RB Directors_NNS and_CC provides_VBZ a_DT Board_NNP level_NN forum_NN for_IN the_DT regular_JJ review_NN of_IN as_RB necessary_JJ ._.
The_DT members_NNS and_CC their_PRP$ responsibilities_NNS are_VBP listed_VBN under_IN external_JJ issues_NNS that_WDT have_VBP the_DT potential_NN for_IN serious_JJ impact_NN upon_IN the_DT Groups_NNS Corporate_JJ Executive_NNP Team_NNP on_IN page_NN 19_CD ._.
business_NN and_CC reputation_NN and_CC the_DT oversight_NN of_IN reputation_NN management_NN ._.
The_DT Committee_NNP is_VBZ also_RB responsible_JJ for_IN annual_JJ governance_NN oversight_NN of_IN the_DT The_NNP Board_NNP comprises_VBZ three_CD Executive_NNP and_CC eight_CD Non-Executive_JJ Directors_NNS ._.
Groups_NNS worldwide_JJ donations_NNS and_CC community_NN support_NN ._.
The_DT Committee_NNP Whilst_NNP the_DT Board_NNP considers_VBZ all_DT of_IN its_PRP$ Non-Executive_JJ Directors_NNS to_TO be_VB meets_VBZ formally_RB three_CD times_NNS a_DT year_NN and_CC otherwise_RB as_RB necessary_JJ ._.
independent_JJ in_IN character_NN and_CC judgement_NN ,_, it_PRP has_VBZ determined_VBN that_IN Dr_NNP Shapiro_NNP should_MD not_RB be_VB considered_VBN as_IN independent_JJ under_IN the_DT Combined_VBN FINANCIAL_NNP RESULTS_NNS COMMITTEE_NNP Code_NNP on_IN Corporate_NNP Governance_NNP Combined_NNP Code_NNP ._.
This_DT is_VBZ The_DT Financial_NNP Results_NNS Committee_NNP reviews_VBZ and_CC approves_VBZ ,_, on_IN behalf_NN of_IN the_DT due_JJ to_TO the_DT remuneration_NN that_IN she_PRP receives_VBZ from_IN the_DT Group_NNP as_IN a_DT member_NN Board_NNP ,_, the_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_NN ,_, the_DT Annual_JJ Review_NNP and_CC the_DT of_IN the_DT GSK_NNP scientific_JJ Advisory_NNP Board_NNP ._.
convening_VBG of_IN the_DT AGM_NNP ,_, together_RB with_IN the_DT preliminary_JJ and_CC quarterly_JJ statements_NNS of_IN trading_NN results_NNS ._.
Each_DT Director_NNP is_VBZ a_DT member_NN of_IN the_DT Committee_NNP The_NNP Board_NNP considers_VBZ that_IN Mr_NNP Culp_NNP ,_, Sir_NNP Crispin_NNP Davis_NNP ,_, Sir_NNP Deryck_NNP Maughan_NNP ,_, and_CC the_DT quorum_NN for_IN a_DT meeting_NN is_VBZ any_DT three_CD members_NNS ._.
To_TO be_VB quorate_JJ ,_, each_DT Sir_NNP Ian_NNP Prosser_NNP ,_, Dr_NNP Schmitz_NNP and_CC Sir_NNP Robert_NNP Wilson_NNP are_VBP independent_JJ under_IN meeting_NN must_MD include_VB the_DT Chairman_NNP or_CC the_DT Chairman_NNP of_IN the_DT Audit_NNP the_DT Combined_NNP Code_NNP ._.
Sir_NNP Ian_NNP Prosser_NNP is_VBZ the_DT Senior_JJ Independent_NNP Director_NNP ._.
Committee_NNP and_CC the_DT CEO_NNP or_CC the_DT CFO_NNP ._.
The_DT Committee_NNP meets_VBZ as_RB necessary_JJ ._.
At_IN the_DT date_NN of_IN publication_NN and_CC throughout_IN 2004_CD ,_, a_DT majority_NN of_IN the_DT Board_NNP CORPORATE_JJ ADMINISTRATION_NNP &_CC TRANSACTIONS_NNP COMMITTEE_NNP members_NNS ,_, excluding_VBG the_DT Chairman_NNP ,_, were_VBD independent_JJ Non-Executive_JJ The_DT Corporate_JJ Administration_NNP &_CC Transactions_NNS Committee_NNP reviews_VBZ and_CC Directors_NNS ,_, in_IN accordance_NN with_IN the_DT recommendations_NNS of_IN the_DT Combined_NNP approves_VBZ matters_NNS in_IN connection_NN with_IN the_DT administration_NN of_IN the_DT Groups_NNS Code_NNP ._.
business_NN ,_, and_CC of_IN certain_JJ corporate_JJ transactions_NNS ._.
The_DT Committee_NNP consists_VBZ of_IN the_DT Directors_NNS ,_, CET_NNP members_NNS and_CC the_DT Company_NNP Secretary_NNP ._.
The_DT Committee_NNP BOARD_NNP PROCESS_NNP meets_VBZ as_RB necessary_JJ ._.
The_DT Board_NNP meets_VBZ at_IN least_JJS six_CD times_NNS a_DT year_NN ._.
It_PRP has_VBZ a_DT formal_JJ schedule_NN of_IN matters_NNS reserved_VBN to_TO it_PRP for_IN decision_NN but_CC otherwise_RB delegates_NNS specic_JJ responsibilities_NNS REMUNERATION_NNP OF_IN DIRECTORS_NNP to_TO Board_NNP committees_NNS ,_, as_IN described_VBN below_IN ._.
The_DT Board_NNP works_VBZ to_TO an_DT agreed_VBN Information_NN on_IN the_DT remuneration_NN of_IN Directors_NNS is_VBZ given_VBN in_IN the_DT Summary_NNP business_NN agenda_NN in_IN reviewing_VBG the_DT key_JJ activities_NNS of_IN the_DT business_NN ,_, and_CC receives_VBZ Remuneration_NNP Report_NNP on_IN pages_NNS 20_CD to_TO 22_CD ._.
papers_NNS and_CC presentations_NNS to_TO enable_VB it_PRP to_TO do_VB so_RB effectively_RB ._.
The_DT Board_NNP considers_VBZ and_CC reviews_VBZ the_DT work_NN undertaken_VBN by_IN its_PRP$ Committees_NNS ._.
The_DT Company_NNP Secretary_NNP is_VBZ responsible_JJ to_TO the_DT Board_NNP and_CC is_VBZ available_JJ to_TO individual_JJ Directors_NNS in_IN respect_NN of_IN Board_NNP procedures_NNS ._.
The_DT Company_NNP Secretary_NNP is_VBZ Mr_NNP Simon_NNP Bicknell_NNP who_WP was_VBD appointed_VBN in_IN May_NNP 2000_CD ._.
He_PRP is_VBZ a_DT barrister_NN and_CC joined_VBD the_DT Group_NNP in_IN 1984_CD ._.
He_PRP is_VBZ secretary_NN to_TO all_PDT the_DT Board_NNP Committees_NNS ._.
BOARD_NNP COMMITTEES_NNPS AUDIT_NNP COMMITTEE_NNP The_NNP Audit_NNP Committee_NNP reviews_VBZ the_DT financial_JJ and_CC internal_JJ reporting_NN process_NN ,_, the_DT system_NN of_IN internal_JJ control_NN and_CC management_NN of_IN risks_NNS and_CC the_DT external_JJ and_CC internal_JJ audit_NN process_NN ._.
The_DT Committee_NNP also_RB proposes_VBZ to_TO shareholders_NNS the_DT appointment_NN of_IN the_DT external_JJ auditors_NNS and_CC is_VBZ directly_RB responsible_JJ for_IN their_PRP$ remuneration_NN and_CC oversight_NN of_IN their_PRP$ work_NN ._.
The_DT Committee_NNP consists_VBZ entirely_RB of_IN independent_JJ Non-Executive_JJ Directors_NNS ._.
It_PRP meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN ._.
REMUNERATION_NNP COMMITTEE_NNP The_NNP Remuneration_NNP Committee_NNP determines_VBZ the_DT terms_NNS of_IN service_NN and_CC remuneration_NN of_IN the_DT Executive_NNP Directors_NNS and_CC members_NNS of_IN the_DT CET_NNP and_CC ,_, with_IN the_DT assistance_NN of_IN external_JJ independent_JJ advisors_NNS ,_, it_PRP evaluates_VBZ and_CC makes_VBZ recommendations_NNS to_TO the_DT Board_NNP on_IN overall_JJ executive_NN remuneration_NN policy_NN ._.
It_PRP meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN and_CC otherwise_RB as_RB necessary_JJ ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 23_CD 23_CD RESPONSIBILITY_NN STATEMENTS_NNS Annual_JJ Review_NNP Corporate_NNP governance_NN The_DT Annual_JJ Review_NNP is_VBZ a_DT summary_NN report_NN and_CC does_VBZ not_RB contain_VB sufficient_JJ The_DT Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP is_VBZ specified_VBN by_IN the_DT Listing_NN information_NN to_TO allow_VB as_IN full_JJ an_DT understanding_NN of_IN the_DT results_NNS and_CC state_NN Rules_NNS of_IN the_DT Financial_NNP Services_NNPS Authority_NNP for_IN the_DT guidance_NN of_IN listed_VBN of_IN affairs_NNS of_IN the_DT Group_NNP as_IN is_VBZ provided_VBN by_IN the_DT Annual_JJ Report_NNP 2004_CD ._.
companies_NNS Combined_VBN Code_NNP ._.
The_DT Board_NNP considers_VBZ that_IN throughout_IN 2004_CD Shareholders_NNS requiring_VBG more_JJR detailed_JJ information_NN may_MD obtain_VB ,_, free_JJ of_IN and_CC up_IN to_TO the_DT date_NN of_IN approval_NN of_IN this_DT review_NN ,_, GlaxoSmithKline_NNP plc_NN applied_VBD charge_NN ,_, a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP 2004_CD and_CC may_MD also_RB elect_VB to_TO receive_VB the_DT principles_NNS of_IN the_DT Combined_NNP Code_NNP and_CC ,_, with_IN the_DT exception_NN of_IN matters_NNS a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP in_IN future_JJ years_NNS refer_VBP to_TO Shareholder_NN where_WRB the_DT Companys_NNPS position_NN is_VBZ described_VBN in_IN the_DT Annual_JJ Report_NNP ,_, complied_VBD information_NN ._.
with_IN the_DT provisions_NNS of_IN the_DT Combined_NNP Code_NNP ,_, and_CC the_DT guidance_NN on_IN internal_JJ control_NN issued_VBN by_IN the_DT 1998_CD Turnbull_NNP Committee_NNP ._.
The_DT Independent_NNP Auditors_NNS report_VBP on_IN the_DT full_JJ financial_JJ statements_NNS of_IN the_DT Group_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD is_VBZ unqualied_JJ and_CC does_VBZ The_DT Annual_JJ Review_NNP ,_, including_VBG Summary_NNP financial_JJ statements_NNS ,_, has_VBZ been_VBN not_RB contain_VB any_DT statement_NN concerning_VBG inadequate_JJ accounting_NN records_NNS approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN or_CC failure_NN to_TO obtain_VB necessary_JJ information_NN and_CC explanations_NNS ._.
Sir_NNP Christopher_NNP Gent_NNP Chairman_NNP 2_CD March_NNP 2005_CD Summary_NNP financial_JJ statements_NNS A_DT columnar_NN presentation_NN has_VBZ been_VBN adopted_VBN in_IN the_DT Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN in_IN order_NN to_TO illustrate_VB 2004_CD statutory_JJ performance_NN Independent_NNP auditors_NNS against_IN 2003_CD business_NN performance_NN ._.
During_IN the_DT years_NNS 2000_CD to_TO 2003_CD ,_, statement_NN to_TO the_DT members_NNS business_NN performance_NN was_VBD the_DT primary_JJ performance_NN measure_NN used_VBN by_IN management_NN and_CC was_VBD presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, integration_NN of_IN GlaxoSmithKline_NNP plc_NN and_CC restructuring_NN costs_NNS and_CC disposals_NNS of_IN businesses_NNS ._.
Management_NNP believed_VBD that_IN exclusion_NN of_IN these_DT items_NNS provided_VBD a_DT better_JJR comparison_NN of_IN the_DT way_NN in_IN We_PRP have_VBP examined_VBN the_DT Summary_NNP financial_JJ statements_NNS which_WDT comprise_VBP which_WDT the_DT business_NN was_VBD managed_VBN and_CC gave_VBD an_DT indication_NN of_IN the_DT the_DT Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN ,_, Summary_NNP consolidated_JJ performance_NN of_IN the_DT Group_NNP in_IN terms_NNS of_IN those_DT elements_NNS of_IN revenue_NN and_CC balance_NN sheet_NN and_CC Summary_NNP consolidated_JJ cash_NN ow_NN statement_NN and_CC the_DT expenditure_NN which_WDT local_JJ management_NN was_VBD able_JJ to_TO inuence_NN ._.
For_IN 2004_CD ,_, Summary_NNP Report_NNP of_IN the_DT Directors_NNS including_VBG the_DT Summary_NNP Remuneration_NNP with_IN the_DT completion_NN of_IN these_DT programs_NNS ,_, the_DT Group_NNP is_VBZ reporting_VBG results_NNS on_IN Report_NNP ._.
Growth_NN rates_NNS are_VBP presented_VBN comparing_VBG 2004_CD statutory_JJ results_NNS with_IN 2003_CD business_NN performance_NN results_NNS ._.
Management_NNP RESPECTIVE_NNP RESPONSIBILITIES_NNPS OF_IN DIRECTORS_NNPS AND_CC AUDITORS_NNPS considers_VBZ that_IN the_DT comparison_NN of_IN 2004_CD statutory_JJ results_NNS with_IN 2003_CD business_NN The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT Annual_JJ Review_NNP in_IN accordance_NN performance_NN results_NNS gives_VBZ the_DT most_RBS appropriate_JJ indication_NN of_IN the_DT Groups_NNS with_IN applicable_JJ law_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT performance_NN for_IN the_DT period_NN under_IN review_NN ._.
consistency_NN of_IN the_DT Summary_NNP financial_JJ statements_NNS within_IN the_DT Annual_JJ Review_NNP with_IN the_DT Annual_JJ financial_JJ statements_NNS ,_, the_DT Report_NNP of_IN the_DT Directors_NNS and_CC the_DT In_NNP 2004_CD ,_, the_DT Group_NNP adopted_VBD UITF_NNP Abstract_NNP 38_CD and_CC the_DT revised_VBN Abstract_NNP 17_CD Directors_NNS Remuneration_NNP Report_NNP ,_, and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ relating_VBG to_TO shares_NNS held_VBN by_IN the_DT ESOP_NNP Trusts_NNPS and_CC share_NN options_NNS and_CC awards_NNS ._.
requirements_NNS of_IN Section_NN 251_CD of_IN the_DT United_NNP Kingdom_NNP Companies_NNP Act_NNP 1985_CD Comparative_JJ information_NN for_IN 2003_CD has_VBZ been_VBN restated_VBN accordingly_RB ._.
Trading_NN and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN profit_NN and_CC profit_NN before_IN tax_NN in_IN 2003_CD have_VBP been_VBN reduced_VBN by_IN 16_CD million_CD and_CC contained_VBN in_IN the_DT Annual_JJ Review_NNP and_CC consider_VB the_DT implications_NNS for_IN our_PRP$ report_NN net_JJ assets_NNS at_IN 31_CD December_NNP 2003_CD by_IN 2,661_CD million_CD ._.
if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN inconsistencies_NNS with_IN the_DT Summary_NNP financial_JJ statements_NNS ._.
Earnings_NNS and_CC shareholders_NNS funds_NNS are_VBP also_RB restated_VBN in_IN accordance_NN with_IN US_NNP GAAP_NNP as_IN additional_JJ information_NN provided_VBN to_TO US_NNP shareholders_NNS ._.
This_DT statement_NN ,_, including_VBG the_DT opinion_NN ,_, has_VBZ been_VBN prepared_VBN for_IN and_CC only_RB for_IN the_DT Companys_NNPS members_NNS as_IN a_DT body_NN in_IN accordance_NN with_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC for_IN no_DT other_JJ purpose_NN ._.
We_PRP do_VBP not_RB ,_, in_IN giving_VBG this_DT opinion_NN ,_, accept_VB or_CC assume_VB responsibility_NN for_IN any_DT other_JJ purpose_NN or_CC to_TO any_DT Statement_NN by_IN the_DT Directors_NNS other_JJ person_NN to_TO whom_WP this_DT statement_NN is_VBZ shown_VBN or_CC into_IN whose_WP$ hands_NNS it_PRP may_MD come_VB save_IN where_WRB expressly_RB agreed_VBN by_IN our_PRP$ prior_JJ consent_NN in_IN writing_VBG ._.
The_DT Annual_JJ Review_NNP 2004_CD is_VBZ the_DT Summary_NNP Directors_NNS report_NN and_CC includes_VBZ the_DT Summary_NNP financial_JJ statements_NNS of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN ended_VBD BASIS_NNP OF_IN OPINION_NNP 31_CD December_NNP 2004_CD ,_, which_WDT is_VBZ published_VBN in_IN hard-copy_JJ printed_VBN form_NN and_CC on_IN We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN Bulletin_NNP 1999_CD 6_CD ,_, The_DT auditors_NNS the_DT website_NN ._.
The_DT Business_NN operating_VBG review_NN ,_, the_DT Summary_NNP financial_JJ statements_NNS ,_, statement_NN on_IN the_DT Summary_NNP financial_JJ statement_NN issued_VBN by_IN the_DT Auditing_VBG the_DT Summary_NNP Remuneration_NNP Report_NNP and_CC the_DT Statement_NN on_IN corporate_JJ Practices_NNPS Board_NNP for_IN use_NN in_IN the_DT United_NNP Kingdom_NNP ._.
governance_NN are_VBP summaries_NNS of_IN information_NN in_IN the_DT Annual_JJ Report_NNP 2004_CD ._.
OPINION_NNP The_NNP Directors_NNS are_VBP responsible_JJ for_IN the_DT maintenance_NN and_CC integrity_NN of_IN the_DT In_NNP our_PRP$ opinion_NN the_DT Summary_NNP financial_JJ statements_NNS are_VBP consistent_JJ with_IN Annual_JJ Review_NNP on_IN the_DT website_NN in_IN accordance_NN with_IN the_DT UK_NNP legislation_NN the_DT Annual_JJ financial_JJ statements_NNS ,_, the_DT Report_NNP of_IN the_DT Directors_NNS and_CC the_DT governing_VBG the_DT preparation_NN and_CC dissemination_NN of_IN financial_JJ statements_NNS ._.
Remuneration_NNP Report_NNP of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN ended_VBD Access_NNP to_TO the_DT website_NN is_VBZ available_JJ from_IN outside_IN the_DT UK_NNP ,_, where_WRB comparable_JJ 31_CD December_NNP 2004_CD and_CC comply_VB with_IN the_DT applicable_JJ requirements_NNS of_IN Section_NN legislation_NN may_MD be_VB different_JJ ._.
251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
LLP_NNP Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS Embankment_NNP Place_NNP ,_, London_NNP ,_, England_NNP ._.
2_CD March_NNP 2005_CD 24_CD 24_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG SUMMARY_NNP FINANCIAL_NNP STATEMENTS_NNP Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN 2004_CD 2003_CD Business_NN performance_NN Merger_NNP ,_, restructuring_NN and_CC Statutory_NNP Statutory_NNP Growth_NNP restated_VBD disposal_NN of_IN subsidiaries_NNS restated_VBN m_NN CER_CD %_NN m_NN m_FW m_FW Turnover_NN Pharmaceuticals_NNS 17,146_CD 1_CD 18,181_CD 18,181_CD Consumer_NN Healthcare_NNP 3,213_CD 3_CD 3,260_CD 3,260_CD Total_JJ turnover_NN 20,359_CD 1_CD 21,441_CD 21,441_CD Cost_NN of_IN sales_NNS 4,309_CD 7_CD 4,188_CD 356_CD 4,544_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenditure_NN 7,061_CD 2_CD 7,579_CD 18_CD 7,597_CD Research_NNP and_CC development_NN expenditure_NN 2,839_CD 8_CD 2,770_CD 21_CD 2,791_CD Trading_NN profit_NN 6,150_CD 1_CD 6,904_CD 395_CD 6,509_CD Other_JJ operating_NN income_NN expenses_NNS 60 133 133_CD Disposal_NNP of_IN interests_NNS in_IN associates_NNS 138_CD profits_NNS of_IN joint_JJ ventures_NNS and_CC associates_NNS 95_CD 93_CD 93_CD Loss_NN profit_NN on_IN disposal_NN of_IN products_NNS and_CC businesses_NNS 1_CD 5_CD 5_CD Net_JJ interest_NN payable_JJ 203 161 161_CD profit_NN before_IN taxation_NN 6,119_CD 2_CD 6,703_CD 390_CD 6,313_CD Taxation_NNP 1,701_CD 1,838_CD 109_CD 1,729_CD profit_NN after_IN taxation_NN 4,418_CD 1_CD 4,865_CD 281_CD 4,584_CD Minority_NNP interests_NNS 114_CD 94_CD 94_CD Preference_NN share_NN dividends_NNS 2_CD 12_CD 12_CD Earnings_NNS 4,302_CD 1_CD 4,759_CD 281_CD 4,478_CD Earnings_NNS per_IN share_NN pence_NN 75.0_CD p_NN 2_CD 82.0_CD p_NN 4.9_CD p_NN 77.1_CD p_NN Dividends_NNS Per_IN share_NN 42.0_CD p_VBP 41.0_CD p_JJ Total_JJ 2,402_CD 2,374_CD During_IN the_DT years_NNS 2000_CD to_TO 2003_CD ,_, business_NN performance_NN was_VBD the_DT primary_JJ management_NN performance_NN measure_NN and_CC was_VBD presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposal_NN of_IN businesses_NNS ._.
For_IN 2004_CD ,_, the_DT Group_NNP is_VBZ reporting_VBG results_NNS on_IN a_DT statutory_JJ basis_NN ._.
Management_NNP considers_VBZ that_IN the_DT comparison_NN of_IN 2004_CD statutory_JJ results_NNS and_CC 2003_CD business_NN performance_NN gives_VBZ the_DT most_RBS appropriate_JJ indication_NN of_IN the_DT groups_NNS performance_NN for_IN the_DT period_NN ._.
Summary_JJ consolidated_JJ balance_NN sheet_NN 2003_CD 2004_CD restated_VBN m_NN m_NN Fixed_VBN assets_NNS 8,945_CD 8,575_CD Current_JJ assets_NNS 13,633_CD 12,625_CD Creditors_NNPS :_: amounts_NNS due_JJ within_IN one_CD year_NN 8,722_CD 8,471_CD Net_JJ current_JJ assets_NNS 4,911_CD 4,154_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 13,856_CD 12,729_CD Creditors_NNPS :_: amounts_NNS due_RB after_IN one_CD year_NN 4,625_CD 3,883_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 3,029_CD 3,042_CD Net_JJ assets_NNS 6,202_CD 5,804_CD Capital_NN and_CC reserves_NNS Equity_NNP shareholders_NNS funds_NNS 5,925_CD 5,059_CD Minority_NNP interests_NNS 277_CD 745_CD Capital_NN employed_VBN 6,202_CD 5,804_CD Summary_NNP consolidated_JJ cash_NN ow_NN statement_NN 2003_CD 2004_CD restated_VBN m_NN m_NN Net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS 6,527_CD 7,005_CD Dividends_NNS from_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 11_CD 1_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 252_CD 231_CD Taxation_NNP paid_VBD 1,583_CD 1,917_CD Capital_NN expenditure_NN and_CC financial_JJ investment_NN 1,035_CD 954_CD Acquisitions_NNS and_CC disposals_NNS 69_CD 12_CD Equity_NNP dividends_NNS paid_VBD 2,475_CD 2,333_CD Management_NN of_IN liquid_JJ resources_NNS and_CC nancing_VBG 867_CD 1,586_CD Increase_VBP decrease_NN in_IN cash_NN in_IN the_DT year_NN 257_CD 27_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 25_CD 25_CD SUMMARY_NN INFORMATION_NN UNDER_IN US_NNP GAAP_NNP for_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO profit_VB and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
profit_NN 2003_CD 2004_CD restated_VBN m_NN m_NN profit_NN attributable_JJ to_TO shareholders_NNS under_IN UK_NNP GAAP_NNP 4,302_CD 4,478_CD US_NNP GAAP_NNP adjustments_NNS :_: Product_NN rights_NNS and_CC goodwill_NN 1,620_CD 2,371_CD Fixed_VBN assets_NNS 19_CD 28_CD Inventory_NNP 13_CD Disposal_NNP of_IN interests_NNS in_IN associates_NNS and_CC subsidiaries_NNS 78_CD Equity_NN investments_NNS 30_CD 31_CD Employee_NN costs_NNS 458_CD 494_CD Derivative_JJ instruments_NNS and_CC hedging_VBG 33_CD 41_CD Guarantor_NNP obligations_NNS 19_CD 21_CD Restructuring_NN 12_CD 98_CD Taxation_NNP 651_CD 774_CD Variable_JJ interest_NN entities_NNS and_CC minority_NN shareholders_NNS put_VBD option_NN 43_CD Net_JJ income_NN under_IN US_NNP GAAP_NNP 2,732_CD 2,420_CD Basic_JJ income_NN per_IN share_NN under_IN US_NNP GAAP_NNP 47.6_CD p_NN 41.7_CD p_VBP Diluted_JJ income_NN per_IN share_NN under_IN US_NNP GAAP_NNP 47.5_CD p_NN 41.6_CD p_NN Equity_NN shareholders_NNS funds_NNS 2003_CD 2004_CD restated_VBN m_NN m_NN Equity_NNP shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 5,925_CD 5,059_CD US_NNP GAAP_NNP adjustments_NNS :_: Product_NN rights_NNS and_CC goodwill_NN 31,976_CD 33,638_CD Fixed_VBN assets_NNS 223_CD 243_CD Marketable_JJ securities_NNS 49_CD 84_CD Other_JJ investments_NNS 554_CD 832_CD Inventory_NN 1_CD Employee_NN costs_NNS 1,185_CD 1,574_CD Derivative_JJ instruments_NNS 15_CD 26_CD Guarantor_NNP obligations_NNS 2_CD 21_CD Restructuring_NN 80_CD 92_CD Dividends_NNPS 683_CD 808_CD Deferred_JJ taxation_NN 4,204_CD 5,071_CD Variable_JJ interest_NN entities_NNS and_CC minority_NN shareholders_NNS put_VBD option_NN 43_CD Shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP 34,042_CD 34,116_CD A_DT summary_NN of_IN the_DT material_NN differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP that_IN apply_VB to_TO the_DT Group_NNP is_VBZ set_VBN out_RP in_IN the_DT Annual_JJ Report_NNP 2004_CD ._.
During_IN the_DT year_NN ,_, the_DT Group_NNP implemented_VBD FASB_NNP Staff_NNP Position_NNP FSP_NNP FAS_NNP 106-2_CD ,_, Accounting_NNP and_CC Disclosure_NNP Requirements_NNP Related_NNP to_TO the_DT Medicare_NNP Prescription_NNP Drug_NNP ,_, Improvement_NNP and_CC Modernization_NNP Act_NNP of_IN 2003_CD the_DT Act_NNP ,_, superseding_VBG FSP_NNP 106-1_CD ._.
FSP_NNP 106-2_CD addresses_NNS the_DT accounting_NN implications_NNS of_IN the_DT Act_NNP for_IN an_DT entity_NN that_WDT sponsors_VBZ a_DT post-retirement_JJ health_NN care_NN plan_NN providing_VBG prescription_NN drug_NN benets_NNS ._.
26_CD 26_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG SHAREHOLDER_NNP INFORMATION_NNP SHARE_NNP PRICE_NNP INFORMATION_NNP Ordinary_NNP shares_NNS Share_NN price_NN information_NN is_VBZ available_JJ on_IN the_DT website_NN at_IN www_NN ._.
Information_NNP made_VBD available_JJ on_IN the_DT website_NN does_VBZ not_RB constitute_VB part_NN of_IN The_DT Companys_NNP shares_NNS are_VBP listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP LSE_NNP ._.
Information_NN in_IN the_DT UK_NNP is_VBZ also_RB available_JJ on_IN Ceefax_NNP ,_, REGISTRAR_NNP Teletext_NNP ,_, and_CC from_IN FT_NNP Cityline_NNP by_IN calling_VBG 0906 003 5694_CD or_CC 0906 843 5694_CD The_DT Companys_NNP share_NN register_NN is_VBZ administered_VBN by_IN Lloyds_NNP TSB_NNP Registrars_NNPS ,_, calls_VBZ charged_VBN at_IN 60p_CD a_DT minute_NN plus_CC VAT_NNP at_IN all_DT times_NNS ._.
which_WDT also_RB provides_VBZ the_DT following_JJ services_NNS :_: GlaxoSmithKline_NNP Investment_NNP Plan_NNP enables_VBZ shareholders_NNS to_TO reinvest_VB quarterly_JJ dividends_NNS and_CC or_CC make_VB monthly_JJ investments_NNS in_IN the_DT Company_NN 's_POS Share_NN buy-back_NN program_NN ordinary_JJ shares_NNS using_VBG a_DT special_JJ dealing_NN arrangement_NN ._.
In_IN October_NNP 2002_CD ,_, following_VBG the_DT completion_NN of_IN the_DT first_JJ 4_CD billion_CD share_NN GlaxoSmithKline_NNP Individual_NNP Savings_NNP Account_NNP is_VBZ a_DT tax-efficient_JJ way_NN buy-back_NN program_NN announced_VBN in_IN 2001_CD ,_, the_DT Company_NN announced_VBD plans_NNS to_TO invest_VB in_IN the_DT Companys_NNP ordinary_JJ shares_NNS ._.
for_IN a_DT new_JJ 4_CD billion_CD share_NN buy-back_JJ program_NN ._.
Of_IN this_DT second_JJ program_NN GlaxoSmithKline_NNP Corporate_NNP Sponsored_NNP Nominee_NNP provides_VBZ a_DT facility_NN 219_CD million_CD was_VBD accounted_VBN for_IN in_IN 2002_CD ,_, 980_CD million_CD in_IN 2003_CD and_CC for_IN shareholders_NNS to_TO hold_VB shares_NNS without_IN the_DT need_NN for_IN share_NN certicates_NNS ._.
The_DT program_NN covers_VBZ purchases_NNS by_IN the_DT Company_NN Shareholders_NNS details_NNS will_MD not_RB be_VB held_VBN on_IN the_DT main_JJ share_NN register_NN ,_, and_CC so_RB of_IN shares_NNS for_IN cancellation_NN or_CC to_TO be_VB held_VBN as_IN Treasury_NNP shares_NNS ,_, in_IN accordance_NN with_IN the_DT authority_NN given_VBN by_IN shareholders_NNS at_IN the_DT AGM_NNP in_IN 2004_CD ._.
will_MD remain_VB condential_JJ ._.
Shareview_NNP service_NN provides_VBZ shareholders_NNS with_IN information_NN on_IN their_PRP$ In_IN May_NNP 2004_CD the_DT Company_NN was_VBD authorised_VBN to_TO purchase_VB a_DT maximum_NN of_IN investment_NN in_IN the_DT Company_NN ._.
Shareholders_NNS may_MD register_VB for_IN this_DT service_NN 594.6_CD million_CD shares_NNS 600_CD million_CD shares_NNS in_IN May_NNP 2003_CD ._.
18_CD million_CD shares_NNS were_VBD purchased_VBN for_IN cancellation_NN and_CC 70_CD million_CD shares_NNS were_VBD purchased_VBN to_TO be_VB held_VBN as_IN Treasury_NNP shares_NNS see_VBP Note_NN 27_CD to_TO the_DT Financial_NNP Shareview_NNP dealing_VBG service_NN is_VBZ a_DT telephone_NN and_CC internet_NN share_NN dealing_VBG statements_NNS ,_, Share_NN capital_NN and_CC share_NN premium_NN account_NN in_IN the_DT Companys_NNP facility_NN available_JJ to_TO ordinary_JJ shareholders_NNS by_IN logging_VBG on_IN to_TO Annual_JJ Report_NNP 2004_CD ._.
The_DT exact_JJ amount_NN and_CC timing_NN of_IN future_JJ purchases_NNS ,_, www_NN ._.
co._FW uk_FW dealing_VBG or_CC by_IN calling_VBG 0870 850 0852_CD ._.
and_CC the_DT extent_NN to_TO which_WDT repurchased_VBD shares_NNS will_MD be_VB held_VBN as_IN Treasury_NNP shares_NNS rather_RB than_IN being_VBG canceled_VBN ,_, will_MD be_VB determined_VBN by_IN the_DT Company_NN and_CC is_VBZ dependent_JJ on_IN market_NN conditions_NNS and_CC other_JJ factors_NNS ._.
American_JJ Depositary_NNP Shares_NNP The_NNP Companys_NNP shares_NNS are_VBP listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP NYSE_NNP in_IN the_DT form_NN of_IN American_JJ Depositary_NNP Shares_NNP ADSs_NNP and_CC these_DT are_VBP evidenced_VBN SmithKline_NNP Beecham_NNP plc_NN Floating_VBG by_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS ,_, each_DT one_CD of_IN which_WDT represents_VBZ two_CD ordinary_JJ shares_NNS ._.
Rate_NNP Unsecured_NNP Loan_NNP Stock_NNP 1990_CD 2010_CD In_IN general_JJ ,_, the_DT NYSEs_NNP rules_NNS permit_VBP the_DT Company_NN to_TO follow_VB UK_NNP corporate_JJ governance_NN practices_NNS instead_RB of_IN those_DT that_WDT apply_VBP in_IN the_DT US_NNP ,_, provided_VBD The_DT loan_NN stock_NN is_VBZ not_RB listed_VBN on_IN any_DT exchange_NN but_CC holders_NNS may_MD require_VB that_IN the_DT Company_NN explains_VBZ any_DT significant_JJ variations_NNS ._.
This_DT explanation_NN is_VBZ SmithKline_NNP Beecham_NNP plc_NN to_TO redeem_VB their_PRP$ loan_NN stock_NN at_IN par_NN ,_, i._FW e._FW 1_CD for_IN every_DT provided_VBN on_IN the_DT Companys_NNP website_NN ._.
1_CD of_IN loan_NN stock_NN held_VBN ,_, on_IN the_DT first_JJ business_NN day_NN of_IN March_NNP ,_, June_NNP ,_, September_NNP and_CC December_NNP ._.
Holders_NNS wishing_VBG to_TO redeem_VB all_DT or_CC part_NN of_IN their_PRP$ loan_NN stock_NN ADR_NNP PROGRAMME_NNP ADMINISTRATOR_NNP should_MD complete_VB the_DT notice_NN on_IN the_DT back_NN of_IN their_PRP$ loan_NN stock_NN certicate_NN and_CC The_DT ADR_NNP program_NN is_VBZ administered_VBN by_IN The_DT Bank_NNP of_IN New_NNP York_NNP ,_, which_WDT return_VBP it_PRP to_TO the_DT registrar_NN ,_, to_TO arrive_VB at_IN least_JJS 30_CD days_NNS before_IN the_DT relevant_JJ provides_VBZ Global_JJ BuyDIRECT_NNP ,_, a_DT direct_JJ ADS_NNPS purchase_NN sale_NN and_CC dividend_NN redemption_NN date_NN ._.
reinvestment_NN plan_NN for_IN ADR_NNP holders_NNS ._.
SHARE_NN DEALING_NN SERVICE_NNP Hoare_NNP Govett_NNP Limited_NNP operates_VBZ a_DT postal_JJ dealing_VBG service_NN in_IN the_DT Companys_NNP Cautionary_NNP statement_NN ordinary_JJ shares_NNS ._.
It_PRP enables_VBZ investors_NNS to_TO buy_VB or_CC sell_VB shares_NNS at_IN competitive_JJ commission_NN charges_NNS ._.
Transactions_NNS are_VBP executed_VBN and_CC settled_VBN by_IN Pershing_NNP Under_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT US_NNP Private_NNP Securities_NNP Litigation_NNP Securities_NNPS Limited_NNP ._.
Further_JJ details_NNS of_IN this_DT service_NN ,_, together_RB with_IN purchase_NN Reform_NNP Act_NNP of_IN 1995_CD ,_, the_DT Company_NN cautions_VBZ investors_NNS that_IN any_DT forwardand_JJ sale_NN forms_NNS ,_, may_MD be_VB obtained_VBN by_IN telephoning_VBG 44_CD 0_CD 207 661 6555_NNS ._.
looking_VBG statements_NNS or_CC projections_NNS made_VBN by_IN the_DT Company_NN ,_, including_VBG those_DT made_VBN in_IN this_DT Annual_JJ Review_NNP ,_, are_VBP subject_JJ to_TO risks_NNS and_CC uncertainties_NNS that_WDT may_MD cause_VB actual_JJ results_NNS to_TO differ_VB materially_RB from_IN those_DT projected_VBN ._.
Factors_NNS that_WDT Smith_NNP Barney_NNP ,_, part_NN of_IN Citigroup_NNP ,_, also_RB offers_VBZ a_DT share_NN dealing_VBG service_NN in_IN the_DT may_MD affect_VB the_DT Groups_NNS operations_NNS are_VBP described_VBN under_IN Legal_NNP proceedings_NNS Companys_NNP ordinary_JJ shares_NNS and_CC ADSs_NNS ._.
Further_JJ details_NNS of_IN this_DT service_NN can_MD be_VB and_CC Risk_NNP factors_NNS in_IN the_DT Companys_NNP Annual_JJ Report_NNP 2004_CD ._.
obtained_VBN by_IN contacting_VBG their_PRP$ ofces_NNS in_IN the_DT UK_NNP or_CC US_NNP see_VBP contact_NN details_NNS on_IN the_DT inside_JJ back_JJ cover_NN for_IN further_JJ information_NN ._.
The_DT provision_NN of_IN the_DT details_NNS above_IN are_VBP not_RB intended_VBN to_TO be_VB an_DT invitation_NN or_CC inducement_NN to_TO engage_VB in_IN an_DT investment_NN activity_NN ._.
Advice_NNP on_IN share_NN dealing_NN ,_, should_MD be_VB obtained_VBN from_IN a_DT stockbroker_NN or_CC independent_JJ financial_JJ adviser_NN ._.
New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD 27_CD 27_CD SHAREHOLDER_NN INFORMATION_NN continued_VBD Financial_JJ reporting_NN Dividends_NNS FINANCIAL_NNP REPORTING_NNP CALENDAR_NNP 2005_CD GSK_NNP pays_VBZ dividends_NNS quarterly_RB ._.
Announcement_NN of_IN 1st_CD Quarter_NN Results_NNS 28_CD April_NNP 2005_CD The_NNP Board_NNP has_VBZ declared_VBN dividends_NNS for_IN 2004_CD as_IN follows_VBZ :_: Announcement_NN of_IN 2nd_CD Quarter_NN Results_NNS 28_CD July_NNP 2005 2004 2003_CD Announcement_NN of_IN 3rd_CD Quarter_NN Results_NNS 27_CD October_NNP 2005_CD Dividends_NNPS per_IN share_NN pence_NN pence_NN Preliminary_JJ Announcement_NN of_IN Annual_JJ Results_NNS 9_CD February_NNP 2006_CD First_NNP interim_JJ paid_VBN 1_CD July_NNP 2004_CD 10_CD 9_CD Publication_NN of_IN Annual_JJ Report_NNP Review_NNP March_NNP 2006_CD Second_JJ interim_JJ paid_VBN 30_CD September_NNP 2004_CD 10_CD 9_CD Third_NNP interim_JJ paid_VBN 6_CD January_NNP 2005_CD 10_CD 9_CD RESULTS_NNS ANNOUNCEMENTS_NNS Fourth_JJ interim_JJ payable_JJ 7_CD April_NNP 2005_CD 12_CD 14_CD Results_NNS Announcements_NNS are_VBP issued_VBN to_TO the_DT London_NNP Stock_NNP Exchange_NNP ,_, and_CC Total_JJ 42_CD 41_CD made_VBN available_JJ on_IN their_PRP$ news_NN service_NN ,_, and_CC at_IN the_DT same_JJ time_NN ,_, or_CC shortly_RB afterwards_RB ,_, they_PRP are_VBP issued_VBN to_TO the_DT media_NNS ,_, are_VBP made_VBN available_JJ on_IN the_DT website_JJ As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT table_NN below_IN sets_NNS out_IN the_DT dividends_NNS paid_VBN and_CC are_VBP submitted_VBN to_TO the_DT Securities_NNPS and_CC Exchange_NNP Commission_NNP in_IN the_DT US_NNP per_IN ADS_NNPS in_IN US_NNP dollars_NNS in_IN the_DT last_JJ five_CD years_NNS ._.
The_DT dividends_NNS are_VBP adjusted_VBN for_IN and_CC the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
UK_NNP tax_NN credit_NN less_RBR withholding_VBG tax_NN ,_, where_WRB applicable_JJ ,_, and_CC are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN applicable_JJ exchange_NN rates_NNS ._.
FINANCIAL_NNP REPORTS_NNS The_DT Company_NN publishes_VBZ an_DT Annual_JJ Report_NNP and_CC ,_, for_IN the_DT investor_NN not_RB needing_VBG Since_IN 6_CD April_NNP 1999_CD ,_, claims_VBZ for_IN refunds_NNS of_IN tax_NN credits_NNS on_IN dividends_NNS from_IN the_DT the_DT full_JJ detail_NN of_IN the_DT Report_NNP ,_, an_DT Annual_JJ Review_NNP ._.
These_DT are_VBP available_JJ on_IN the_DT UK_NNP tax_NN authorities_NNS are_VBP of_IN negligible_JJ benefit_NN to_TO US_NNP shareholders_NNS ._.
The_DT Annual_JJ Review_NNP is_VBZ sent_VBN to_TO all_DT shareholders_NNS on_IN the_DT date_NN of_IN publication_NN ._.
Shareholders_NNS may_MD also_RB elect_VB to_TO receive_VB the_DT Report_NNP by_IN writing_VBG to_TO Year_NN GSK_NNP $_$ GW_CD $_$ SB_CD $_$ the_DT Companys_NNPS registrars_NNS ._.
Alternatively_RB ,_, shareholders_NNS may_MD elect_VB to_TO receive_VB 2004_CD 1.53_CD notication_NN by_IN email_NN of_IN the_DT publication_NN of_IN financial_JJ reports_NNS by_IN registering_VBG on_IN 2003_CD 1.39_CD www_NN ._.
Copies_NNS of_IN previous_JJ financial_JJ reports_NNS are_VBP available_JJ on_IN 2002_CD 1.24_CD the_DT website_NN ._.
Printed_NNP copies_NNS can_MD be_VB obtained_VBN from_IN the_DT Registrar_NNP in_IN the_DT UK_NNP and_CC 2001_CD 1.11_CD from_IN the_DT Customer_NN Response_NNP Center_NNP in_IN the_DT US_NNP ._.
2000_CD 1.10_CD 0.87_CD PUBLICATIONS_NNS This_DT year_NN ,_, GSK_NNP is_VBZ again_RB producing_VBG a_DT Corporate_JJ Responsibility_NN Report_NNP covering_VBG Dividends_NNS paid_VBN to_TO Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP ADR_NNP holders_NNS are_VBP performance_NN in_IN areas_NNS including_VBG community_NN investment_NN ,_, business_NN ethics_NNS and_CC expressed_VBN as_IN dividends_NNS per_IN GSK_NNP ADS_NNPS ._.
integrity_NN ,_, access_NN to_TO medicines_NNS ,_, R&D_NNP and_CC environment_NN health_NN and_CC safety_NN ._.
The_DT report_NN will_MD be_VB published_VBN on_IN the_DT website_NN at_IN the_DT end_NN of_IN March_NNP ._.
DIVIDEND_NN CALENDAR_NN Fourth_JJ quarter_NN 2004_CD Ex-dividend_NN date_NN 16_CD February_NNP 2005_CD Record_NNP date_NN 18_CD February_NNP 2005_CD Share_NN price_NN Payable_JJ 7_CD April_NNP 2005 2004 2003_CD Share_NN price_NN First_JJ quarter_NN 2005_CD At_IN 1_CD January_NNP 12.80_CD 11.92_CD Ex-dividend_NN date_NN 11_CD May_NNP 2005_CD High_NNP during_IN the_DT year_NN 12.99_CD 13.90_CD Record_NNP date_NN 13_CD May_NNP 2005_CD Low_NNP during_IN the_DT year_NN 10.42_CD 10.00_CD Payable_JJ 7_CD July_NNP 2005_CD At_IN 31_CD December_NNP 12.22_CD 12.80_CD Decrease_NNP Increase_VB over_IN year_NN 5_CD %_NN 7_CD %_NN Second_JJ quarter_NN 2005_CD Ex-dividend_NN date_NN 3_CD August_NNP 2005_CD The_DT table_NN above_IN sets_NNS out_IN the_DT middle_JJ market_NN closing_NN prices_NNS derived_VBN from_IN the_DT Record_NNP date_NN 5_CD August_NNP 2005_CD London_NNP Stock_NNP Exchange_NNP Daily_NNP Ofcial_NNP List_NN ._.
The_DT Companys_NNP share_NN price_NN Payable_JJ 6_CD October_NNP 2005_CD decreased_VBN by_IN 5_CD %_NN in_IN 2004_CD from_IN a_DT price_NN of_IN 12.80_CD at_IN 1_CD January_NNP 2004_CD to_TO Third_JJ quarter_NN 2005_CD 12.22_CD at_IN 31_CD December_NNP 2004_CD ._.
This_DT compares_VBZ with_IN an_DT increase_NN in_IN the_DT FTSE_NNP 100_CD index_NN of_IN 8_CD %_NN during_IN the_DT year_NN ._.
Ex-dividend_NN date_NN 2_CD November_NNP 2005_CD Record_NNP date_NN 4_CD November_NNP 2005_CD Payable_JJ 5_CD January_NNP 2006_CD MARKET_NNP CAPITALISATION_NNP The_DT market_NN capitalization_NN of_IN GSK_NNP at_IN 31_CD December_NNP 2004_CD was_VBD 72_CD billion_CD ._.
Annual_JJ General_NNP Meeting_VBG 2005_CD At_IN that_DT date_NN GSK_NNP was_VBD the_DT fourth_JJ largest_JJS company_NN by_IN market_NN capitalization_NN on_IN the_DT FTSE_NNP index_NN ._.
The_DT Annual_JJ General_NNP Meeting_VBG will_MD be_VB held_VBN at_IN the_DT Queen_NNP Elizabeth_NNP II_NNP Conference_NNP Centre_NNP ,_, Broad_NNP Sanctuary_NNP ,_, Westminster_NNP ,_, London_NNP SW1P_NNP 3EE_NNP on_IN 25_CD May_NNP 2005_CD ._.
28_CD 28_CD GSK_NNP Annual_JJ Review_NNP 2004_CD GSK_NNP Annual_JJ Review_NNP 2004_CD New_NNP challenges_NNS ,_, new_JJ thinking_VBG Internet_NNP Our_PRP$ Reports_NNS ANNUAL_NNP REVIEW_NNP Information_NNP for_IN investors_NNS and_CC about_IN the_DT A_NNP review_NN of_IN major_JJ company_NN is_VBZ available_JJ on_IN GSKs_NNS corporate_JJ communication_NN website_NN at_IN www_NN ._.
com_NN themes_NNS for_IN 2004_CD and_CC an_DT abridged_JJ version_NN of_IN the_DT financial_JJ results_NNS ._.
Head_NNP Ofce_NNP and_CC Registered_NNP Ofce_NNP GlaxoSmithKline_NNP plc_NN 980_CD Great_NNP West_NNP Road_NNP Brentford_NNP Middlesex_NNP TW8_NNP 9GS_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD ANNUAL_NNP REPORT_NNP The_NNP full_JJ Financial_NNP statements_NNS for_IN the_DT year_NN United_NNP Kingdom_NNP United_NNP States_NNPS of_IN America_NNP ended_VBD 31_CD December_NNP Investor_NNP relations_NNS Investor_NNP relations_NNS 2004_CD ._.
980_CD Great_NNP West_NNP Road_NNP One_CD Franklin_NNP Plaza_NNP Brentford_NNP PO_NNP Box_NNP 7929_CD Middlesex_NNP TW8_NNP 9GS_NNP Philadelphia_NNP PA_NNP 19101_CD Tel_NNP :_: 44_CD 0_CD 20 8047 5557 5558_CD Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Fax_NN :_: 44_CD 0_CD 20 8047 7807_CD Tel_NNP :_: 1_CD 215 751 7003_CD outside_IN the_DT US_NNP Fax_NNP :_: 1_CD 215 751 3233_CD Registrar_NNP Lloyds_NNP TSB_NNP Registrars_NNPS ADR_NNP program_NN administrator_NN The_DT Causeway_NNP The_NNP Bank_NNP of_IN New_NNP York_NNP Our_PRP$ Corporate_JJ Responsibility_NN Worthing_NNP Shareholder_NN Relations_NNP Report_NNP may_MD be_VB found_VBN online_NN at_IN West_NNP Sussex_NNP BN99_NNP 6DA_NNP PO_NNP Box_NNP 11258_CD www_NN ._.
co._FW uk_FW Church_NNP Street_NNP Station_NNP New_NNP York_NNP NY_NNP 10286-1258_CD General_NNP enquiries_NNS ,_, Annual_JJ Report_NNP orderline_NN www_NN ._.
com_NN and_CC Corporate_JJ Nominee_NN service_NN Tel_NNP :_: 1_CD 877 353 1154_CD toll_NN free_JJ Tel_NNP :_: 0870 600 3991_CD inside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 610 382 7836_CD outside_IN the_DT US_NNP Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP Customer_NN Response_NNP Center_NNP Shareholder_NN Investment_NN Plans_NNS Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Produced_VBN by_IN Corporate_NNP Communications_NNPS ,_, GSK_NNP ._.
Dividend_NN re-investment_NN enquiries_VBZ Design_NNP consultancy_NN by_IN salterbaxter_NN ._.
Tel_NNP :_: 0870 241 3018_CD inside_IN the_DT UK_NNP Corporate_NNP share_NN dealing_VBG facility_NN Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD Smith_NNP Barney_NNP Printed_NNP in_IN the_DT UK_NNP by_IN St._NNP Ives_NNP Direct_NNP Edenbridge_NNP Ltd._NNP outside_IN the_DT UK_NNP Ordinary_NNP holders_NNS Attention_VB :_: GSK_NNP Services_NNPS The_DT paper_NN used_VBN in_IN the_DT production_NN of_IN this_DT document_NN is_VBZ Tel_NNP :_: 44_CD 0_CD 121 415 7146_CD 53_CD State_NNP Street_NNP made_VBD from_IN pulps_NNS harvested_VBN from_IN sustainable_JJ forests_NNS ,_, also_RB using_VBG sawmill_NN residues_NNS and_CC forest_NN thinnings_NNS ._.
It_PRP is_VBZ outside_IN the_DT UK_NNP Employees_NNP 39th_NNP Floor_NNP elemental_JJ chlorine-free_NN ._.
Boston_NNP Monthly_JJ Savings_NNPS Plan_NNP enquiries_VBZ MA_NNP 02109_CD Brand_NNP names_NNS appearing_VBG in_IN italics_NNS throughout_IN this_DT publication_NN are_VBP trademarks_NNS either_CC owned_VBN by_IN and_CC or_CC Tel_NNP :_: 0870 606 0268_CD inside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 800 347 6179_CD toll_NN free_JJ licensed_VBN to_TO GSK_NNP or_CC associated_VBN companies_NNS ,_, with_IN the_DT Tel_NNP :_: 44_CD 0_CD 131 527 3746_CD outside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 617 589 3341_CD outside_IN the_DT US_NNP exception_NN of_IN Boniva_NNP Bonviva_NNP ,_, a_DT trademark_NN of_IN Roche_NNP ,_, Fax_NNP :_: 1_CD 617 589 3474_CD and_CC Entereg_NNP ,_, a_DT trademark_NN of_IN Adolor_NNP Corporation_NNP ,_, ISA_NNP enquiries_VBZ Email_NNP :_: TheTaylorGroup@SmithBarney_NNP ._.
com_NN both_DT of_IN which_WDT are_VBP used_VBN under_IN licence_NN by_IN the_DT Group_NNP ._.
Tel_NNP :_: 0870 242 4244_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 190 385 4062_CD outside_IN the_DT UK_NNP Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP corporate_JJ PEPs_NNS The_DT Share_NN Centre_NNP Limited_NNP Oxford_NNP House_NNP Oxford_NNP Road_NNP Aylesbury_NNP Bucks_NNP HP21_NNP 8SZ_NNP Tel_NNP :_: 44_CD 0_CD 129 641 4144_CD Corporate_JJ share_NN dealing_VBG facility_NN Smith_NNP Barney_NNP Attention_NN :_: GSK_NNP Services_NNPS Citigroup_NNP Centre_NNP ,_, Level_NNP 20_CD Canada_NNP Square_NNP ,_, Canary_NNP Wharf_NNP London_NNP E14_NNP 5LB_NNP Tel_NNP :_: 44_CD 0_CD 20 7508 1795_CD Fax_NNP :_: 44_CD 0_CD 20 7890 7281_CD Email_NNP :_: TheBalaesGroup@Citigroup_NNP ._.
com_NN New_NNP challenges_NNS ,_, new_JJ thinking_VBG GSK_NNP Annual_JJ Review_NNP 2004_CD 29_CD www_NN www_NN ._.
